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ABSTRACT

Microorganisms and invertebrate animals from cold water marine environments, such as
in Antarctica and in Ireland’s deep sea, are a rich source of secondary metabolites. In this
dissertation, research was centered around secondary metabolism and natural product biosynthesis.
The projects include the delineation of biosynthetic gene clusters hypothesized to be responsible
for the biosynthesis of the palmerolides, stratification of the microbiome of the Antarctic ascidian
Synoicum adareanum, genomic and peptidomic analysis of a host-associated Antarctic
Pseudovibrio sp., and isolation and characterization of secondary metabolites from the Irish deepsea coral Drifa sp.
Palmerolide A, the principle secondary metabolite associated with S. adareanum, is a
potent V-ATPase inhibitor with selectivity for malignant melanoma cell lines; however, drug
development efforts have not been feasible due to a lack of supply. Identification of the producing
organism and of the biosynthetic gene cluster could solve the supply issue through
biotechnological methods of heterologous gene expression and large scale microbial cultivation
efforts. The putative biosynthetic gene cluster responsible for palmerolide A production has now
been identified and delineated in a host-associated bacterium. The biosynthetic gene cluster is a
hybrid Type-I PKS/NRPS with several interesting non-canonical features, including a truncated
condensation termination domain, a luciferase-like monooxygenase that is hypothesized to play a
xv

biosynthetic role as a hydroxylase, and a HMG-CoA synthetase cassette that installs a β-branch.
Additionally, five variants of the pal biosynthetic gene cluster were identified, some of which
explain the architectural diversity seen in the family of palmerolides.
The microbiome of S. adareanum was stratified through statistical analysis in efforts to
identify the microbial producer of palmerolide A. A suite of ecological statistics was used for
analysis of the ASV occurrence data. Twenty-one amplicon sequence variants (ASVs) were
persistent in at least 80% of the 63 samples collected. These core members demonstrated coherence
across samples. Genomic associations with members of the core microbiome, rather than
correlations with concentrations of palmerolide A, has led to the positive identification of the
producing organism.
Another member of the Synoicum adareanum core microbiome is Pseudovibrio sp. str.
TunPSC04-5.I4, which possesses a genome replete with biosynthetic potential. In this research,
several non-ribosomal peptide synthetase biosynthetic gene clusters were identified. Bacterial
cultures were analyzed using peptidomic methods. The research focused on the triangulation of
the biosynthetic gene clusters, compound structure predictions, and bioinformatic peptide
sequencing tools to develop a new method of drug discovery.
Additionally, the secondary metabolome of four samples of a deep-sea Drifa sp. was
evaluated using NMR-guided fractionation methods. This resulted in the discovery of a new
natural product, NEA-1. The diterpene represents new carbon scaffold containing a chromene core
with a highly substituted benzopyran ring system with an aldehyde, methyl, and two phenol
features on the aromatic ring, along with a monoterpene tail. Molecular networking was also
performed, which suggests the presence of natural analogues. This is a potential source for further
discovery. Additionally, steroid natural products were isolated from the Drifa sp. samples.
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CHAPTER ONE:
A BRIEF INTRODUCTION TO NATURAL PRODUCTS

1.1 NATURAL PRODUCTS CHEMISTRY AS A SCIENTIFIC FIELD
1.1.1

SECONDARY METABOLITES
The scientific field of Natural Products Chemistry involves an exploration of the molecules

derived from Nature, namely secondary metabolites. Secondary metabolites, usually less than
3,000 Daltons, are from a variety of compound classes, and have vast architectural diversity. They
are by definition distinct from primary metabolites, as they are not necessary for the survival of
organisms, but rather enhance survival through a number of mechanisms to “repel or attract” in
order to gain a survival advantage.1 Specialized metabolites are usually a result of evolutionary
adaptation and enhance survival through promotion of reproduction (e.g. pheromones), through
antipredation (e.g. toxins), as antifouling agents or to gain a competitive edge (e.g. antiinfectives).
Secondary metabolites are responsible for much of the chemodiversity seen in Nature, and
chemodiversity is often a direct reflection of the biodiversity in a given milieu. Explorations of the
chemistry of secondary metabolites cover terrestrial and marine environments and arise from
organisms that range from eukaryotic megafauna to prokaryotic microorganisms.

1

1.1.2

TECHNIQUES FOR THE DISCOVERY OF NATURAL PRODUCTS
Natural Products can be categorized in a variety of ways; however, classification usually

falls within one of four schemes: (1) chemical architecture and compound class, (2) biosynthesis,
(3) chemotaxonomy, and (4) biological activity.2 Chemical ecology, or understanding the chemical
communication of living things via specialized metabolites in the natural world, is a key
component of natural products chemistry. Often, these chemicals, which are evolutionarily
designed for biological targets, are also found to possess activity within biological systems outside
their natural habitat. They can be applied to human disease as antitumor agents, anti-infectives,
and neurologic modulators with great success. In fact, over 65% of FDA-approved medications
are directly from Nature or inspired by Nature.3 The unique and diverse chemical scaffolds make
natural products appealing as potential pharmaceuticals; however, the tight stereochemical control
that is enzymatically possible through the biosynthetic machinery responsible for specialized
metabolite production, make natural products a particular challenge to synthetic chemists.
Traditional methods for isolation and elucidation of new natural products includes NMRguided or bioactivity-guided fractionation using analytical techniques such as iterations of
chromatography; flash chromatography, medium pressure liquid chromatography (MPLC), and
high performance liquid chromatography (HPLC), for separation. Characterization and elucidation
of structures are heavily reliant upon spectroscopic techniques, namely nuclear magnetic
resonance (NMR), ultraviolet-visible (UV-vis) spectroscopy, and infrared (IR) spectroscopy, as
well as the spectrometric technique of mass spectrometry (MS).4 In addition, molecular biology
and increased throughput, sensitivity, and cost-effectiveness of genomic sequencing have opened
up new frontiers in natural product discovery, in the search for the biosynthetic gene clusters that
encode for the molecular machinery responsible for the production of novel natural products.
2

1.1.3

CLASSES OF SECONDARY METABOLITES
Natural products, or secondary metabolites, are biosynthesized by megaenzymes that are

evolutionarily divergent from their primary metabolic counterparts. Most natural products fall
within one of the following classes: polyketides, terpenes, peptides, alkaloids, phlorotannins, or
nucleosides. Sequential additions of subunits from basic biologic building blocks are used to create
a diverse and unique repertoire of compounds (Figure 1.1).5

Figure 1.1. The biosynthetic precursors for the main classes of natural products include sugars, acetyl
coenzyme A, and amino acids. Great structural diversity is represented in each class of secondary
metabolites, despite the simplicity of the precursors. From “The Chemistry of Algal Secondary
Metabolism,” by J. A. Mascheck and B. J. Baker, 2008, Algal Chemical Ecology, p.7. Copyright 2008
by Springer Nature. Reprinted with permission.
3

1.1.3.1 POLYKETIDES
Polyketides are enzymatically related to fatty acids and are biosynthesized by polyketide
synthases (PKS) through modular domains that act iteratively (Type II and III) or non-iteratively
(Type I) in repeated Claisen-like condensations leading to sequential 2-carbon elongations. The
assembly-like formation of the polyketide backbone carries different degrees of oxidation based
on the tailoring enzymes are present in the megaenzyme. Additionally, trans-acting enzymatic
domains can act upon the growing polyketide to enhance architectural diversity (Figure 1.2). These
molecules can be released from the PKS in linear form or as macrocycles. This class of compounds
is discussed extensively in Chapter II.
O
O

O

O

HO

O

O HO

O

OH

OH
O

O

O

O
OH

O
O

O

O

OH

OH
O

H
O

O

O

O

O
HO

O

Lovastatin

Erythromycin

Figure 1.2. Selected polyketide natural products: bryostatin 1, lovastatin, and erythromycin.
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1.1.3.2 NONRIBOSOMAL PEPTIDES
Peptidic natural products fall into two classes of natural products: non-ribosomal peptides
(NRPs) and ribosomally synthesized and posttranslationally modified peptides (RiPPs).
Biosynthesis of nonribosomal peptides results from action of nonribosomal peptide synthetases
(NRPS) that utilize a thiotemplate mechanism for sequential addition of amino acid residues to
form peptides. Type I NRPS systems rely on iteratively-acting enzymatic modules for progressive
elongation of the peptide chain, whereas type II NRPS systems utilize a non-iteratively acting
megaenzyme with multiple domains that typically act in a co-linear fashion. The megaenzyme is
comprised of adenylation domains that select for amino acid residues followed by condensation
domains that catalyze a nucleophilic attack by a free amine on one residue to an activated thioester
bond on a neighboring residue tethered to a carrier protein. At each step in the elongation process,
the adenylation domain can select a standard proteogenic residue or one of hundreds of
nonstandard amino acids. Tailoring enzymes act in-line with the sequential transpeptidation
reactions, on the individual subunits prior to incorporation into the growing amino acid chain, and
after the amino acid sequence is fully formed (Figure 1.3). Elements of NRPS megaenzymes are
sometimes hybridized with PKS modules to create even more extensive structural diversity.
Elements of NRPS biosynthesis are discussed further in Chapter IV.
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Figure 1.3. Selected non-ribosomal peptide synthetase products: bleomycin, theonellapeptolide Id, and
barangamide A.

1.1.3.3 RIBOSOMALLY SYNTHESIZED AND POSTTRANSLATIONALLY MODIFIED PEPTIDES
RiPPs on the other hand, rely on a ribosomal mechanism for biosynthesis. RiPPS are
encoded by structural genes that are translated into a series of peptides. This includes a precursor
peptide, typically twenty to 110 amino acid residues in length, that begins with a leader sequence
and is followed by a core peptide.6 During biosynthesis, cleavage of the leader peptide occurs and
the core peptide remains, which produces the natural product scaffold.7 Posttranslational
modifications (PTMs) are responsible for a tremendous degree of diversity seen in this particular
6

class, though hypervariability in the initial sequence and in a variety of recognition sequences can
augment the formation of natural analogues (Figure 1.4).
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Figure 1.4.
Selected ribosomally synthesized and posttranslationally modified peptide natural
products: patellazole A, thiomuracin A, and (R)-telomestatin.

1.1.3.4 TERPENES
Terpenes are the largest class of natural products and demonstrate great structural diversity
(Figure 1.5). They arise from mevalonate and non-mevalonate pathways. The carbon-hydrogen
backbone is biosynthesized by a single enzyme with repeating isoprene units that are joined in a
head-to-tail manner through isopentenyl pyrophosphate intermediates. After backbone assembly,
cyclization occurs followed by the action of a series of tailoring enzymes that further enhance
structural features of the molecule.8 The number of isoprene subunits determines the name of the
compound class. For example, a monoterpene contains two isoprene units (C10), while a
7

sesquiterpene contains three isoprene units (C15), a diterpene contains four isoprene subunits (C20),
and a triterpene contains six isoprene units (C30).
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Figure 1.5. Selected terpene natural products: keikipukalide B, lobocrasol A, and shagene A.

1.1.3.5 ALKALOIDS
Alkaloids arise from the shikimic acid pathway, are derived from aromatic amino acids
such as tryptophan, tyrosine, and phenylalanine. Shikimate metabolites include tryptophan-related
compounds with indoles, tyrosine-related compounds such as quinones, and phenylalanine-related
compounds (Figure 1.6). Tannins and some flavonoids are also products of this biosynthetic
pathway.9
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Figure 1.6. Selected alkaloid natural products: lyngbyatoxin A, domoic acid, and discorhabdin C.
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1.2 A BRIEF HISTORY OF NATURAL PRODUCTS
1.2.1 NATURAL PRODUCTS IN ANTIQUITY
Humans have used natural products long before the role of secondary metabolites was
understood. Traditional medicinal practices date back for thousands of years. The Sumerians,
Greeks, Chinese, and ancient Egyptians have all written documents outlining the use of natural
products to treat various ailments and diseases. Ayurveda practices were recorded as long as 7,000
years ago, while records in Mesopotamia show natural product use 4,000 years ago. Cuneiform
writing on clay tables from Mesopotamia date back to 2,600 B.C. and describe the use of myrrh
and cypress oils to treat inflammation, cough, and other upper respiratory symptoms.10 The
Egyptian Ebers Papyrus dates back to 2,900 years ago and outlines medical treatments using
natural products for a variety of ailments.11 Traditional Chinese medicine dates back to 3,000 years
ago and records of the medicinal practices include a series of texts with prescriptive use of natural
products, including the Chinese Materia Medica (1,100 B.C.), the Shannong Herbal (100 A.D.),
and the Yaoxing Lun, or Treatise on the Nature of Medicinal Herbs (659 A.D.).10
In the West and Near East, the use of natural products thrived in antiquity. In 300 B.C,
Theopharasius, a natural scientist and philosopher from Greece, recorded the use of medicinal
herbs. Several hundred years later in 100 A.D., Dioscorides, a Greek physician, outlined methods
for the preparation and storage of natural products for therapeutic use.10 In 700 A.D., the first
privately-owned pharmacies were established and soon after, Avicenna, a Persian poet,
philosopher, and physician, wrote the Canon Medicinae.10
Evidence of the use of natural products is not confined to ancient texts. In the 1990’s, Ötzi
or Iceman, a 5,300-year-old mummy, was discovered by hikers journeying in the Alps. His

9

preserved body was analyzed and he was found to have evidence of joint inflammation and
helminthic disease.12,13 In addition to carrying weapons and provisions, he also carried two
spheroid masses on a leather string determined to be Piptoporus betulinus, a bracket fungus.14 This
fungus produces agaric acid, a secondary metabolite that is now known to have analgesic
properties and antihelmenthic properties.14 Researchers hypothesize that he was using the natural
product to treat the parasitic infection and musculoskeletal inflammation.
1.2.2 THE ADVENT OF PHARMACOGNOSY
Natural products remain a key source and inspiration for modern pharmaceuticals and the
treatment of human diseases. The branch of knowledge that centers around natural products as
therapeutics is known as pharmacognosy. As techniques and methods in the field of natural
products has progressed, isolation of pure compounds that account for the activity of the ancient
remedies have been possible. Pharmacognosy as a field of science gathered data around these
sources of ancient healing and validated many of the practices through chemical analysis. Though
opium use dates back to at least 3,500 years ago in Mesopotamia, where poppy was grown for
medicinal purposes, it was not until 1806, that morphine was isolated from opium by
Serthürner.15,16 The structure of the alkaloid was elucidated in 1925 by Gulland and Robinson via
a series of degradation and rearrangement experiments.16 This represented the first natural product
to be isolated, purified, and characterized (Figure 1.7).
Other potent natural products have been isolated from terrestrial sources. Paclitaxel was
isolated from the Pacific Yew tree and is effective as a chemotherapeutic agent. This compound
represents the result of a symbiosis that produces novel and biologically active molecules. It is
produced both by the plant and by an endophytic fungus. This fungus has been cultured and
fermented to effectively synthesize biosynthetic precursors as a means of drug development.
10

Artemesinin, derived from wormwood, has been used in Chinese traditional medicine for over
2,000 years for symptoms consistent with malaria. It was not until 1979 that the chemical
properties of the compound were described. This led to development of artemisinin as a
pharmaceutical agent which is now approved as an antimalarial drug, and in 2015, the Nobel Prize
in Chemistry was awarded for its discovery (Figure 1.7). The bark and leaves of the willow tree
were used in ancient traditional medicine as an antipyretic, anti-inflammatory, and analgesic;
salicylic acid that was isolated from the willow tree was later derivatized to acetylsalicylic acid to
reduce toxicity and side effects, including nausea and vomiting (Figure 1.7).17
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Figure 1.7. Natural products representing the advent of pharmacognosy. Potent compounds were
isolated and characterized from many medicinal plants used in ancient times, including morphine,
paclitaxel, artemisinin, and aspirin, all of which are still in use today.
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1.2.3

THE CURRENT IMPACT OF NATURAL PRODUCTS
Natural products are a rich source of pharmaceutical inspiration for the treatment of human

disease. Approximately two-thirds of the Food and Drug Administration (FDA)-Approved
medications are inspired by or derived directly from natural products.3 It is estimated that over
440,000 natural product structures are available from public databases, including PubChem,
ChEMBL, Super Natural II, ZINC, NaprAlert, and REAXYS, pointing to the vast architectural
diversity seen in Nature.18 Additionally, analysis of the chemical space of natural products reveals
that there is not only diversity, but also a high degree of relevance to discovering drug-like
molecules.19 Marine natural products demonstrate a higher rate of success than the synthetic
industry average for new molecular entities and anticancer activity in in vitro assays.18

1.3 MARINE NATURAL PRODUCTS
1.3.1 THE WEALTH IN THE WORLD’S OCEANS
Over 70% of the surface of the earth and 95% of the biosphere is comprised of the world’s
oceans.20 Though the total number of marine species is recorded as less than 500,000 of the total
1.75 million described species on earth, it is estimated that this number is greatly underestimated
due to lack of access to the remote parts of the marine environment.20 To date, over 18 million
DNA microbial genome sequences covering over 100 phyla groups within the oceans have been
obtained.21 With the advent of self-contained underwater breathing apparatus (SCUBA) diving in
the 1950’s, the accessibility to the ocean’s resources improved and the marine environment
became a place for bioprospecting. Remotely operated vehicles (ROVs) have expanded the
territories of exploration to even the deep-sea. Though approximately 27,000 marine natural
12

products have been described, the investigation of chemical diversity in light of this magnificent
degree of biodiversity is far from exhausted.22 Furthermore, some argue that marine natural
products demonstrate a higher rate of structural novelty and bioactivity than terrestrial natural
products.23 The combination of unexplored oceanic territory, vast biodiversity, structural novelty,
and precedence for a high rate of bioactivity makes marine natural products a field with abundant
untapped potential.
Products from Porifera and Cnidaria comprise 57% of marine natural products with known
bioactivity, which makes them the most proliferative phyla in regards to natural products.24
Interestingly, up to one third of the biomass of a sponge can be from bacterial cells and it is known
that host-associated microbes are often responsible for the secondary metabolite biosynthesis that
is often initially attributed to the invertebrate host.25 Statistical analysis by Hu, et al. reveals that
56% of marine natural products have anti-cancer activity, 13% antibacterial activity, 5% antifungal
activity, 3% antiviral activity, 1% neurotoxicity or neuromodulation, and 1% cardiovascular
activity ascribed to them.24 There are multiple factors that influence this breakdown of activity
including availability of bioassays and underlying funding driving research in specific areas of
human health. Additionally, with the advent of computational screening, testing for bioactivity can
be informed based on screening for specific biological targets that does not require the expenditure
of compounds with limited quantity; this expands the potential impact of natural products in drug
discovery efforts.26
1.3.2

MICROBIAL SYMBIOSIS AS A SOURCE OF NATURAL PRODUCTS
Over the last decade, interest in microbial sources for the discovery of new natural products

has grown substantially. In three years alone, the number of novel metabolites isolated from
microbial sources increased over thirty-five percent, from 493 in 2013 to 677 in 2016.27 In addition,
13

many previously described compounds that were isolated from macroorganisms are now being
attributed to bacterial or fungal origin from a microorganism that is associated or in a symbiotic
relationship with the macroorganism. There are several examples of a single compound being
isolated from different genera of macroorganisms, from vastly different geographical locations,
and from completely different phyla. These observations have validated the suspicions and
solidified the hypothesis that many secondary metabolites, including polyketides, had been
initially attributed to biosynthesis by marine invertebrates, but are actually microbially produced.
Laulimalide, also known as fijianolide B, is a macrolide with a 20-membered ring system
that promotes microtubule stabilization. It represents a compound isolated from multiple sponge
genera (Figure 1.8). It has been isolated from Pacific sponges from three distinct genera:
Cacospongia mycofijiensis, Hyatella sp., and Fasciospongia rimosa.28,29,30
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Figure 1.8. Laulimalide has been found in several genera of sponges, including Fasciospongia,
Dactylospongia, and Cacospongia; a finding that points to a common microbial producer of the compound.

Dictyostatin is a macrolide with a 22-membered ring system that possesses cytotoxicity as
a tubulin inducer, arresting the cell cycle at the pre-mitotic and mitotic (G2/M) phases. It was
isolated from two distinct geographical locations in two different sponge genera (Figure 1.9).
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Initially, the compound was isolated from Spongia sp. near Maldives in the Indian Ocean and later
from a Corallistidae sp. sponge from the Caribbean waters near Jamaica.31,32

Figure 1.9. Dictostatin has been isolated from sponges of different genera from distinct geographical
locations; a finding that also points to a common microbial producer of this polyketide.

In addition, onnamide and pederin were both isolated from a marine sponge and a terrestrial
insect (Figure 1.10). Theonella swinhoei is a marine sponge that is known to be a rich source of
secondary metabolites, including not only onnamide, but also theopederins, along with dozens of
bioactive peptides and polyketides with scaffolds belonging to seven chemical classes. As early as
1992, it was thought that the prolific producers of this diverse set of compounds were microbial in
nature, serving as symbionts living in a rich microbial community within the T. swinhoei sponge.33
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Figure 1.10. Onnamide and pederin have been isolated not only from Theonella swinhoei, a marine
sponge. but also the Paederus beetle (photo by Joaquim Alves Gaspar; used under Creative Commons
license); another finding that points to a microbial source of some secondary metabolites. Image of
Theonella swinhoei is from “A talented genus,” by M. Jaspars and G. Challis, Nature 506, 38-39.
Reprinted with permission. Image of the Paederus beetle is from Joaquim Alves Gaspar, 2016, CCBY-SA 4.0 by Copyright Holder. Used with permission.

Biosynthetic cassettes can be identified either from a single bacterial strain or using a
metagenomic approach. Genomic work done by Piel decades after Fusetani and Matsunaga’s
conjecture confirmed that ‘Entotheonella factor,’ a bacterial symbiont community rich in PKS
genes, contained the PKS BGC required for production of onnamide, theoperedins, and
misakinolide A, among others. Candidatus Entotheonella, a new bacterial genus, has been
identified in the metgenomic sequence assembly from multiple sponges from vastly different
geographical locations and has proved to be rich in biosynthetic potential across the globe with the
identification of over forty BGCs.34 Paederus sabaeus, a terrestrial roove beetle, utilizes pederin
and onnamide as chemical weapons; dermatitis linearis and conjunctivitis can occur in humans
who come in physical contact with the toxin when released from the beetle. Investigation of the
16

adult beetle and its larvae revealed that a gram-negative Proteobacteria is the microbial symbiont.
This bacteria, most closely related to Pseudomonas sp., was determined to be the producer of the
compounds.35 It is possible that convergent evolution in divergent hosts or horizontal gene transfer
of these biosynthetic gene clusters is responsible for the production of this toxic secondary
metabolite in both the marine sponge and terrestrial insect. This is just one example of many
bacterial symbionts, rich in biosynthetic cassettes, that appear to be the source of many secondary
metabolites that were previously ascribed to the macroorganisms from which the compounds were
isolated.
1.3.3

MARINE PHARMACEUTICALS
Thousands of structurally diverse and potentially bioactive compounds have been isolated

from the marine environment. Early in the National Cancer Institute’s drive to fund research for
discovery of antitumor agents from marine invertebrates, several families of promising compounds
were isolated. These included the bryostatins from the bryozoan Bugula neritina, the dolastatins
from the nudibranch Dolabella auricularia, and the didemnins from the ascidian Trididemnum
solidum.36 One of the primary challenges with drug development efforts of marine natural products
remains supply; however, development efforts have been successful for many marine natural
products. Hundreds of marine-derived compounds enter the preclinical pipeline yearly, several of
which move forward to the Phase I, II, and II clinical studies.37 As of the end of 2019, there were
thirty compounds in the global marine pharmaceutical clinical pipeline, twenty-two of which were
in some stage of clinical trials.18 Seven natural products from marine invertebrates and marine
microorganisms have made it through the pharmaceutical pipeline and have been approved by the
Food and Drug Administration (FDA), European Medicines Agency (EMEA), or Australia’s
Therapeutic Goods Administration and are described below.
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1.3.3.1 CYTARBINE (ARA-C; CYTOSAR-U®, DEPOCYT®)
Cytosine arabinoside, also known as cytarabine, was initially approved by the FDA in 1969
(Figure 1.11). The conventional formulation (Cytosar-U®) was approved for treatment of acute
lymphocytic leukemia, acute myelocytic leukemia, meningeal leukemia, and blast crisis associated
with chronic myelogenous leukemia.38,39 An intrathecal formulation of liposomal cytarabine
(Depocyt®) is approved for lymphomatous meningitis.37 It is a synthetic derivative of
spongothymidine, which is a nucleoside isolated from Tectitethya crypta.40 As an antimetabolite
that is specific to the S-phase, cytarabine acts to inhibit DNA polymerase and DNA synthesis.37,41
A fluorinated analogue has been approved for treatment of breast, bladder, lung, and pancreatic
cancers.42
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Figure 1.11. Chemical structure of cytarabine.

1.3.3.2 VIDARABINE (ARA-A; VIRA-A®)
Arabinofuranosyladenine, or vidarabine, was approved in 1976 by the FDA for the
ophthalmic indications of herpes simplex virus-induced recurrent epithelial keratitis, acute
keratoconjunctivitis, and superficial keratitis caused by herpes simplex virus and refractory to
idoxuridine. It is a synthetic derivative of spongouridine, a purine nucleoside also from the
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Caribbean sponge Tectitethya crypta.40,41 Because of its relatively narrow therapeutic window and
other antiviral compounds available, Vira-A was discontinued in the United States in 2001.37
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Figure 1.12. Chemical structure of vidarabine.

1.3.3.3 ZICONOTIDE (Ω-CONOTOXIN MVIIA; PRIALT®)
Isolated from Conus magus venom, ω-conotoxin MVIIA is a ribosomally synthesized and
posttranslationally modified peptide that is comprised of twenty-five amino acids and has
antinocioceptive properties due to its antagonism of neuronal calcium channels.43 It was approved
by the Food and Drug Administration (FDA) in 2004. It is administered intrathecally in
conjunction with morphine to treat refractory cancer pain.44 It is also used to treat severe
neuropathic pain that is resistant to first-line therapeutics, particularly for phantom limb pain.45
Though over 200 analogues were created, the native peptide was most efficacious in treating pain
(Figure 1.13).36
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Figure 1.13. Chemical structure of ziconotide.

1.3.3.4 ECTEINASCIDIN 743 (TRABECTEDIN, YONDELIS®)
Trabectedin is a tetrahydroisoquinoline alkaloid that was approved as an anticancer agent
and the first to be approved for cancer in its native state (Figure 1.14). It was extracted from the
mangrove tunicate Ecteinascidia turbinata in the Caribbean. It serves as an alkylating agent that
binds to guanines at the exocyclic-2 amino group in the minor groove of DNA.46 The compound
was fully characterized in 1986, though the initial description of its antiproliferative properties
proceeded the successful isolation and characterization by seventeen years.36 Larger-scale
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collections and aquaculture were used to obtain adequate amounts of the compound for the early
clinical trials. Synthetic and semi-synthetic processes were outlined; the obstacle of adequate
supply was later resolved by a semi-synthetic process utilizing cyanosafracin B, an antibiotic
produced by fermentation of the marine bacterium Pseudomonas fluorescens.47–49 It was approved
by the European Medicines Agency for treatment of soft-tissue sarcomas and ovarian cancer.
Several phase I-III trials in the United States have included ET-743 for a number of cancers.36
Through metagenomic sequencing efforts focused on the biosynthetic gene clusters with homology
to safracin and saframycin, the endosymbiotic bacterial producer, Candidatus Endoecteinascidia
frumentensis (AY054370), was discovered.50,51 The metagenome assembled genome (MAG) and
other components of the host-associated relationship for C. Endoecteinascidia frumentensis is
discussed further in Chapter III.
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Figure 1.14. Chemical structure of ecteinascidin 743.

1.3.3.5 ERIBULIN MESYLATE (TRUNCATED HALICHONDRIN B, HALAVEN®)
Isolated from the sponge Halichondria okadai from the Pacific coast of Japan, halichondrin
B is a large polyether macrolide found to have antitumor bioactivity due to its ability to destabilize
tubulin.52,53 The initial isolation was described by Hirata and Uemura in 1986; however, clinical
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trials were pursued by the National Cancer Institute after Blunt, Munro, and colleagues harvested
a metric tonne of Lissodendoyx sp., which was known to also contain the compound, from the
waters of New Zealand to obtain 300mg of halichondrin B.54 This was followed by successful
aquaculture efforts to create a more sustainable means to source the compound.54 Synthetic
approaches were also developed and successful, despite the highly complex structure of the
molecule. The synthetic work done by Yoshito Kishi with follow-up structure activity relationship
studies revealed that the bioactivity of the compound was due to the macrocycle; therefore, the
ring became the focus for derivatization and development.36,55,56 One of the over 200 truncated
analogs of halichondrin B, known as eribulin, had increased potency in in vivo studies. In 2010,
eribulin (Halaven®) was approved by the FDA for treatment of refractory breast cancer (Figure
1.15).56
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Figure 1.15. Chemical structure of eribulin mesylate.

1.3.3.6 BENTUXIMAB VEDOTIN (DERIVATIVE OF DOLASTATIN 10, ADCETRIS®)
Brentuximab vedotin (Adcetris®) was approved by the FDA in August 2011 for treatment
of systemic anaplastic large cell lymphoma and Hodkin’s lymphoma. The pharmaceutical is
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comprised of a chimeric immunoglobin GI anti-CD30 monoclonal antibody, a protease-cleavable
linker, and auristatin E, a dolastatin 10 derivative (Figure 1.16).57 Dolastatin 10 is an NRPS product
that was initially isolated from the sea hare Dolabella auricularia off the coast of Mauritius using
a bioassay-guided strategy to obtain the compound, though in very low amounts.58 Synthetic
strategies were used to confirm the absolute stereochemistry of dolastatin 10’s complex structure
with nine chiral centers.59 This linear pentapeptide showed marked potency as an antitumor agent
with a mechanism that included tubulin interactive agent binding near the vinca domain.60 Many
of the compounds within the family of dolastatins demonstrate bioactivity, though dolastatin 10 is
among the most potent. The compound showed promise in early clinical trials, but did not progress
beyond phase II trials for prostate cancer or metastatic melanoma, despite the initial bioactivity in
the NCI program.36 Interestingly, dolastatin 10 was later isolated from Symploca sp. VP642 from
Palau, a free-living marine cyanobacteria.61
The potency of dolastatin 10 against breast cancer in phase II trials revealed a high degree
of toxicity, leading to a shift in strategy toward the development of an antibody-drug conjugate.
Related molecules were created through total synthesis, resulting in the drug class of the
auristatins. This synthetic process led to formation of the analogue auristatin E, which included a
structural feature suited for the attachment of a covalent linker. The development of the ADC
progressed with the analogue to create a targeted delivery system of the potent antimitotic agent
to tumor cells.62
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1.3.3.7 PLITIDEPSIN (APLIDIN®)
Isolated from Aplidium albicands, a Mediterranean tunicate, plitidepsin is a depsipeptide
that has architectural similarity to the didemnins and shows potent bioactivity as an antitumor
agent even at subnanomolar concentrations (Figure 1.17).63,64 The mechanism of action of
plitidepsin involves the induction of cell-cycle arrest and actue apopstosis that are mediated by
oxidative stress leading to activation of c-Jun N-terminal kinase and p38 mitogen protein kinase
activation.65 Antiangiogenesis has also been observed.63 In 2018, this first-in-class drug was
approved in Australia for refractory or relapsed multiple myeloma.66 A press release from
PharmaMar reports nanomolar potency of plitidepsin in in vitro studies against human coronavirus
HCoV-229E, which is similar to SARSCoV-2, revealing that this medication may have potential
to be repurposed as an antiviral in the fight against COVID-19 infections.67
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1.4 CONCLUSION
Natural products are a rich source of inspiration for pharmacological treatments of human
disease. The scaffolds that Nature provides have been utilized for their medicinal properties for
thousands of years and continue to be a direct source of and an inspiration for new pharmaceutical
agents. The field of pharmacognosy continues to contribute to drug discovery efforts. The rise of
marine natural products due to technological advancement with SCUBA and the use of remotely
operated vehicles in the world’s underexplored oceans has led to a greater ability to sample
organisms. This, in turn, has provided tremendous insights into novel scaffolds, chemical ecology,
microorganism-invertebrate associations, and biosynthesis of key chemical classes.
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CHAPTER TWO:
THE BIOSYNTHETIC PATHWAY FOR PALMEROLIDES

2.1 THE POLYKETIDE CLASS OF NATURAL PRODUCTS
Polyketides are a group of highly diverse secondary metabolites that are characterized by
long hydrocarbon chains with varying degrees of oxidation. They have been isolated from a variety
of terrestrial and marine organisms, including macroorganisms such as sponges, tunicates,
dinoflagellates, bryozoan, sea hares, nudibranchs, corals, and plants and microorganisms such as
bacteria and fungi. The intrinsic molecular machinery responsible for the biosynthesis of
polyketides is made up of genome-encoded modular megaenzymes, which form an intricate
network of multiple catalytic enzymes arranged in a manner conducive to efficient, though
complex, formation of these diverse compounds with tight stereochemical control.

2.2 POLYKETIDE SYNTHASES
2.2.1

A NEW WAVE OF NATURAL PRODUCTS DRUG DISCOVERY
Historically, natural product discovery has relied heavily on extraction of secondary

metabolites of macro- and microorganisms, followed by bioassay or NMR-guided fractionation,
and finally, compound isolation and characterization. This once very productive method has
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become less and less effective over time with regard to the discovery of novel chemistry and has
increasingly led to the rediscovery of previously characterized compounds.1 New natural product
discovery platforms are needed to ensure that the rich resources of Nature can be explored in a
novel and sustainable manner. Shifting the focus to the biosynthetic information encoded in the
genome can aid in discovery of natural products from cryptic BGCs and can allow for derivatized
or completely novel products through combinatorial biosynthesis. This new wave of natural
product chemistry explores how the intricate designs of megaenzymes responsible for the
production of valuable secondary metabolites, such as polyketides, can be modified and expressed
to enhance novelty of compounds and explore new frontiers in natural product chemistry.
It is estimated that that over 11,000 secondary metabolites understood to be of polyketide
synthase (PKS) and nonribosomal peptide synthetase (NRPS) origin have been isolated and
described; however, only about a tenth of these compounds have been linked to PKS biosynthetic
gene clusters (BCGs).2 Genome sequencing and subsequent annotation of biosynthetic gene
clusters is becoming more accessible and therefore more widely used. Genomics as an integral
component of the workflow to discover novel natural products is now becoming the norm. The
intriguing relationship between gene cluster, biosynthetic enzyme complex, and product is being
defined. The process of integrating genomics holds great promise for a new wave of natural
product discovery, as expression of cryptic BGCs, combinatorial biosynthesis, and heterologous
expression of BGCs can be used for compound production with high yields and tight
stereochemical control of biologically-active molecules possessing pharmaceutical potential.
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2.2.2

GENES AND TRANSLATION
Biosynthetic gene clusters (BGCs) are discrete genomic packages that encode for

megaenzymes that serve as molecular assembly lines for the natural product. These genomic
packages can be horizontally transferred from one organism to another.3,4 In addition, based on
evolutionary pressures or streamlining, modules for biosynthesis can be lost, gained, or their
functions altered to form new secondary metabolites to aid in survival.3 These can not only be
transferred from bacteria to bacteria, but also evidence of horizontal transfer of BGCs has been
seen from prokaryotes to eukaryotes.3,5 BGCs can sometimes be found encoded on plasmids, but
are often integrated into the genome of the organism.6–9
Polyketides are biosynthesized by polyketide synthases (PKSs), which are multidomain
enzymatic complexes with many catalytic sites, that are genetically encoded in BGCs (Figure 2.1).
The PKS BGCs are comprised of genetic material which is translated to form individually-folded
protein domains that form discrete enzymatic modules. The modules assemble to form a
megaenzyme that produces the polyketide in a stepwise, assembly-line fashion. PKSs involve a
pathway that is evolutionarily divergent from, but similar to, the fatty acid synthases (FASs). This
deviation is responsible for the remarkably diverse molecular architecture seen in this class of
secondary metabolites.10,11
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Biosynthetic
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erythromycin

Natural
Product

Megaenzyme

Figure 2.1. Biosynthetic gene clusters encode for large, multidomain megaenzymes that produce secondary
metabolites. Type I PKS megaenzymes are often genetically encoded in a co-linear fashion, allowing
predictions about the structure of the final compound to be made based on the sequence of encoded
enzymatic domains.

2.2.3

TYPE I, TYPE II, AND TYPE III POLYKETIDE SYNTHASE SYSTEMS
Polyketide synthases are divided into three classifications (Figure 2.2) based on whether

the biosynthetic process is iterative or non-iterative and to which class of compounds the final
product belongs. Type I PKSs, initially described in 1990, involve multienzyme complexes that
act in a non-iterative manner with each enzymatic module leading to a prolongation of the
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Figure 2.2. Polyketide synthases are classified into three types. (a) Type I: non-iterative with each
module leading to a linear assembly and chain elongation; these products tend to have unique and
complex chemical architectures; an example product is lovastatin. (b) Type II: iterative; few enzymes
which act in a repeated manner leading to chain elongation; the products are often polycyclic aromatic
products, as exemplified by tetracenomycin. (c) Type III: iterative; homodimeric units with sequential
condensation leading to elongation of the polyketide chain; products are often mono- or bicyclic aromatic
in nature; an example is resveratrol.
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polyketide chain by a single subunit.12 The type II PKSs, first described in 1984, consist of an
iteratively-acting set of a few enzymatic modules for biosynthesis of polyketides which typically
result in the formation of polycyclic aromatic compounds. Type III PKS systems, initially
described in 1999, rely on homodimeric units for sequential condensation and therefore elongation
of the polyketide chain resulting in monocyclic or bicyclic aromatic polyketides. Because of the
resultant scaffold, which often resembles the aromatic ketone chalcone, this pathway is also known
as “chalcone synthase-like”.11

2.2.4

SUBTYPES OF TYPE I: TRANS-AT V CIS-AT
Type I PKS systems are further subdivided based on the genetic encoding of the acyl

transferase (AT) module (Figure 2.3). The BGC is classified as cis-AT if the AT domains are
present within the primary sequence of the given module.13 The concept of co-linearity refers to
the parallel relationship between the enzymatic modules and the functional groups present in the
growing polyketide chain.14 The trans-AT PKS system does not abide by the rule of co-linearity
and allows for greater architectural diversity, often with aberrant scaffolds and novel domains that
may or may not be directly related to structure. The AT domains are encoded in a mosaic fashion
and are thought to often be incorporated into the genome as a result of horizontal gene transfer.14
For many years, trans-AT systems went undescribed because the primary organism of study in the
early years of discovery was Actinomyces sp., which possesses a number of genes responsible for
polyketide biosynthesis. The polyketide synthases represented in Actinomyces sp., however, were
exclusively classified as cis-AT PKS systems. Not until other genera of microbes were studied,
was a second system discovered, which is now known as the trans-AT type I PKS. This greatly
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expanded the previous understanding of the biosynthesis of this interesting class of compounds. It
is now estimated that nearly forty percent of PKS systems are of the trans-PKS subtype.10

Figure 2.3. Simplified depiction of cis-AT PKS and trans-AT PKS Megaenzymes. The genomic
information, represented by the dark blue arrows, encodes for the catalytic domains that comprise the
modules. Modules are responsible for a single 2-carbon elongation step. The cis-AT system has the acyltransferase domains in line with the megaenzyme, whereas in the trans-AT system, the acyl transferase
domains are encoded in a mosaic pattern and are free-standing, rather than within the PKS modules. AT:
acyltransferase; KS: keto synthase; ACP: acyl carrier protein; TE: thioesterase; ER: enoyl reductase; V:
variable site (represents a number of potential domains).

2.2.5

BIOSYNTHESIS BY TYPE I TRANS-AT POLYKETIDE SYNTHASES
There are three main steps for type I polyketide biosynthesis: initiation, elongation, and

termination. In Type I polyketide synthases, each discrete module is responsible for a single 2carbon elongation step of a compound.
2.2.5.1 INITIATION
The initiation process occurs with the selection of an appropriate starter unit by an AT
domain, whether in the cis- or in the trans-AT system, followed by enzymatic attachment of this
starter unit to the Acyl Carrier Protein (ACP). Some AT domains are specific for a certain starter
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unit, while others demonstrate relaxed substrate specificity or polyspecificity and select one of
several possible starter units. This enzymatic promiscuity is an additional source of compound
diversity.15 In addition, non-polyketide segments that expand the architectural diversity of the
molecule are often introduced at this juncture, as starter units can be large and unusual. In contrast,
the starter units can also be simple, introducing a basic starter unit like acetyl-CoA.10
ACP domains have a serine residue that has been post-translationally modified with a 4’phosphopantheteninyl (Ppant) arm (Figure 4) by the Ppant transferase (PPTase) enzyme.
Coenzyme A is the primary substrate for the formation of the Ppant arm (Figure 2.4), which serves
as a dynamic chemical arm that transfers the growing polyketide chain to the subsequent modules
in this non-iterative, assembly-line process. The free thiol end is modified by the AT domain,
which links the acyl starter unit by a thioester bond. The primary requirement for a starter unit is
creation of this CoA-thioester moiety.

Figure 2.4. 4’-phosphopantetheinyl (Ppant) component is derived from Coenzyme A and modified with
a free thiol end that is acted upon by AT with appropriate starter unit or subsequent subunits, depending
on the location of the domain within the linear, non-iterative module, creating the necessary thioester.
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2.2.5.2 ELONGATION
During the elongation process, an AT domain selects the desired monomeric subunit and
the ACP Ppant arm translocates the growing chain from one module to the next. Malonyl-CoA
and its derivatives, usually with a methyl, ethyl, or methoxy group in the α-position, serve as
subunits for elongation. A standard enzymatic module contains a ketosynthase (KS) domain which
facilitates a Claisen-like condensation to join the new subunit to the elongating polyketide chain,
forming a β-ketothioester intermediate.13 It is after the elongation process that other enzymatic
domains within the same module act on a given molecule to alter the newly-added subunit before
transfer to the subsequent module.
2.2.5.3 TAILORING
There are a variety of enzymatic domains that ensure the appropriate tailoring of the acetate
monomer by introducing a variety of elements to enhance structural diversity. Tailoring enzymes
typically alter the moiety at the position β to the carbonyl carbon to create double bonds, introduce
branching, create cyclization, and lead to isomerization.10 For example, a ketoreductase (KR)
reduces the β-carbonyl to a hydroxy group and the proton in the α-position. A combination of a
KR domain with a dehydratase (DH) domain reduces the β-carbonyl to a hydroxy group and
eliminates this hydroxy group and the proton in the α-position, leading to the formation of an α,βunsaturated thioester. An additional enol reductase (ER) reduces the α,β-unsaturated thioester to a
saturated moiety (Figure 2.5). The trans-AT systems often involve not only these combinations of
enzymatic domains, but also additional tailoring enzymes beyond the core biosynthetic modules
can enhance compound complexity. For example, carbon-methyl transferase (cMT) domains
introduce catalytic methylation via S-adenosyl methionine as a methyl donor. Lactams, lactones,
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other ring systems, and alkyl branching features are introduced by modules that have the capability
of carrying to polyketide chains by utilizing multiple Ppant arms.10

Figure 2.5. A generic elongation module in a type I PKS System. Enzymatic domain “X” can be further
defined by one or more enzymatic domains within the module to modify the growing polyketide chain
at the β-position before chain translocation occurs. From “Exploiting the mosaic structure of transacyltransferase polyketide synthases for natural product discovery and pathway dissection,” by T.
Nguyen, J. Nat. Biotechnol. 2008, 26 (2), 225–233. Copyright 2008 by Springer Nature. Reprinted with
permission.

2.2.5.4 TERMINATION
Termination typically occurs through one of two routes, hydrolysis of a linear polyketide
or macrocyclization and release of the molecule. The thioesterase (TE) enzyme is responsible for
this liberation of the final product from the megaenzyme.13 When a thioesterase is paired with a
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cyclase (C), this results in macrocyclization and release of the final product. Additional noncanonical modules can also lead to alternative modes of polyketide chain release. These include
non-elongating ketosynthase modules (KS0), NRPS-like condensation domains, reductases, and
combinations of these domains with TE domains.10

2.3 IMPORTANCE OF POLYKETIDES AS BIOACTIVE MOLECULES
2.3.1

POLYKETIDES WITH PHARMACEUTICAL POTENTIAL
Natural products are highly sought after for their use in industry and medicine. Nearly 70%

of anticancer agents and over 50% of anti-infective agents on the pharmaceutical market are natural
products or their derivatives.16 Polyketides demonstrate great pharmaceutical promise. It is
estimated that of the polyketides that have been isolated and characterized, 1% have potential drug
activity, making this class of compounds particularly appealing from a drug discovery and
development standpoint. This potential for bioactivity is approximately five times greater than that
of compounds of other natural product classes.17
Many cytotoxic polyketides are classified as macrolides, macrocyclic polyketides
containing a lactone moiety, which possess important bioactivity that affects the cytoskeleton,
Vacuolar type (H+)-ATPases (V-ATPases), and ribosomal protein biosynthesis. Polyketides that
target actin and tubulin within the cytoskeleton alter cell stability in eukaryotic cells. Alterations
in the cytoplasmic cytoskeleton impact several pathogenic processes including adhesion,
angiogenesis, intracellular transport, metastasis, and cytokinesis.18 Binding of these compounds
often occurs on F-actin and G-actin, representing the filamentous polymer and the globular
monomer respectively. Misakinolide, rhizopodin, kabiramide C, and tolytoxin, among others, are
polyketide macrolides with an effect on the cytoskeleton. Despite the vast diversity seen in the
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chemical scaffolds of these compounds, there are large segments of the compounds that are
conserved and are likely responsible for the effect on actin.19
Multiple targets affecting ribosomal protein biosynthesis have been identified. A few of
the marine macrolides express antitumor activity through the targeting of this system, though many
natural products of other classes have also demonstrated effects in this area. The macrolides
pateamine A, which inhibits initiation of cap-dependent translation by binding to factor 4A, and
tedanolide, which inhibits polypeptide elongation, are two such polyketides.20,21
Another biological target for marine macrolides is Vacuolar type V-ATPases. These
proteins are responsible for acidification of organelles and proton transport across cellular
membranes of lysosomes, vacuoles, and endosomes. V-ATPases appear to have an impact on
angiogenesis, apoptosis, cell proliferation, and tumor metastasis. For this reason, it is an appealing
target for pharmaceutical development. A number of marine macrolides affect V-ATPases,
including lobatamide C, the chondropsins, iejimalides, and palmerolide A. 22–26
2.3.2

PALMEROLIDE A
Initially described in 2006, palmerolide A has significant pharmaceutical promise. This

natural product is a marine macrolide that was isolated from Synoicum adareanum, an Antarctic
ascidian.25 It is a secondary metabolite that belongs to the chemical class of polyketides and has
several unique chemical components. The compound was screened using the 60 cell line panel
from the National Cancer Institute and showed significant sensitivity and specificity in targeting
malignant melanoma (UACC-62) with an LC50 of 18nM (Figure 2.6).25 Cytotoxicity was seen in
a melanoma cell line, a renal cancer cell line (RXF 393 with an LC50 of 6.5μM), and a colon cancer
cell line (HCC-2998 with an LC50 of 6.5μM). Beyond this, however, cytotoxicity and neurotoxicity
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were negligible.25,27 In addition, in vivo murine studies were pursued using a hollow-fiber assay
which confirmed the bioactivity of palmerolide A. The in vivo hollow fiber assay was a model
developed by the NCI as an “intermediate assay” to assist in the prediction of which natural
products that showed bioactivity in vitro would also show positive results in xenograft studies.28
In addition, the NCI COMPARE algorithm identified palmerolide A as a vacuolar V-ATPase
inhibitor.29 This computational finding was confirmed via biochemical screening, establishing an
IC50 of 2nM.25 Further NCI studies revealed palmerolide A induces Hypoxia Induction Factor-1α
and autophagy.27

Figure 2.6. Bioactivity profile of palmerolide A on the National Cancer Institute’s Developmental
Therapeutics Program, which reveals the most potent activity against UACC-62 cell lines.
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There are several key structural features in palmerolide A. These functional groups include
(1) the C-7 hydroxyl group, (2) the C-10 hydroxyl group, (3) the C-11 carbamate group, and (4)
the secondary amide on the tail of the molecule (Figure 7). Based on the Structure-Activity
Relationship Studies done by Nicolaou, et. al in 2008, the chemical handles of the carbamate group
and isoprenoid moiety of the enamide tail are key in the biological activity of the molecule and
modification at these sites significantly alters bioactivity.30 In addition, while a modification at the
site of the C-10 hydroxyl group leads to a loss of bioactivity across all cell lines tested, when the
hydroxyl group associated with the C-7 carbon was modified, there was little effect noted on the
bioactivity profile.30 The nucleophilicity of the C-7 and C-10 hydroxyl groups is greater than that
of the C-11 carbamate and of the vinyl amide, which is important for future considerations of
analogue formation for drug development. Based on previous studies, the C-7 hydroxyl group
proved to be the more nucleophilic of the two hydroxyl groups during stereochemical
determination using Mosher’s method. Ester formation occurred at the C-7 hydroxyl after one
hour, while the diester formation occurred after 16 hours.31
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Figure 2.7. The structure and key chemical handles of palmerolide A: palmerolide A is a macrolide with
several key chemical handles. Based on SAR studies, the isoprenoid moiety, C-10 hydroxyl group, and
C-11 carbamate group are all vital for the bioactivity of the molecule. Modification at the C-7 hydroxyl,
however, does not alter bioactivity.

2.4 RETROBIOSYNTHESIS OF PALMEROLIDE A
A retrobiosynthetic prediction was developed based on the structural architecture of
palmerolide A of the enzymatic domains that would be required to create the PKS-NRPS hybrid
product (Figure 2.8). The initial module would include a PKS portion with an acceptor of an
unusual starter unit, a valeric acid derivative. This would be delivered to an ACP for a single
elongation by a KS. Glycine incorporation would then ensue through NRPS modules of an
adenylation domain, with specificity for a glycine residue, and a condensation domain to catalyze
the nucleophilic attack of the free amine of the amino acid to the activated thioester bond of the
upstream carbonyl. Subsequently, PKS modules would predominate, leading to eleven cycles of
chain elongation to add twenty-two carbons to the contiguous carbon chain. To create the
architectural diversity of the hydrocarbon chain, the predicted co-linear tailoring enzymes would
result in varying degrees of oxidation, resulting in secondary alcohols, olefins, or fully reduced
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segments. Additionally, c-MTs were expected to install the pendent methyl groups on C-20 and
C-22 through enzymatic transfer of the methyl group from SAM. The C-10 hydroxyl group was
expected to result from a hydroxylase or through incorporation of a hydroxy-malonyl acid subunit.
The hydroxyl group is in the α-position and would not result from the reduction of the β-carbonyl.

Figure 2.8. Proposed retrobiosynthesis of palmerolide A. Backbone synthesis is a result of incorporation
of the starter unit, a glycine residue, and acetate subunits (C1 indicated by black squares). Structural
features from trans-acting tailoring enzymes (green circles) utilize additional substrates: methyl transfers
from SAM (purple circles), installation of C-25 methyl from acetate (blue circles) via HCS cassette, and
carbamoyl transfer to the secondary alcohol on C-11. The α-hydroxy group on C-10 from incorporation
of hydroxy-malonyl acid or a trans-acting hydroxylase.

Additionally, other trans-acting modules were predicted to further enhance the unique
features seen in palmerolide A. The pendant methyl on C-17 is a β-branch and, therefore, not
derived from methyl transfer by a c-MT, which installs the methyl on α-carbons. Instead, an
HMGCS cassette which is comprised of an HCS module, a free KS, and at least one enoyl-CoA
hydratase (ECH) module, would be enzymatically responsible for this feature. This biosynthetic
cassette has precedence in other bacterial PKS systems such as those that biosynthesize the
jamaicamides, bryostatins, curacin A, oocydin, pederin, and psymberin.32–36 Additionally, as seen
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in the kalimantacins, a CT would install the carbamate group on C-11.37 A thioesterase was
predicted to be responsible for the cyclization and release of the compound from the megaenzyme.

2.5 OVERVIEW OF ORGANIZATION OF PAL BIOSYNTHETIC GENE CLUSTER
Analysis of the pal BGC occurred over two phases. Initially, a high throughput
metagenome sequence from two different Synoicum adareanum samples was generated using 454
and Ion Torrent Proton technologies. This resulted in 86,387 contigs of nearly 145 MB of
assembled sequence data. These metagenome contigs were then submitted to the antiSMASH
pipeline to identify putative biosynthetic gene clusters.38 The metagenome was rich in BGCs (see
Chapter III for details). There was one BGC in particular with great congruence with the
retrobiosynthetic strategy. The annotation revealed a hybrid trans-AT PKS-NRPS system, many
of the cis-acting tailoring enzymes that were expected, an HMGCS cassette, and a CT. With a
candidate trans-AT type I PKS BGC, the retrobiosynthetic framework was used to delineate the
biosynthetic pathway for Pal A, confirming this BGC as the putative pal biosynthetic gene cluster
(Figure 2.9).
The second phase in metagenome sequencing employed Pac Bio long read technology to
facilitate sequence assembly. Two additional environmental S. adareanum samples were used for
this effort. The data was combined with the first assembly, which resulted in 4,215 contigs
amounting to nearly 98 MB of sequence. Metagenome binning and manual assembly resulted in a
nearly complete metagenome assembled genome (MAG) with five variants of the pal BGC. The
five pal BGC variants were delineated following annotation by antiSMASH and key differences
were noted. Structural predictions were made based on these differences.
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Figure 2.9. The proposed BGC for palmerolide A, showing the hybrid PKS-NRPS system. KS: ketosynthase domain, C: condensation domain,
gly: adenylation domain for glycine incorporation, DH: dehydratase domain, cMT: carbon methyl transferase domain, KR: ketoreductase domain,
E: epimerization domain, ECH: enoyl-CoA hydratase, LLM: luciferase-like monooxygenase, HCS: hydroxymethylglutaryl-CoA synthase; ER:
enoyl reductase; CT: carbamoyl transferase; AT: acyl transferase; blue arrows indicate biosynthetic genes, white arrows reflect a lack of
annotation, the green arrow reflects gene for Band7.
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Figure 2.9. The proposed BGC for palmerolide A (continued).
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2.5.1

SIZE
The BGC is a hybrid type I trans-AT PKS-NRPS system that is comprised of twenty-three

genes and nineteen modules in a single operon of 74,655 bases. Based on the assimilation of
annotations from antiSMASH integrated with protein family homology analysis, active site and
motif identification, and conserved domain searches, the roughly seventy-five kilobase BGC
supports the hypothesis that it is responsible for palmerolide A production.
2.5.2

MODULAR ARRANGEMENT
The modular arrangement reflects what is expected from the retrobiosynthetic prediction.

The initial genes are PKS in nature, followed by an NRPS module, and then a long stretch of PKS.
The AT modules and trans-acting modules are then encoded.

2.6 DELINEATION OF PAL BIOSYNTHETIC GENE CLUSTER
2.6.1

STARTER UNIT
There are two ATs encoded within the BGC, after the core biosynthetic genes (Figure 2.9).

The number of ATs in other trans-AT PKS-NRPS systems ranges from one to three (Figure 2.10)
and the pal BGC has two ATs, the first with consensus for malonyl-CoA selection. Both ATs
contain the necessary active site serine; however, the second of the encoded ATs (AT2) lacks
consensus specificity for malonyl-CoA subunit selection and likely has some degree of
promiscuity or relaxed substrate specificity allowing it to select for the atypical starter unit. As
seen in the cis-AT type I PKS system for avermectin, loading ATs can show relaxed substrate
specificity.39 Additionally, trans-acting systems tend to demonstrate affinity for an even wider
range of subunits than their cis-acting counterparts.40,41 This is what may influence the formation
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of some of the natural analogues in the palmerolide family, as described in detail below. Isovaleric
acid is a degradation product of leucine and is a byproduct of an HCS-mediated pathway, and
serves as a starter unit in the biosynthesis of both avermectin and myxothiazol.42 Isovaleric acid is
likely selected by AT2 (palF) as the starter unit for palmerolide A production.

Figure 2.10. The general architecture for BGCs in trans-AT type I PKS system varies. Typically, one
to three AT modules are seen. If multiple ATs are present, they are encoded adjacent to one another.
There is also variation regarding the relative arrangement of the ATs, core modules, and trans-acting
modules.

2.6.2

INITIAL POLYKETIDE MODULES
The 5’ end of the BGC contains the start of the core biosynthetic domains, which begin

with an ACP (Figure 2.9). The ACP-β is the acceptor of the starter unit. ACP-β domains include
GXNS conserved domains, rather than the GXDX seen in non-β-branching ACP, and are
associated with branched subunits or in HCS-mediated β-branch formation.43 One two-carbon
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elongation is enzymatically mediated by the first ketosynthase while the growing chain is tethered
to a non-β-branching ACP before incorporation of glycine. A tool known as the Trans-AT PKS
Polyketide Predictor (TransATor) can be used to help define the specificity of KS domains based
on phylogenetic analyses of fifty-four trans-AT type I PKS systems with 655 KS sequences.44 The
resulting clades can be referenced to help predict the KS specificity for the upstream unit.
Interestingly, this KS is associated with Clade_104 identified in transATor as accepting β-Omethylated subunit or a β-methylated subunit with a double bond. This demonstrates some
consistency with the KS receiving an α,β-olefin with a γ-methylation (Table 2.1).
Table 2.1. Phylogeny of KS modules from the pal BGC based on transATor. Prediction is for what
the given KS is likely to receive for the Claisen-like condensation from the upstream ACP.

predicted

Clade Clade specificity

e-value

score

KS_1

starter

104

β-O-Me or β-Me doublebond

1.10E-140

461.7

KS_2

gly_singlebond

96

various specificities (mainly α-Me) 5.00E-171

562.1

KS_3

doublebondwMe

2

α-Me shifted double bond or OH

3.20E-189

621.8

KS_4

doublebondwMe

2

α-Me shifted double bond or OH

6.50E-191

627

KS_5

secOH

53

β-D-OH

1.50E-192

633

KS_6

βcarb,βmeth
withdoublebond

2

α-Me shifted double bond or OH

9.70E-192

630

KS_7

doublebond

101

double bonds

4.20E-212

697.3

KS_8

singlebond

101

double bonds

4.40E-214

703.9

KS_9

secOH

104

β-O-Me or β-Me doublebond

9.50E-192

630

KS_10

doublebond

127

double bonds (E-config)

1.40E-209

689

KS_11

secOH

53

β-D-OH

8.90E-198

650

KS_12

singlebond

96

various specificities (mainly α-Me) 1.20E-197

649.8

KS_13

HCSCassette

79

starters or β-OH

117

55

6.30E-36

2.6.3

NONRIBOSOMAL PEPTIDE SYNTHETASE MODULES
Condensation and adenylation domains in the NRPS portion of pal BGC (module 2) are

responsible for the incorporation of a glycine residue, which results in nitrogen and a two-carbon
extension after decarboxylation (Figure 2.9). The elongating molecule is transferred to the next
carrier protein and the polyketide modules, with subunits supplied by the first AT (AT1) in palE.
2.6.4

CONTIGUOUS POLYKETIDE CHAIN WITH MODIFICATIONS
Eleven rounds of elongation with malonyl subunits occur with different modifications to

create the contiguous twenty-four carbon chain (Figure 2.9). As would be expected, an ACP
domain precedes each KS. Module 3 (palB) contains an ACP, KS, DH, and cMT. The KS is
associated with transATor Clade_96, which contains KSs that accept a variety of preceding
monomers. The combination of domains leads to α,β-unsaturation as well as a methylation on the
expected α-carbon. The methylation is a result of enzymatic transfer from SAM by cMT. Module
4 (palB and beginning of palC) includes a KS, DH, KR, E, and cMT. This results in the formation
of the conjugated olefin and α-methylation that is observed. The E domain here is likely
responsible for the shift in conjugation on the macrolide tail to β,γ-positions. The KS associated
with module 4 falls within KS Clade_2, which accepts monomers with α-methylation and shifted
double bonds, consistent with the prediction.
Module 5 (palC) contains a KS, E, and KR, leading to reduction of the β-carbonyl to a
secondary alcohol. This serves as the substrate for later cyclization and release of the molecule
from the megaenzyme. This KS also falls within Clade_2, accepting upstream monomers with αmethylation and shifted double bonds. Interestingly, a domain was initially annotated as a
dehydratase at this location by antiSMASH; however, further investigation of the amino acid
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sequence was not consistent with a dehydratase, as it does not possess the hotdog fold that is
indicative of true dehydratases.45 Manual alignment reveals some homology to condensation
domains, pointing to the possibility that it may aid in the termination step. The KR is consistent
with an A- type KR, which does not possess the LDD motif, and results in reduction to an lconfigured hydroxyl group. The E domain may serve to set the stereochemistry of C-20.
Module 6 (palC) includes a KS and an ECH. This KS falls within Clade_53, associated
with KSs that receive B D-OH. The carbonyl group at C-17 serves as the substrate for the HCS
cassette of module 17. ECH domains belong to the crotonase family of enzymes and are directly
involved in decarboxylation and in shifts of α,β-double bonds to β,γ-double bonds. The ECH may
serve as an enzymatic beacon and act in concert with the KS, HCS, and two ECHs present within
the trans-acting cassette and double bond isomerization. The HCS cassette acts upon the βcarbonyl group to form the C-25 methyl group in the β-position through alkylation and
decarboxylation. Iron coordination with dioxy groups is key for the function of HCS. Siderophore
BGCs are noted in the metagenome and may represent the mechanism for acquiring iron.46 The
combination of a free KS and at least one ECH domain in conjunction with an HCS is seen in other
bacterial BGCs such as bryostatin 1, calyculin A, jamaicamide, mandelalide, phormidolide, and
psymberin.8,33,36,47–49
Module 7 starts with an ACP-β which would accept the monomer with β-branch formation
from module 6. Then a KS, DH, and KR are present. The KS falls within Clade_2, which includes
KSs that accept α-methylations and shifted double bonds, though here the preceding monomer
would include a β,γ-olefin with β-methylation instead of the predicted α-methylation. The KR in
this module is associated with the LDD motif and results in reduction to a d-hydroxyl group, which
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then undergoes enzymatic dehydration by the DH to form a trans-olefin seen between C-14 and
C-15.
Module 8 includes a KS, DH, and KR. As expected, the KS is in Clade_101 which includes
KSs that accept an upstream double bond. The combination of the KR and DH should result in
olefin formation; however, this segment of the hydrocarbon chain is fully saturated. There is no
cis-acting ER encoded. Additionally, the next KS falls within the same clade, Clade_101, and is
expected to accept a polyketide monomer that includes a double bond, though those that receive
fully saturated upstream subunits also fall within this clade. The KR contains the LDD motif,
which in conjunction with the DH, would again produce a trans-olefin. In order for the molecule
to cyclize without significant conformational strain, it is likely that full reduction of this segment
occurs prior to termination. A trans-acting ER is expected to reduce this segment of the molecule
while the growing chain is still tethered to the megaenzyme. Several enzymes within the
metagenome are candidates for such activity. There are several examples of other trans-acting ER
domains, including OocU in oocydin, SorN in sorangicin, and MndM in mandelalide.50–52
Module 9 includes a KS, a luciferase-like monooxygenase (LLM), and a KR. The KR
contains the LDD motif of a B- type KR and results in reduction to a d-hydroxyl group. This
hydroxyl group is the substrate for the action of the carbamoyl transferase, which enzymatically
installs the carbamate group on C-11. The stereochemical prediction is reversed in this location
and perhaps an enzymatic SN2-type reaction is responsible for carbamate transfer. The carbamoyl
transferase is known in other BGC systems to enhance natural analogue formation, which is also
hypothesized in the family of palmerolides, as discussed below. 53–55
There is no evidence of hydroxy-malonate incorporation to explain the α-hydroxylation at
C-10. Instead, it is proposed that the LLM annotated within module 9 serves as a flavin-dependent
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monooxygenase α-hydroxylase, leading to the placement of the secondary alcohol on C-10. Based
on the structure activity relationship studies, it is this alcohol that is key in the V-ATPase
bioactivity of palmerolide A.30 Corallopyronin, oocydin, and phormidolide all contain homologous
domains that are proposed to serve as α-hydroxylases.35,49,56,57 The pal BGC contains both the Lux
R family transcriptional regulator and the DNA-binding response regulator.
Luciferase reactions, as seen in bioluminescence, are oxidative reactions that occur as the
substrate enters an electronically excited state before emitting energy as visible light and returning
to ground state.58 Flavin-dependent monooxygenases are key in luciferase reactions and involve
activation of molecular oxygen by reduced flavin, leading to oxygen incorporation into a molecule
through Beyer-Villiger oxidations, epoxidations, or hydroxylations.59,60 Bacterial luciferases can
accept atypical substrates such as seen in Vibrio harveyi, which converts a long-chain aliphatic
aldehyde into a long chain aliphatic carboxylic acid and light in its luciferase reaction.58 Some
BGCs, such as that for thailandamide, are known to have luciferase genes that act in quorum
sensing. 61
For functional classification of proteins, Pfam and TIGRFAM classifications are used.
Based on Hidden Markov models (HMMs), these tools generate multiple sequence alignments that
can be used for homology-based searches.62,63 Within the Pfam00296 which includes bacterial
LLM, there is a TIGR subfamily 04020 that includes LLMs involved in natural product
biosynthesis.64 Alignment of the LLMs from multiple PKS systems with the pal LLM shows
significant homology (Figure 2.11). The location of the LLM within the pal cluster is consistent
with the α-hydroxylation at C-10. There is no evidence of hydroxy-malonate incorporation to
otherwise explain this structural feature.
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Figure 2.11. Alignment of the proposed palmerolide hydroxylase LLM with the sequence of LLMs
from select BGCs as well as sequences from the Pfam seed for LLMs used to train the HMM.

LLMs that are associated with BGCs may not always serve as true luciferases, but instead
promote oxidations on peptides and polyketides without correlating bioluminescence.65,66 For
instance, there is no known bioluminescence arising from Candidatus Entotheonella; however,
there is an overrepresentation of LLMs in the BGCs.64 LLMs are seen in several type-I PKS
systems and are proposed to serve as hydroxylases in the biosynthesis of onnamide and
nazumamide, and in BGCs from Candidatus Endotheonella.64 Chain shortening reactions through
α-hydroxylation and Baeyer-Villiger-type oxidation are seen in calyculin (LLM of CalD) and
mandelalide (LLM of MndB).8,67 The α-hydroxylation of C-14 in oocydin by either OocK or
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OocM flavin-dependent monooxygenases is key in cyclization of the molecule. These genes are
co-linear with the core biosynthetic genes and are believed to act while the substrate is still bound
to the PKS megaenzyme. 51 The LLM in phormidolide is thought to install a hydroxy group at C16, which then is hypothesized to participate in the cyclization reaction of the macrolide through
a Michael addition with enzymatic assistance from a pyran synthase.49 This hydroxylase activity
is what is proposed for the LLM seen in module 9. The presence of bioluminescence within the
organisms is not established, as the producing organism has yet to be cultured and the BGC has
yet to be expressed. The potential role of the LLM in bioluminescence and quorum sensing may
be explored in future experiments.
Module 10 includes a KS, DH, and KR. The ketosynthase prediction is not consistent with
the upstream monomer, as it is expected based on its presence within Clade_104 to receive an
upstream subunit with a β-O-methylation or β-methylation and double bond. The KR, on the other
hand, is consistent with the predictions, and based on the presence of the LDD motif would
catalyze reduction of the β-carbonyl to a d-hydroxyl group. Following dehydration by the DH, this
would be expected to form a trans-olefin, which is what is observed.
Module 11 includes a KS and KR. The ketosynthase falls within Clade_127, which
includes KSs that accept E-configured (trans) double bonds, which is consistent with palmerolide
A. Additionally, the type B KR contains the LDD motif, which is expected to reduce the β-carbonyl
to a d-hydroxyl group.
The segment of the molecule that results from module 12 is fully reduced; however, there
is no ER in-line with the core biosynthetic genes. It is predicted that a trans-ER is responsible,
similar to what is predicted for module 8.
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The final elongating module, module 13, includes KS, DH, and KR domains resulting in
elongation and α,β-olefin formation. The KS falls within Clade_96, which contains KSs possessing
various specificities, and does not have a clear prediction for the structure of upstream monomer.
The prediction based on the active site of the type B KR domain, which includes the LDD motif,
is consistent with the formation of a d-hydroxy group, which then forms a trans-olefin after
dehydration by the DH.
2.6.5

CONDENSATION TERMINATION DOMAIN
Typically, thioesterase domains are responsible for cleavage of the thiol bond through

hydroloysis, leading to either linear release or cyclization and release of polyketides from the
megaenzyme; however, no thioesterase domain was identified in the pal BGC. Examples of noncanonical termination domains include non-elongating ketosynthase domains (KS0), condensation
domains, condensation-reductase domains, and other α,β-hydrolases. In the case of the pal BGC,
the final module in the core biosynthetic genes includes a truncated portion of an NRPS
condensation domain (Figure 2.9). This non-canonical termination domain is not without
precedent in PKS-NRPS and PKS systems, as basiliskamide, and phormidolide include
condensation domains which result in cyclization via lactone formation and release of the
compound from the megaenzyme.49,68 The alignment for this truncated condensation domain in
module 14 is convincing for this termination step and much of the HHXXDDG motif is conserved
(Figure 2.12). Though the first histidine of the motif is not present, it is the second histidine which
serves as the catalytic histidine for the condensation reaction.
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Figure 2.12. Alignment of the proposed termination condensation domain of the pal BGC with that
of basiliskamide, and phormidolide as well as the HMM seed sequences for PF00668 (condensation
domains); Conservation of the HXXDG of the HHXXXDG motif can be seen.

2.6.6

TRANS-ACTING MODULES
In the biosynthesis of Pal A, a carbamoyl transferase is encoded in module 18 (palX) which

is likely responsible for the carbamate installation seen on C-11 (Figure 2.9). The β-carbonyl at
this site is reduced by a KR to a hydroxyl group, which then serves as the substrate for carbamate
transfer. Removal of the carbamate group in structure activity relationship studies of Pal A
performed by K. C. Nicolaou’s group demonstrated about a five-fold decrease in bioactivity across
multiple cell lines.30 There are other BGC with CT modules, such as concanamycin A, another V63

ATPase inhibitor. In the case of concanamycin A, the carbamate is transferred to a pendant sugar
rather than to the polyketide backbone.53 There are also other BGCs that encode for carbamoyl
transferase, including polyoxin (PolO) and saxitoxin analogs (SxtI).53–55
2.6.7

ADDITIONAL DOMAINS
A glycosyl transferase (PalV) and a lactone oxidase (PalI) are two trans-acting modules in

the pal BGC that have been associated with glycosylation of secondary metabolites (Figure 2.9).
Two glycosyl transferases (OleI and OleD) are encoded in the genome of oleandomycin-producing
Streptomyces antibioticus and have been determined to play a role in self-resistance from the
macrolide natural product.69 There are significant differences in the substrate specificity of these
two glycosyl transferases; OleI is specific for oleandomycin, while OleD has relaxed substrate
specificity and has the ability to glycosylate all macrolides tested.69,70 It is proposed that
glycosylation results in intracellular inactivation, which confers resistance to the secondary
metabolite that the organism makes in the case of OleI and serves as a mechanism for resistance
to non-natively produced macrolides.69 A glycosidase is secreted by S. antibioticus, which would
serve to cleave the pro-drug into its active form once outside of the producer.69,71 Streptomyces
lividans and Streptomyces ambofaciens have similar macrolide inactivation mechanisms for
hydroxylated polyketides.72,73 The D-arabinono-1,4-lactone oxidase (mod) seen in the pal BGC is
a FAD-dependent oxidoreductase that likely further modifies the glycosyl group. The system of
reversible inactivation provides a competitive and evolutionary advantage for the producer and is
proposed for the pal BGC.

64

2.7 OTHER MEMBERS OF THE PALMEROLIDE FAMILY EXPLAINED
There are 5 variants of the pal BGC within the Candidatus Synoicohabitans palmerolidicus
metagenome-assembled genome (MAG). Two are identical and represent the palmerolide A BGC
and variants thereof (Figure 2.13). Much of the structural diversity seen in the family of
palmerolides (Figure 2.14) can be explained by (1) differences due to starter unit promiscuity, (2)
differences in the core modules of the multiple pal BGCs, and (3) differences in the sites of action
for the trans-acting tailoring enzymes.

Figure 2.13. The five variants of the pal BGC help explain the structural diversity seen in the family
of palmerolides. pal BGC_I is responsible for palmerolide A production. pal BGC_II and pal BGC_III
are variants with an additional KS module. Areas in grey on pal BGC_IV and pal BGC_V depict
portions of the gene cluster that are missing compared to what is present in pal BGC_I.
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Figure 2.14. The family of palmerolides. Many of the key structural differences can be explained by
starter unit promiscuity, differences in the core biosynthetic modules, and differences in the site of
action of trans-acting enzymes.
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2.7.1

VARIANTS FROM THE PALMEROLIDE A BIOSYNTHETIC GENE CLUSTER (PAL BGC_I)

2.7.1.1 PALMEROLIDE B
Palmerolide B (Pal B) shares the scaffold of Pal A; however, the structural features due to
trans-acting modules create the architectural differences seen in this analogue. The placement of
the carbamate group by the CT occurs on the C-7 hydroxyl, rather than the C-11 hydroxyl.
Additionally, the C-11 hydroxyl group is modified by sulfonation, likely through a trans-acting
sulfatase, which likely post-translationally modifies the molecule. Though there are no sulfatases
present within the pal BGC, there are several with homology to known sulfatases present in the
metagenome-assembled genome (MAG), including P51691, P15289, O69787, Q8ZQJ2 from the
Uniprot database. Additionally, the hydroxylation which occurs in the α-position of C-10 in Pal A
is instead found in the C-8 position, with olefin placement between C-9 and C-10. This
hydroxylation is likely due to a trans-acting hydroxylase or the action of the LLM catalyzing the
hydroxylation in a non-colinear fashion.
2.7.1.2 PALMEROLIDE C
Palmerolide C (Pal C) is another natural analogue that shares the same scaffold as Pal A
and Pal B with structural differences that can be attributed to the tailoring enzymes. The
hydroxylation on C-8, again, is likely due to a trans-acting hydroxylase or due to non-colinear
action of the LLM. Subsequently, the CT domain acts on this hydroxy group in the α-position,
rather than in the C-11 position. A Δ6,7 olefin, rather than the Δ8,9 olefin in Pal A is observed.
2.7.1.3 PALMEROLIDE F
The macrolide tail in palmerolide F (Pal F) is different than that of Pal A. This is likely due
to the relaxed substrate specificity for the AT that selects the starter unit. Another variant of valeric
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acid is incorporated leading to a terminal alkene, rather than the internal alkene present in Pal A.
This enzymatic promiscuity is supported by the lack of consensus in the predictive annotations
regarding AT2 between PKS sig and Minowa, tools embedded within antiSMASH that help predict
monomeric specificity of ATs.
2.7.1.4 PALMEROLIDE G
Palmerolide G (Pal G) differs from Pal A at the site of the Δ21,22 olefin which has a cisconformation rather than the trans-olefin observed in Pal A. Since the conformational outcome of
this olefin is not determined solely by whether the KR in module 4 contains the LDD motif, but
rather by an epimerase, leading to a olefinic shift to a β,γ-position. The genomic difference at this
site is proposed; however, it has yet to be identified in the samples that have been sequenced. It is
likely that larger sequencing efforts could lead to further insights on differences in the module
leading to the structural difference seen in palmerolide G. The samples are often batch processed
for secondary metabolite evaluation and the isolated compound could have been a result of a BGC
with a slight variant to that sampled.
2.7.2

CLUSTER WITH ADDITIONAL KS ELONGATION (PAL BGC_II AND PAL BGC_III)
There are two identical clusters within the MAG that show an additional module with ACPs

and a KS domain.
2.7.2.1 PALMEROLIDE D
Palmerolide D (Pal D) preserves the structural features of Pal A, but has an additional 2carbon unit on the macrolide tail, distal to the glycine incorporation. Biosynthetically, it would be
expected to arise from one extra polyketide elongation step with a methylated monomeric subunit.
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The trans-acting enzymes function at the same location in the molecule, and the stereochemistry
is maintained when compared to the structure of Pal A.
2.7.2.2 PALMEROLIDE H
The combined differences seen in Pal B and in Pal D are reflected in the structure of
palmerolide H (Pal H). In addition to the additional PKS elongation step and additional 3-carbon
addition to the macrolide tail, a terminal olefin is observed. The site of action of the trans-acting
enzymes also differs from Pal A. Carbamate transfer occurs on the C-7 hydroxyl group, while
sulfonation occurs on C-11. There is a hydroxyl group placed on C-8, rather than C-10, likely
again arising from non-colinear activity of the LLM or through trans-hydroxylation. There is no
genomic evidence for incorporation of hydroxy-malonate as an alternative.
2.7.3

UNKNOWN PAL (PAL BGC_IV)
An additional pal variant has been identified in the MAG; however, a compound that

correlates with the cluster has not been isolated. The cluster is missing the pre-NRPS PKS
modules. Though palmerolide E has a truncated tail, there is an unexplained carbon when
compared to the proposed biosynthesis from this pal variant, even if hydrolysis of the amide
occurs.
2.7.4

TRUNCATED CLUSTER (PAL BGC_V)
Another pal BGC variant is present in the MAG; however, it only contains enough KS

domains to biosynthesize a ten-carbon structure. Interestingly, the trans-acting tailoring enzymes
are all present downstream of the core biosynthetic genes; however, based on the encoded PKS
portion, the substrates for activity would be missing if the BGC were to biosynthesize this
molecule. No compound has been identified that would correlate with this BGC.
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2.8 DISCUSSION AND CONCLUSIONS
2.8.1

INTERESTING FINDINGS
This is the first time that a BGC from an Antarctic organism has been discovered and

delineated. The pal BGC is a hybrid trans-AT type I PKS-NRPS that produces a macrolide with
potent activity against malignant melanoma cell lines. There are five copies with some variation
seen that can be linked to the architectural differences seen in the family of palmerolides.
Additionally, unique domains are present in the pal BGC, including an HCS to biosynthesize a
pendent carbon, a CT, and an LLM. The terminal domain is a non-canonical condensation domain
that cyclizes and releases the molecule from the megaenzyme. Delineation of the BGC not only
adds to the growing knowledge on secondary metabolite biosynthesis, but also opens up
biotechnological prospects to enhance drug development opportunities of palmerolide A.
2.8.2 FUTURE DIRECTIONS IN THE FIELD
The exploration of biosynthetic potential through genomics represents a burgeoning area for
the field of natural products. Many challenges exist in our attempts to identify novel natural
products from microbial sources. The vast majority of associated and symbiotic microbes have not
been cultured. In addition, the secondary metabolites obtained under standard culture techniques
are a small proportion of what is represented by BGCs that have been discovered through microbial
genomic sequencing strategies. Eliciting the cryptic, or silent, BGCs could be fruitful in
uncovering novel natural products. Strategies to unmask BGCs include One Strain – Many
Compounds (OSMAC) approaches, introducing chemical or thermal stressors, co-cultivation,
ribosomal engineering, introduction of artificial gene promotors, deletion of gene suppressors, and
addition of epigenetic modifiers.74 The OSMAC approach promotes production of different
secondary metabolite profile of a single microbial strain will when grown under different
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conditions, as seen in the initial studies on six microorganisms: Aspergillus ochraceus,
Sphaeropsidales sp., and 4 strains of Streptomyces sp.75 External cues can be used to induce
bacterial stress and therefore promote an increase in secondary metabolite production. These cues
can include ethanol, heat, various inhibitors, and even low-dose antibiotics to create a state of
cellular shock. Co-culture techniques have been successful in isolating novel natural products in
systems with fungi, bacteria, and a combination of the two. Utilization of regulatory proteins used
to promote the transcription of silent or cryptic BGCs has also been used to increase secondary
metabolite production.74
Successful cultivation, however, is not required for downstream research. After BGCs are
identified, heterologous expression in an optimized host can be used to produce the natural product
from an otherwise silent or cryptic BGC or from an unculturable host. After a genome is
assembled, putative BGCs can be annotated by searching the genomic information against
databases with known biosynthetic motifs and genomic signatures.15 Metagenomic strategies are
being used for not only the identification of novel compounds, but also for the identification of
new microorganisms. In the face of unculturable microbial producers, target compounds often
cannot be isolated in yields adequate for comprehensive bioassay and structure elucidation work,
let alone for drug development.76 Success using heterologous gene expression has been seen with
readily cultivatable microbial hosts such as Saccharomyces cerevisae, Streptomyces coelicolor,
Streptomyces venezuelae, Synechococcus elongatus, and Escherichia coli.77–80 For example, S.
cerevisae was used for heterologous expression of a seven-step biosynthetic process of the
flavanone naringenin, and the biosynthetic process to produce kaempferol. In this case, the genes
of interest were cloned and then amplified in E. coli to produce eYAC molecules. This genetic
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information was then transformed into yeast via spheroplasting with successful expression of the
flavones in the S. cerevisae, as confirmed by UV-spectroscopy and NMR.78
Combinatorial biosynthesis often takes advantage of the co-linearity which exists within PKS
by harnessing the modularity of the system to engineer completely novel or derivatized
compounds. Since the enzymatic activity of a specific domain is directly linked to the genomic
information that encodes each enzymatic site of each module, alterations in the domain assembly
through genomic manipulation via deletion, substitution, or addition, can change the structure of
the final compound.15 This strategy is most effective for the type I PKS systems due to the noniterative nature of the megaenzymes. Type II and type III PKS systems present a combinatorial
challenge as the iteratively acting enzymes are fewer in number, less predictable, and have a
greater impact on the final product.15
Synthetic biology can currently intervene at three main steps in the biosynthetic process to
alter polyketide synthesis: “core scaffold” biosynthesis, the tailoring process that occurs during
chain elongation, and post-translational modifications.15 Khosla and colleagues identified the
mechanism that leads to unidirectional movement of the growing polyketide chain and
reengineered the ACP-KS interface of a module in the 6-deoxyerthronolide B synthase to create
an iterative catalysis of two elongation steps at a single PKS module.81 A bioengineering technique
identifying a site for enzymatic chlorination in a polyketide chain was described by Moore and
colleagues. Utilizing this halogenation technique could potentiate bioactivity in bioengineered
polyketides, as halogenation often correlates with a higher bioavailability.82 In addition, preexisting polyspecificity of the enzymes can be exploited to introduce rare or new starter units,
thereby altering chemical structure substantially. For example, PikAVA, a pikromycin synthase
found in S. venezuelae, was found to have polyspecificity that included substrates not readily
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available in the producer with subsequent studies showing high levels of incorporation of the
experimentally-introduced non-native malonyl-CoA derivatives.83
Enzymatic tailoring domains further enhance diversity of polyketide synthase products. A
number of modifications to induce hydroxylation, epoxidation, alkylation, desaturation,
transamination, and glycosylation have been bioengineered to modify natural products.15 These
strategies can include the addition of key enzymes for adjustments in the polyketide backbone or
can be additional modules that add specific moieties that improve a specific activity profile.
Glycosyl transferases often display a degree of promiscuity, accepting a variety of non-native
substrates. For example, the type II PKS systems responsible for the production of anthracyclines
results in both aglycone structures and glycosylated compounds. The glycosylated compounds
tend to have an improved anti-cancer effect.84 There is also a correlation of glycosylation and
subsequent modifications in the sugar with reduction in toxicity, as seen in epirubicin as compared
to doxorubicin.85 This concept could be utilized to tune the bioactivity of polyketides, as glycosyl
transferases can be inserted into the BGCs and the desired sugar subunits can be added as substrates
to increase the likelihood of incorporation, potentially modulating bioactivity and toxicity.15
Though methods of combinatory biosynthesis and synthetic biology remain a promising source of
novel polyketides, the realization of this method in scientific practice requires addressing many of
the challenges inherent with understanding complex systems.

2.9 EXPERIMENTAL METHODS
A metagenomic sequencing effort led by Dr. Alison Murray (DRI) in collaboration with Dr.
Patrick Chain and his group at Los Alamos National Laboratory (LANL) was employed to access
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the genomic content of the Synoicum adareanum microbiome. The details of the procedure and
results were being written concurrently with this dissertation (Murray et al. in preparation).46
Briefly, the first step in data analyzed in this chapter was the result of metagenome sequencing of
two Antarctic S. adareanum samples (Nor-2C-2007 and Nor2a-2007) in which the microorganisms
were separated from host tissue using a mortar-pestle homogenization protocol followed by
differential centrifugation to partition the larger host debris from the microbial cells. Two different
high throughput DNA sequencing technologies were employed (454 and Ion Proton). The
sequence data was assembled at LANL independently using Newbler86 and SPAdes87 then the
results were merged (MeGAmerge),88 resulting in 86,387 contigs with a maximum contig size
153,680 and total contig size 144,953,904 bases. The assembled metagenome was annotated using
antiSMASH (v. 5.0).89 These annotations were integrated with information from protein family
homology analysis, conserved domain searches, active site and motif identification to delineate
the biosynthetic steps.
The second step in metagenome sequencing used two additional S. adareanum samples
(Bon1C-2011 and Del2B-2011) that were homogenized using a MiniLys (Bertin Instruments) and
the microbial component separated from host using a differential centrifugation procedure.90 Four
rounds of Pacific Biosciences Sequel Systems technology were used employing a circular
consensus sequence (CCS) protocol. The CCS reads were assembled on EDGE Bioinformatics
using wtdbg291 a fast and accurate long-read assembler. Finally, a combined assembly with contigs
from all three metagenome sequencing technologies (with 4 different ascidian samples) was
produced that contained 4,215 contigs and 97.97 MB DNA sequence ranging from a maximum
sequence length of 2.24 MB, and minimum of 239 bases.
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The assembled metagenome was annotated using antiSMASH (v. 5.0).89 These annotations
were integrated with information from protein family homology analysis, conserved domain
searches, active site and motif identification to delineate the biosynthetic steps. BGCs were
obtained from public NCBI databases for phormidolide, basiliskamide, oxazolamycin, and other
PKS systems. ClustalO alignment tool in the CLC Genome Workbench (Quiagen aarhau A/S v.
20.0.3 on Windows 10 10.0 amd64 with Java version 11.0.6) was used for alignments of enzymatic
domains with the HMM PFam Seed obtained from EMBL-EBI and the amino acid sequence of
from the other PKS BGCs.
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CHAPTER THREE:
COMMUNITY STRUCTURE OF THE SYNOICUM ADAREANUM MICROBIOME

3.1 INTRODUCTION TO MICROBIOMES
3.1.1

THE IMPORTANCE OF MICROBIOMES
The world is teeming with microbial life. It is estimated that there are one-hundred million

times the bacteria in the ocean than stars in the known universe.1 Technologies to analyze the
composition and importance of the host-associated microbial communities known as the
“microbiome” include cultivation-based studies and integrate multiple ‘omics subfields: 16S
rRNA gene sequencing, metagenomics, metatranscriptomics, metaproteomics, and metabolomics.
The use of marker genes, such as sequencing of the 16S subunit of rRNA allows for evaluation of
phylogenic composition and diversity through identification of highly variable regions in
conjunction with highly conserved ribosomal genes. This results in data regarding the occurrences
of Operational Taxonomic Units (OTUs) or Amplicon Sequence Variants (ASVs). Though
efficient and relatively cost effective, this technology has low resolution and is known to introduce
bias due to PCR amplification. This results in relative occurrence of OTUs or ASVs from sample
to sample, but absolute occurrence is more difficult to ascertain. Mutli-omic techniques allow for
analysis of marine microbial communities, which exist in a number of states, free-living or host89

associated in addition to as consortia within the water column, the sediment, or within complex
microbial communities of animals. When paired with metagenomics, which involves the
sequencing of the total DNA from the microbiota, and with metabolomics, which includes
profiling of specific metabolite differences usually through mass spectrometry, 16S rRNA gene
sequencing is a powerful tool for analyzing the rich, synergistic and symbiotic relationships that
exist in the marine environment to enhance host and microbial survival.2
3.1.2

MICROBIOMES OF MARINE INVERTEBRATES
Host-associations and symbiotic relationships of microbes and marine invertebrates result

in rich communities with interplay involving both primary and secondary metabolism. These
interactions include mechanisms for environmental adaptation, carbon and other nutrient cycling,
and production of compounds to deter predation.3 It has been demonstrated in some coral species
that the holobiont is comprised of a distinct core membership that is resident, redundant, and
persistent through most of the invertebrate samples as well as a transient set of microbes that is
environmentally responsive and dynamic in nature.4 The microbiomes of sponges, on the other
hand, tend to express even greater diversity and variability.5
It is estimated that as much as a tenth of some bacterial genomes are dedicated to genes for
secondary metabolite production, as seen in the Actinobacteria Salinispora arenicola.6 As
symbiotic relationships become obligate, genome streamlining is observed with a shedding of the
genes no longer required outside of the symbiotic relationship. In the marine environment, this is
seen in the genomes of the microbial producers of some cyanobactins, the patellazoles, and the
mandelalides.7–9 Host-associated microbes are sometime the source of secondary metabolites
previously ascribed to the host invertebrate; however, compound attribution is not always
straightforward and can result from biosynthesis by the host, a collaborative biosynthetic process
90

between the host and the microbial community, production by multiple microbial strains, and
acquisition through diet.10 Symbiotic relationships are not always easy to define, though evidence
of defensive mutualism is increasingly demonstrated in host-microbe associations where
secondary metabolites are translocated to host tissues.
3.1.3

SYMBIOSIS IN ASCIDIANS AND ASCIDIAN NATURAL PRODUCTS LINKED TO MICROBIOME
Microbial chemical symbiosis has been associated with key mechanisms to enhance

ascidian survival as seen in examples for antipredation, protection against ultraviolet radiation with
mycosporine-like amino acids, and antifouling agents.11 Some compounds that are defensive in
nature have been ascribed to ascidians, as seen in the tambjamine alkaloids from Ataposoa sp
(Figure 3.1).12,13 In field studies, the tambjamines, which have also been isolated from bryozoa
and as sequestered nudibranch compounds, proved effective as an ichthyodeterrent against
carnivorous fish.12 These compounds, which contain a bipyrrole core scaffold, have demonstrated
a wide range of bioactivity beyond feeding deterrents, including as antifouling agents, antitumor
agents, antifungals, antimalarials, and antimicrobials.14–16 A more recent hypothesis is that they
are microbially produced secondary metabolites, and to date, at least three microbial producers of
tambjamines have been identified. The terrestrial Streptomyces sp. BA 18591 was identified as the
producer of BE-18591 and marine host-associated Proteobacteria Pseudoalteromonas tunicata as
the producer of tambjamine YPI.17,18 The biosynthetic gene cluster (BGC) for tambjamine YPI has
been identified and delineated.19 In 2019, tambjamine MYP1, a macrocyclic natural product with
the conserved methoxy-bipyrrole core, was isolated from the marine Proteobacteria
Pseudoalteromonas citrea (Figure 3.1).20 Though tambjamines C, D, and F have yet to be
associated with a microbial producer, the biosynthetic machinery for production of the core
tambjamine scaffold is encoded in microbial genomes.
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Figure 3.1. Production of tambajines C, D, and F have been ascribed to invertebrate animals; however,
at least three microbial producers have been identified in the biosynthesis of other compounds in the
tambajine family.

The patellazoles are a family of cytotoxic secondary metabolites isolated from the ascidian
Lissoclinum patella (Figure 3.2). The ascidian has a rich microbiome that includes several
microbes with notable biosynthetic potential, including the cyanobacterium Prochloron didemni.21
The Prochloron didemni cyanobacterium provides much of the required carbon requirement of the
ascidian through photosynthesis and play a role in nitrogen recycling in light-rich, nutrient-poor
tropical waters.22–24 Not only are they key in primary metabolism, but they also are producers of
important secondary metabolites, the cyanobactins, which are ribosomally synthesized and posttranslationally modified peptides (RiPPs).9 Interestingly, genomic evidence has not definitively
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demonstrated co-speciation of L. patella and P. didemni; however, there is a distinct correlation
between ascidian phylogeny and the cyanobactins present within the animal suggesting persistence
of symbiosis across samples based on secondary metabolite production.25 Another member of the
microbiome, Candidatus Endolissoclinum faulkneri, was identified as the microbial symbiont
responsible for the biosynthesis of the patellazoles.8 The microbial producer was discovered by
evaluation of the metagenomes of the zooids of L. patella colonies that were associated with
presence of the patellazoles, as the samples with the secondary metabolites present appear to be
sporadic in nature. This resulted in the identification of an 86 Kbp trans-AT PKS pathway that
was consistent with biosynthesis of the patellazoles.8
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Figure 3.2. The patellazoles are produced by Candidatus Endolissoclinum faulkneri, a microbial
symbiont of the ascidian Lissoclinum patella.
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Additionally, the tetrahydroisoquinoline alkaloid ecteinascidin (ET-743, Yondelis,
Trabectedin), is a clinically approved chemotherapeutic agent that was initially isolated from
Ecteinascidia turbinata, a Caribbean mangrove colonial tunicate (Figure 3.3). The compound has
been approved in the United States and in the European Union for advanced soft-tissue sarcoma
treatment and has been classified as an orphan medicine for treatment in rare diseases.26 There are
clinical trials underway to expand the breadth of treatment to include prostate, breast, and other
cancers.26,27 Though it was suspected that the compound was microbially produced and multiple
efforts for identification of the putative BGC were attempted, it was not until 2015 after an
extensive and successful metagenomic effort that the complete genome of the ET-743 producing
bacterial endosymbiont, Candidatus Endoecteinascidia frumentensis, was described.28,29 The
producer was consistently identified in the microbiome of samples collected. Genome reduction
and low G+C content is evident in the metagenome-assembled genome (MAG), pointing to the
obligate endosymbiotic relationship of producer with host.29 This is a powerful example of how a
member of the core microbiome, living in a symbiotic milieu, can provide a compound that confers
protection to the host and can also prove to be a potent pharmaceutical agent against human
disease.
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Figure 3.3. Esteinascidia turbinata (left), a Caribbean ascidian from which ecteinascidin (right) was
isolated; the compound was later found to originate from a symbiotic microbial producer. Photo of
Esteinascidia turbinata by Bill J. Baker. Used with permission.

3.1.4

MICROBIAL COMMUNITIES IN THE WATER COLUMN
Data suggest that core microbiomes are host-specific and are not simply a reflection of the

surrounding water column and sediments, though seeding of bacteria may occur through flow of
the microbes via ocean currents through the water column.3,30 Therefore, when considering the
holobiont, microbial species from the water column are more likely to represent ephemeral
associations or dietary intake of the invertebrate than integral members of the community structure.
It is interesting to note that the biogeographical distribution of specific bacterial communities in
the water column is distinct. The phylogenetic diversity of bacterioplankton in the water columns
of the world’s oceans have been evaluated through the ribosomal ribonucleic acid (rRNA)
sequencing across latitudes, depths, and seasons.31 Based on work done by Alison Murray and her
collaborators, the data from polar environments have been compared to datasets from lower
latitudes, and though the bacterial communities in the water column from the polar regions had
more similarities than those of the mid-latitude waters, samples from the Arctic and Antarctic were
distinct from one another, with 78% of the OTUs from the Southern Ocean determined to be
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exclusive to that environment.31 Microbes are thought to have less biogeographical confinement
due to dispersal capacities based on distance-decay relationships that are more robust than that of
macroorganisms.32 Therefore, bacterial diversity often arises more from environmental filtering
than from biogeographical confinement in both terrestrial and marine environments.33,34 Oceanic
currents often promote dispersion; however, there are mechanisms which increase oceanic
isolation of the Southern Ocean when compared to other oceanic systems, such as the Antarctic
Circumpolar Current (ACC) and the effects of glaciation. These geographical and environmental
factors make the waters of the Southern Ocean relatively isolated compared to the global ocean
system.
3.1.5

OPTIMAL DEFENSE THEORY AND BIOACCUMULATION
The Optimal Defense theory can be applied to marine invertebrate tissues to help explain

bioaccumulation and spatial differences in secondary metabolite concentration. It is based on the
hypothesis that distribution of specialized or secondary metabolites within the tissues of organisms
is based on the anatomic susceptibility and exposure to predation.35 One well-studied example of
both bioaccumulation and differential distribution of sequestered toxic compounds is seen in
nudibranchs, where cytotoxic compounds are stored in the portion of the organism that is most
vulnerable to predatory efforts, the mantle.

36–41

The phylum porifera has also been studied for

differential levels of bioaccumulation based on cell type and layers and has revealed that
bioaccumulation of secondary metabolites in invertebrates also occurs in organisms with less
anatomical differentiation than that of nudibranchs.42–46 In the sponge Latrunculia apicalis, the
marine alkaloid discorhabdin G that is associated with chemical defense was found to be
sequestered on the surface of the organism.47 The bioaccumulation of sesterterpenoid secondary
metabolites which serve as feeding deterrents in the more apical portions of sponge tissues has
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been demonstrated in Cocospongia sp.48 In another example, concentrations of the kabiramide
macrolides were determined to differ between the extracts from the base and the captium of the
sponge, Pachastrissa nux, indicating that this sponge is also able to differentially bioaccumulate
its cytotoxic secondary metabolites in the portion of the invertebrate that is presumably more
susceptible to predation.49
Though less numerous, there are ascidian-specific studies that also reveal evidence of
bioaccumulation in Ascidiacea. There is evidence of bioaccumulation of the patellazoles in
Lissoclinum patella with levels that are seven orders of magnitude higher than the cytotoxic levels
in bioassays involving mammalian cells.8,50 Additionally, bioaccumulation of secondary
metabolites in host tissues points to metabolic cooperation and translocation between the host and
the microbial producer of secondary metabolites.51–53 The precedence of bioaccumulation of hostassociated microbially-produced cytotoxic compounds in marine invertebrate tissues may account
for a non-linear correlation between the compound concentration in tissues and ASV occurrence
when these two sets of data points are compared.

3.2 PALMEROLIDE A AS A MICROBIAL NATURAL PRODUCT
Early attempts to find the producer of palmerolide A and the pal BGC were culture-based.
Sixteen bacterial isolates were successfully characterized from Synoicum adareanum in the hunt
to find the palmerolide producer. If the producer could be discovered, it could serve as the gateway
for an ongoing supply of the compound. Most were from five genera of Gammaproteobacteria and
one was an Alphaproteobacteria.54 Liquid cultures from all 16 isolates were used to screen for the
presence of palmerolide A based on liquid chromatography techniques, but none revealed the
presence of the secondary metabolite. Microbes from the marine environment are often difficult
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to culture in standard laboratory conditions, sometimes due to the difficulty mimicking
environmental conditions and due to metabolic codependency.55 Early genomic approaches to
identify the palmerolide A producer lead to identification of polyketide biosynthetic potential in
Synoicum adareanum microbiome.54 A 16S rRNA gene clone library consisting of 72 total
sequences, of which 12 were distinct. Sequences consistent with Proteobacteria, Bacteriodetes,
and Verrucomicrbia comprised 97% of the genes that were cloned, with Actinobacteria and
phylum TM7 representing the bulk of the remaining sequences.54 The genes consistent with
biosynthetic machinery for production of polyketides, notably ketosynthase domains, were
present, though were not phylogenetically informative in terms of identifying the producer. These
data, however, laid the groundwork for more comprehensive evaluations of the Synoicum
adareanum microbiome and the spatial survey described below.
One genome from the cultivar library was sequenced: Pseudovibrio sp. str. TunPSC045.I4. This genus is known to be rich in BGCs, but this was the first of its genus to be isolated from
Antarctica. It has an interesting phenotype and an interesting branching division pattern. We were
able to obtain its full genome sequence and can see that it is also biosynthetically talented with
many BGCs, but none consistent with the production of the palmerolides. This isolate is the
foundation of the project discussed in Chapter IV.

3.3 IN SEARCH OF THE PRODUCER OF PALMEROLIDE A
Portions of this chapter are also discussed in the publication “Uncovering the Core
Microbiome and Distribution of Palmerolide in Synoicum adareanum Across the Anvers Island
Archipelago, Antarctica,” by A.E. Murray, N.E. Avalon, L. Bishop, K.W. Davenport, E. Delage,
A.E.K. Dichosa, D. Eveillard, M.L. Higham, S. Kokkaliari, C. Lo, C.S. Riesenfeld, R.M. Young,
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P.S.G. Chain, and B.J. Baker. Mar Drugs 2020, 18(6), 298. CC 4.0 by MDPI. Used with
permission.
The candidate pal BGC (discussed in Chapter II) discovered through the metagenome
sequencing techniques of the microbial enrichment from host tissues using 454 and Ion Torrent,
Ion Proton techniques was not associated with phylogenetically conserved genes to point to the
microbial producer. Since BGCs are sometimes horizontally transferred, it is not uncommon that
a cluster can have different composition than that of the primary metabolic genes of the producer
in regards to GC content, tetra-nucleotide frequency, and relationship to conserved domains
specific to a species or strain. Additionally, genes in a BGC are under environmental and
evolutionary selective pressures so they do not undergo change at uniform rates.

3.4 SAMPLING DESIGN
Analysis of the metabolomic profile, specifically palmerolide A concentration, and
microbiome composition were based on a carefully designed sampling approach to perform a
spatial survey of S. adareanum in the region. The microbiome composition was analyzed in order
to narrow down those microorganisms that are persistent across samples from the Anver’s Island
Archipelago, near Palmer Station, Antarctica. In 2011, samples were carefully collected based on
a nested sampling design from seven sites within the boating area around Palmer Station: Norsel
Point (Nor), Litchfield Island (Lit), DeLaca Island (Del), Killer Whale Rocks (Kil), Janus Island
(Jan), Bonaparte Point (Bon), and Laggard Island (Lag) (Figure 3.4). During a series of collections
via scuba diving, three colonies of the ascidian were selected from each site, and three lobes from
each colony were then collected. This resulted in a total of 63 samples.
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Figure 3.4. The boating area near Palmer Station, Antarctica. The red triangles indicate the locations where
samples of S. adareanum colonies were collected by SCUBA. Three lobes of the ascidian were collected
from each of three colonies at each dive location, resulting in a total of 63 samples for analysis.

This careful sampling was designed to look for the pattern of chemistry across the samples,
with the ability to analyze lobe-to-lobe and colony-to-colony differences in the principle
metabolite and in the microbial communities. Rather than batching organisms together for mass
isolation and evaluation as is typically done in natural product isolation, each sample was carefully
processed to allow for statistical analysis of composition based on lobe, colony, and site (Figure
3.5) with consideration of environmental factors such as depth, temperature, adjacent
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invertebrates, and distance from Palmer Station. Metadata including date, time, depth, and water
temperature (as registered from a dive computer) was recorded for each sample collected. In
addition, videos were taken at each site for colony collection, and topographical taxonomical
assessment was done to look at the neighboring invertebrates (Table 3.1).

Palmerolide A

Figure 3.5. (a) A colony of Synoicum adareanum in Antarctic waters, (b) the sagittal view of the
colonial ascidian following collection, (c) the structure of palermolide A, a marine polyketide originally
isolated from S. adareanum, but found to be produced by a host-associated bacterium.
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Table 3.1. Environmental metadata for each collection site. Three lobes of the ascidian were collected of
each of three colonies at a given dive site.
Distance from Water
Depth (m) Palmer (m)* Temp (oC)

Presence of Presence of Presence Presence of
Red Algae Brown Algae of Sponge Bryozoan

Sample

Dive Site

Collection Date

GPS Location

Bon-1

Bonaparte
Point

24-Mar-11

S 64o 46.679',
W 64o 04.013'

28.7

870

2

+

+

+

+

Bon-2

Bonaparte
Point

24-Mar-11

S 64o 46.679',
W 64o 04.013'

27.7

870

1

+

+

+

+

Bon-3

Bonaparte
Point

24-Mar-11

S 64o 46.679',
W 64o 04.013'

29

870

1

+

--

--

+

Del-1

DeLaca
Island

28-Mar-11

S 64o 46.749',
W 64o 05.945'

27.3

2400

1

--

+

--

--

Del-2

DeLaca
Island

28-Mar-11

S 64o 46.749',
W 64o 05.945'

24

2400

1

--

+

--

+

Del-3

DeLaca
Island

28-Mar-11

S 64o 46.749',
W 64o 05.945'

25

2400

1

+

+

+

--

Jan-1

Janus Island

23-Mar-11

S 64o 47.062',
W 64o 05.857'

26.3

2725

1

+

+

--

--

Jan-2

Janus Island

23-Mar-11

26.3

2725

1

+

+

+

--

Jan-3

Janus Island

23-Mar-11

S 64o 47.062',
W 64o 05.857'

26.3

2725

1

+

+

+

--

Kil-1

Killer Whale
Rocks

2-Apr-11

S 64o 46.771',
W 64o 06.725'

29

3000

1

+

+

+

+

Kil-2

Killer Whale
Rocks

2-Apr-11

S 64o 46.771',
W 64o 06.725'

28

3000

1

+

+

+

--

Kil-3

Killer Whale
Rks

2-Apr-11

S 64o 46.771',
W 64o 06.725'

27.7

3000

1

+

+

+

--

Lag-1

Laggard
Island

31-Mar-11

S 64o 48.497',
W 64o 00.564'

28.7

4250

1

+

+

--

+

Lag-2

Laggard
Island

31-Mar-11

S 64o 48.497',
W 64o 00.564'

27

4250

1

+

--

--

+

Lag-3

Laggard
Island

31-Mar-11

S 64o 48.497',
W 64o 00.564'

29

4250

1

+

+

--

--

Lit-1

Litchfield
Island

3-Apr-11

S 64o 46.464',
W 64o 05.280'

28.7

2170

1

+

+

+

+

Lit-2

Litchfield
Island

3-Apr-11

S 64o 46.464',
W 64o 05.280'

24.7

2170

1

+

+

--

+

Lit-3

Litchfield
Island

3-Apr-11

S 64o 46.464',
W 64o 05.280'

26

2170

1

--

+

+

--

Nor-1

Norsel Point

27-Mar-11

S 64o 45.620',
W 64o 05.883'

31

2600

2

+

+

+

+

Nor-2

Norsel Point

27-Mar-11

S 64o 45.620',
W 64o 05.883'

28

2600

1

+

+

--

+

Nor-3

Norsel Point

27-Mar-11

S 64o 45.620',
W 64o 05.883'

27.7

2600

1

--

+

+

+

S 64o 47.062',
W 64o 05.857'
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3.5 METABOLOMIC ANALYSIS
The lobes from each of the 63 samples were divided in half for the two arms of the
experiment. One half of the lobe was used by Sofia Kokkaliari for Liquid Chromatography-Mass
Spectrometry (LC-MS) analysis, specifically looking for palmerolide A. LC-MS on the
dichloromethane:methanol metabolite fraction was used to confirm the presence of palmerolide A
in all samples, which ranged from 0.49-4.06 mg PalA x g-1. The chromatographic peak associated
with palmerolide A was consistently the most prominent. The mass spectrum obtained of the peak
associated with palmerolide A revealed an m/z of 585 correlating with the [M + H]+, 607
correlating with [M + Na]+, and 567 correlating with [M - H2O + H]+. All samples had significant
levels of palmerolide A with concentrations ranging from 0.49 mg to 4.06 mg per gram of host dry
weight. Colony-to-colony differences and lobe-to-lobe differences were observed; however, there
was no clear association between the level of palmerolide and the presence of a specific ASV from
the microbiome analysis (Figure 3.6).3
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Figure 3.6. (a) Example total ion chromatogram (Lit-1a) which demonstrates a prominent peak that
correlates with palmerolide A at scan number 631. (b) Mass spectrum of palmerolide A from scan number
631, [M – H2O + H]+ (C33H47N2O6 calculated m/z 567.3429), [M + H]+ (C33H48N2O7 calculated m/z
585.3534) and [M + Na]+ (C33H47N2O7Na calculated m/z 607.3359). (c) Palmerolide A levels normalized
per grams of dry weight, based on site, colony, and lobe. Error bars represent standard deviation of the
technical replicates. Colonies with statistically significant differences between lobes are indicated by a
triangle over the individual lobe (open = different than one lobe from that colony; filled = different than
both colonies, upward direction = lobe is higher in concentration than the other colonies; downward
direction = lobe is lower than the other colonies).3 From “Uncovering the Core Microbiome and
Distribution of Palmerolide in Synoicum adareanum Across the Anvers Island Archipelago, Antarctica,”
by A. E. Murray, et al, Mar Drugs 2020, 18(6), 298. CC 4.0 by MDPI. Used with permission.
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3.6 AMPLICON SEQUENCE VARIANT AND SUBSET DETERMINATION
The other half of each of the 63-lobes were used for genomic analysis. This was part of the
collaboration between Alison Murray’s group at the Desert Research Institute and Patrick Chain’s
group at Los Alamos National Laboratory for this project. Illumina tag sequencing targeting the
V3-V4 region of the 16S rRNA gene was performed using prokaryote-targeted primers. The
methodological details of the 16S rRNA gene sequencing can be found in the publication,
“Uncovering the Core Microbiome and Distribution of Palmerolide in Synoicum adareanum
Across the Anvers Island Archipelago, Antarctica,” by A.E. Murray, N.E. Avalon, L. Bishop,
K.W. Davenport, E. Delage, A.E.K. Dichosa, D. Eveillard, M.L. Higham, S. Kokkaliari, C. Lo,
C.S. Riesenfeld, R.M. Young, P.S.G. Chain, and B.J. Baker. Mar Drugs 2020, 18(6), 298.
The bioinformatic analysis of microbiome composition began with using a QIIME2
pipeline with a DADA2 plug-in to create matrices of the amplicon sequence variant (ASV)
occurrences. In each sample, the ASVs were subsampled to just under 10 K reads in an effort to
include all 63-samples, as one sample had depth of sequence coverage of only 9,987 reads. The
total number of reads was 619,194. Those ASVs that were unassigned or assigned to Eukarya were
removed from analysis.
While evaluating the structure of the microbiome from Synoicum adareanum, the
precedent set by Hernandez-Agreda defining the microbiome into 3 subclasses was used.56 The
first subclass represented the Core microbiome, which consists of ASVs with persistence across at
least 80% of samples. Since the depth of ASV sequencing subsampling was less than 10,000 the
delineation for core membership was deemed reasonable and, in fact, all the members of the core
had persistence across 90% or greater. The second subgroup is the Dynamic microbiome, which
is comprised of ASVs that have persistence between 50-80% of the samples. These may serve key
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metabolic roles but may be ecologically interchangeable with another species. The Variable
microbiome are ASVs that are present in less than 50% of samples. These members are more likely
to represent those ephemeral species that are environmentally stochastic and may represent a food
source for the ascidian or are a passerby from the water column. Interesting patterns that may
support this within the Synoicum adareanum microbiome were noted in the co-occurrence network
within the Variable subgroup, though further investigations are warranted before conclusions can
be drawn.3

3.7 WORKFLOW FOR THE STATISTICAL ANALYSIS OF THE MICROBIOME
The ASV occurrence data was analyzed to determine both the coherence and diversity of
the host-associated microbial consortia based on analysis of the entire data set as well as each
subset: Core, Dynamic, and Variable (Figure 3.7). Ecological samples of microbial communities
often have vastly difference abundance when comparing the most abundant species to the least
abundant species, often with magnitudes of order differences. This phenomenon was observed
with the Synoicum adareanum microbiome. In order to capture the importance of ASVs with
particularly low abundance, while preventing the more dominant species from being the sole
drivers of similarity, square-root transformation was applied to each sample. Resemblance
matrices using Bray-Curtis similarities were created for the subsequent steps. Threshold metric
multidimensional scaling (tmMDS) plots without constraints to the y-axis were used to visual
display the data clouds, displayed below with a site-based legend. Permutational analysis of
variance (PERMANOVA) aided in determining the drivers of the observed variability based on
the nested sampling design factors of colony and site. Dendrograms were created using a clustering
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algorithm. Additionally, the distance to the centroids and permutational dispersion were calculated
to analyze β-diversity.

Figure 3.7. ASV occurrence data for the entire microbiome as well as each subset was square-root
transformed. Bray-Curtis similarity matrices were calculated, and statistical tests were performed.

3.8 GENERAL STRUCTURE OF THE SYNOICUM ADAREANUM MICROBIOME
There are 462 distinct ASVs represented in the microbiome (Figure 3.8) across all 63
samples. Of these, 21 (4.55%) met criteria for the Core subgroup, 14 (3.03%) met criteria for the
Dynamic subgroup, and 427 (92.4%) were in the Variable subgroup. Of the total ASV occurrences,
the core members represent 596,017 (94.8%) of all occurrences, the dynamic members represent
only 20,634 (3.28%), and the variable members only 11,852 (1.89%) of the 628,500 total ASV
occurrences in the subsampled data. This reveals the dominance of the core members within the
microbial community. All but one member of the core is distinct from the bacterioplankton datasets
from multiple field seasons and that occurrence was from a very rare member of the
bacterioplankton data set.
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Figure 3.8. General composition of the microbiome based on the subsets of Core, Dynamic, and
Variable as displayed by distinct ASVs and total ASV occurrences.

3.9 STATISTICAL ANALYSIS OF THE COMPLETE MICROBIOME
3.9.1

MULTIDIMENSIONAL SCALING PLOTS
Statistical evaluation was performed on the entire microbial community and on each of the

subsets of data. Representation of the square-root transformed, multidimensional community data
of the complete microbiome using 2-D structure reveals patterns of difference with certain sites
compared to others. The localization of the data clouds representing the microbial communities
from each group and their degree of dispersion can be seen in this dimensionally reduced graphical
representation (Figure 3.9). For example, when visualized in the tmMDS plot, Norsel Point and
Janus Island are different in both location in Cartesian space and in the degree of dispersion. In
congruence with that of the Core microbiome, the Dynamic microbiome at Norsel Point appears
to have the most dispersion around the average of samples, while Janus Island and Killer Whale
rocks appear to have the most homogeneity between samples collected at these sites. The
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bootstrapped data permutationally increases the sample size and, therefore, visually augments
these similarities and differences. Note, the 2-D stress on the MDS plots representing the total
microbiome is quite high, pointing to the statistical complexity of the samples.

Figure 3.9. tmMDS plot of Bray-Curtis similarities based on square-root transformed ASV occurrence
data of the complete microbiome of each of the 63 samples. Levels of similarity among samples are
indicated by the solid blue lines (65%) and hashed pink lines (75%). From “Uncovering the Core
Microbiome and Distribution of Palmerolide in Synoicum adareanum Across the Anvers Island
Archipelago, Antarctica,” by A. E. Murray, et al, Mar Drugs 2020, 18(6), 298. CC 4.0 by MDPI. Used
with permission.

109

3.9.2

SITE-BASED CENTROIDS
Site-based centroids representing the spatial median, or center of a given data cloud, were

calculated followed by PERMDISP, which is a permutationally-derived degree of dispersion about
the centroids.
3.9.3

PERMUTATIONAL DISPERSION
As observed in the MDS plots, differences in the degree of dispersion around the centroid

using the complete microbiome can be statistically justified based on permutationally-derived
computations. PERMDISP can be used to evaluate the heterogeneity of data dispersion and in
ecological statistics can aid in determination of β-diversity. The degree of dispersion is statistically
different in the following pairs of sites: (1) Bonaparte and Killer Whale Rocks, (2) Bonaparte and
Laggard, (3) Bonaparte and Litchfield, (4) DeLaca and Janus, (5) DeLaca and Killer Whale Rocks,
(6) DeLaca and Laggard, (7) DeLaca and Litchfield, (8) Janus and Killer Whale Rocks, (9) Janus
and Norsel Point, (10) Killer Whale Rocks and Norsel Point, (11) Laggard and Norsel Point, and
(12) Litchfield and Norsel Point. There is no significant difference in the degree of dispersion
around the centroid for the other pairs of sites when analyzing the complete microbial community.
In addition, the individual deviations from the centroid of each sample collected within a given
site can be evaluated to determine the sample or samples that are most responsible for increases in
the overall data dispersion. The overall dispersion trend is much higher for the Dynamic
microbiome compared to that of the Core, but less than that of the Variable groups, whereas the
dispersion for the entire data set is found in the site-specific averages of 12.4-21.6 (Figure 3.10).
(Note: the four pairs with a statistically different degree of dispersion in the Core are also
represented in the Dynamic subset and complete microbiome, though an additional eight pairs are
also identified).
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Figure 3.10. PERMDISP analysis helps with determination of β-diversity. The Core shows a strong
degree of persistence with little variance seen about the centroid, which increases with the Dynamic
subgroup, and is most marked with the Variable subgroup. From “Uncovering the Core Microbiome
and Distribution of Palmerolide in Synoicum adareanum Across the Anvers Island Archipelago,
Antarctica,” by A. E. Murray, et al, Mar Drugs 2020, 18(6), 298. CC 4.0 by MDPI. Used with
permission.

3.9.4

PERMANOVA
A permutationally-derived multivariate analysis (PERMANOVA) was performed with the

null hypothesis that the centroids of all groups are equivalent (Table 3.2).57 The components of
this nested experimental design are site and colony and can be evaluated as drivers of variability.
Significance is determined by a pseudo-F statistic. The component of site-to-site variability
explains 25.04% of total variability in the microbiome. Colony-to-colony variability explains
27.76%, while the remaining 47.19% of variability is unexplained or stochastic.
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Table 3.2. PERMANOVA data for Complete Microbiome; df: degrees of freedom, SS: sum-of-squares,
%: percent contribution, MS: mean square, P(perm): p-value based on permutations; perms: number of
permutations, P(MC): p-value based on random Monte Carlo draws.

Source
Site
Colony(Site)
Res
Total

3.9.5

df
6
14
42
62

SS
6541
7252
12328
26122

%
25.040196
27.7620397
47.1939361

MS
Pseudo-F
1090.2 2.1046
518
1.7647
293.54

P(perm)
0.0002
0.0001

perms
9853
9705

P(MC)
0.0001
0.0001

ANALYSIS OF SIMILARITY
ANOSIM is a non-parametric test utilizing permutations to test the null hypothesis that

there is no differences among groups. Significant differences can be determined based on
calculations of R (from -1.0 to +1.0) based on rank-order from the similarity matrix. As the R
statistic approaches +1, there is perfect separation among the groups. When the entire microbiome
is analyzed, all sites show significant separation with the exception of two site-pairs: (1) Bonaparte
and Norsel Point, and (2) DeLaca Island and Norsel Point (Table 3.3).

Table 3.3. ANOSIM data for Complete Microbiome.

Groups

Bon, Del
Bon, Jan
Bon, Kil
Bon, Lag
Bon, Lit
Bon, Nor
Del, Jan
Del, Kil
Del, Lag

R Statistic

0.146
0.459
0.409
0.182
0.308
0.002
0.599
0.487
0.374

Significance
Level %

1.3
0.01
0.02
0.2
0.03
43.5
0.01
0.01
0.01

Possible
Permutations

24310
24310
24310
24310
24310
24310
24310
24310
24310
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Actual
Permutations

9999
9999
9999
9999
9999
9999
9999
9999
9999

Number ≥
Observed

127
0
1
20
2
4350
0
0
0

Table 3.3. ANOSIM data for Complete Microbiome (continued).

Groups

Del, Lit
Del, Nor
Jan, Kil
Jan, Lag
Jan, Lit
Jan, Nor
Kil, Lag
Kil, Lit
Kil, Nor
Lag, Lit
Lag, Nor
Lit, Nor

3.10

R Statistic

0.393
0.039
0.432
0.287
0.302
0.445
0.413
0.302
0.314
0.189
0.211
0.17

Significance
Level %

0.01
22.3
0.01
0.06
0.09
0.02
0.03
0.01
0.01
0.5
0.2
0.7

Possible
Permutations

24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310

Actual
Permutations

9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999

Number ≥
Observed

0
2224
0
5
8
1
2
0
0
49
14
64

STATISTICAL EVALUATION OF THE CORE MICROBIOME

3.10.1 MULTIDIMENSIONAL SCALING PLOTS
Representation of the square-root transformed, multidimensional community data of the
Core microbiome using 2-D structure reveals patterns of difference with certain sites compared to
others (Figure 3.11). For example, the community at Janus appears to be distinct from De Laca.
Visually, it can be observed that both the Cartesian location of the data cloud, as well as degree of
variability within the site, differs. The microbial community within samples collected at Killer
Whale rocks demonstrates less dispersion of difference than that of Norsel Point, a visual
observation that is supported by the PERMDISP calculations. Bootstrapped data, which artificially
increases the sample size through permutational re-selection of samples, demonstrates a futher
seperation of samples based on similarity matricies. Differences can be observed in nearly all
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groups, with some overlap existing in the Litchfield and Killer Whale Rocks samples. Norsel Point
has the largest degree of dispersion around the average of samples, while Janus and Killer Whale
rocks appear to have the most homogeneity between samples. Note that the 2-D stress resulting
from the reduction in dimensionality is relatively high at 0.196. This points to the highly-complex
nature of the community even within the occurance data of the estabilished Core microbes.

Figure 3.11. tmMDS plots without and with bootstrapping for the Core microbiome. Bootstrapped data
includes 43 bootstraps; the resulting data cloud for each site is shaded to aid visualization of the cluster.
The site-based centroid is demarcated by its respective symbol in black.

3.10.2 SITE-BASED CENTROIDS
Site-based centroids were calculated followed by PERMDISP, which is permutationallyderived degree of dispersion about the centroids. Centroids can be calculated based on the averages
of the data points in cartesian space of the data, based on Bray-Curtis similarity and with reduced
dimensionality represented in MDS plots. The centroids are demarked by black symbols on the
bootstrapped tmMDS plot above (Figure 3.11).
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3.10.3 PERMUTATIONAL DISPERSION
As observed in the MDS plots, differences in the degree of dispersion around the centroid
using the Dynamic microbiome can be statistically justified based on permutationally-derived
computations. The degree of dispersion is statistically different in the following pairs of sites: (1)
Killer Whale Rocks and Norsel Point, (2) Bonaparte and Killer Whale Rocks, (3) DeLaca and
Janus, and (4) DeLaca and Killer Whale Rocks. There is no significant difference in the degree of
dispersion around the centroid for the other pairs of sites when analyzing the core microbial
community. In addition, the individual deviations from the centroid of each sample collected
within a given site can be evaluated to determine the sample or samples that are most-responsible
for increases in the overall data dispersion. For example, Bon-3b-2011 represents a difference from
the mean, or centroid, of only 6.2, while Bon-1b-2011 has a difference from the mean of 18.1.
3.10.4 PERMANOVA
A PERMANOVA analysis was performed, with the nested components of site and colony
evaluated as drivers of variability (Table 3.4). The component of site-to-site variability explains
26% of total variability in the Core microbiome. Colony-to-colony variability explains 31%, while
the remaining 42% of variability is unexplained or stochastic and represents lobe-to-lobe
differences.

Table 3.4. PERMANOVA data for Core Microbiome; df: degrees of freedom, SS: sum-of-squares, %:
percent contribution, MS: mean square, P(perm): p-value based on permutations; perms: number of
permutations, P(MC): p-value based on random Monte Carlo draws.

Source
Site
Colony(Site)
Res
Total

df
6
14
42
62

SS
2120.2
2556.1
3429.9
8106.2

%
26.1552885
31.532654
42.3120574

MS
Pseudo-F
353.37 1.9355
182.58 2.2357
81.664
115

P(perm)
0.005
0.0001

perms P(MC)
9889
0.0077
9823
0.0001

3.10.5 ANALYSIS OF SIMILARITY
In the Core microbiome, all sites show significant separation with the exception of three sitepairs: (1) Bonaparte and Norsel, (2) DeLaca and Norsel, and (3) Bonaparte and Laggard (Table
3.5). The R-statistic for the pair (1) Bonaparte and Norsel is a negative number, which reveals that
these are more interspersed than expected with random permutation.

Table 3.5. ANOSIM data for Core Microbiome.

Groups

R Statistic

Significance
Level %

Bon, Del
Bon, Jan
Bon, Kil
Bon, Lag
Bon, Lit
Bon, Nor
Del, Jan
Del, Kil
Del, Lag
Del, Lit
Del, Nor
Jan, Kil
Jan, Lag
Jan, Lit
Jan, Nor
Kil, Lag
Kil, Lit
Kil, Nor
Lag, Lit
Lag, Nor
Lit, Nor

0.146
0.459
0.409
0.182
0.308
0.002
0.599
0.487
0.374
0.393
0.039
0.432
0.287
0.302
0.445
0.413
0.302
0.314
0.189
0.211
0.17

1.3
0.01
0.02
0.2
0.03
43.5
0.01
0.01
0.01
0.01
22.3
0.01
0.06
0.09
0.02
0.03
0.01
0.01
0.5
0.2
0.7

Possible
Permutations

Actual
Permutations

Number ≥
Observed

24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310

9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999

127
0
1
20
2
4350
0
0
0
0
2224
0
5
8
1
2
0
0
49
14
64
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3.11 STATISTICAL EVALUATION OF THE DYNAMIC MICROBIOME
3.11.4 MULTIDIMENSIONAL SCALING PLOTS
Representation of the square-root transformed, multidimensional community data of the
Dynamic microbiome using 2-D structure reveals patterns of difference with certain sites
compared to others, though the site-to-site distinctions are less prominent than that of the Core
MDS plots (Figure 3.12). The localization of the data clouds representing the microbial
communities from each group and their degree of dispersion can be seen in this demensionallyreduced graphical representation. For example, when visualized in the MDS plot, Norsel Point and
Janus show differences in Cartesian space and in degree of dispersion. In congruence with that of
the Core microbiome, the dynamic microbiome at Norsel Point appears to have the most dispersion
around the average of samples, while Janus and Killer Whale rocks appear to have the most
homogenity between samples collected at these sites. The bootstrapped data visually augments
these similarities and differences by permutationally increasing the data points. Note, the 2-D
stress on the MDS plots representing the Dynamic microbiome is even higher than that of the Core
microbiome, pointing to a further increase in complexity and dimensionality.
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Figure 3.12. tmMDS plot without and with bootstrapping for the Dynamic microbiome. Bootstrapped
data includes 43 bootstraps; the resulting data cloud for each site is shaded to aid visualization of the
cluster. The site-based centroid is demarcated by its respective symbol in black.

3.11.2 SITE-BASED CENTROIDS
Centroids can be calculated based on the averages of the data points in cartesian space of
the data, based on Bray-Curtis similarity and with reduced dimensionality represented in MDS
plots. The centroids are demarked by black symbols on the bootstrapped tmMDS plot above
(Figure 3.12).
3.11.1 PERMUTATIONAL DISPERSION
As observed in the MDS plots, differences in the degree of dispersion around the centroid
using the Dynamic microbiome can be statistically justified based on permutationally-derived
computations. The degree of dispersion is statistically different in the following pairs of sites: (1)
Bonaparte and Janus, (2) Bonaparte and Killer Whale Rocks, (3) DeLaca and Janus, (5) DeLaca
and Killer Whale Rocks, (6) Janus and Norsel Point, (7) Killer Whale Rocks and Norsel Point, (8)
Lagard and Norsel Point, and (9) Litchfield and Norsel Point. There is no significant difference in
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the degree of dispersion around the centroid for the other pairs of sites when analyzing the dynamic
microbial community. In addition, the individual deviations from the centroid of each sample
collected within a given site can be evaluated to determine the sample or samples that are most
responsible for increases in the overall data dispersion. For example, Bon-3b-2011 represents a
difference from the mean, or centroid, of only 13.3, while Bon-2a-2011 represents a difference
from the mean of 50.5. The overall dispersion trend is much higher for the Dynamic microbiome
compared to that of the Core, but is less than that of the Variable groups. (Note: the four pairs with
a statistically different degree of dispersion in the Core continue to be represented as statistically
different pairs in the Dynamic, though an additional five pairs are also identified).
3.11.2 PERMANOVA
A PERMANOVA analysis was performed, with the nested components of site and colony
evaluated as drivers of variability (Table 3.6). The component of site-to-site variability explains
28% of total variability in the Dynamic microbiome. Colony-to-colony variability explains 27%,
while the remaining 44% of variability is unexplained or stochastic and represents lobe-to-lobe
differences.

Table 3.6. PERMANOVA data for Dynamic Microbiome; df: degrees of freedom, SS: sum-of-squares,
%: percent contribution, MS: mean square, P(perm): p-value based on permutations; perms: number of
permutations, P(MC): p-value based on random Monte Carlo draws.

Source
Site
Colony(Site)
Res
Total

df
6
14
42
62

SS
23501
22522
36806
82829

%
MS
28.372912 3916.8
27.190959 1608.7
44.436127 876.34
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Pseudo-F
2.4348
1.8357

P(perm) perms
0.0012 9897
0.0002 9834

P(MC)
0.0012
0.0006

3.11.3 ANALYSIS OF SIMILARITY
ANOSIM uses calculations of R (from -1.0 to +1.0) based on rank-order from the similarity
matrix. As the R statistic approaches +1, there is perfect separation among the groups. In the
Dynamic microbiome, all sites show significant separation with the exception of thee site-pairs:
(1) Bonaparte and Norsel, (2) DeLaca and Norsel, and (3) Bonaparte and Laggard (Table 3.7). The
R-statistic for the pairs (1) Bonaparte and Norsel and (2) DeLaca and Norsel are negative numbers,
which reveals that these are more interspersed than expected with random permutation.

Table 3.7. ANOSIM data for Dynamic Microbiome.

Groups

R Statistic

Significance
Level %

Possible
Permutations

Actual
Permutations

Number ≥
Observed

Bon, Del
Bon, Jan
Bon, Kil
Bon, Lag
Bon, Lit
Bon, Nor
Del, Jan
Del, Kil
Del, Lag
Del, Lit
Del, Nor
Jan, Kil
Jan, Lag
Jan, Lit
Jan, Nor
Kil, Lag
Kil, Lit
Kil, Nor
Lag, Lit
Lag, Nor
Lit, Nor

0.111
0.438
0.321
0.082
0.144
-0.014
0.601
0.588
0.428
0.402
-0.022
0.377
0.263
0.395
0.464
0.129
0.362
0.501
0.172
0.28
0.202

4.4
0.01
0.05
10.1
2
49.9
0.02
0.01
0.01
0.01
56.6
0.02
0.5
0.1
0.07
4.2
0.1
0.05
2.3
0.4
1.4

24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310

9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999

434
0
4
1004
202
4992
1
0
0
0
5661
1
52
12
6
417
13
4
226
41
136
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3.12 STATISTICAL EVALUATION OF THE VARIABLE MICROBIOME
3.12.1 MULTIDIMENSIONAL SCALING PLOTS
Representation of the square-root transformed, multidimensional community data of the
Variable microbiome using 2-D structure reveals some patterns of difference with certain sites
compared to others, though the site-to-site distinctions are less promient than that of the Core and
Dynamic MDS plots (Figure 3.13). The localization of the data clouds representing the microbial
communities from each group and their degree of dispersion can be seen in this demensionallyreduced graphical representation. For example, when visualized in the MDS plot, Norsel Point and
Janus show differences in Cartesian space and in degree of dispersion. In congruence with that of
the Core and Dynamic groups, the Variable microbiome at Norsel Point appears to have the most
dispersion around the average of samples, while Janus and Killer Whale rocks appear to have the
most homogenity between samples collected at these sites. This trend is notably less prominent as
we move to the Dynamic group. The bootstrapped data permutationally increases the sample size
and, therefore, visually augments these similarities and differences. Note, the 2-D stress on the
MDS plots representing the Dynamic microbiome is even higher than that of the Core and
Dynamic groups of the microbiome, pointing to a further increase in complexity and
dimensionality. There is also more observable overlap of the site-based data clouds.
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Figure 3.13. tmMDS plot without and with bootstrapping for the Variable microbiome. Bootstrapped data
includes 43 bootstraps; the resulting data cloud for each site is shaded to aid visualization of the cluster.
The site-based centroid is demarcated by its respective symbol in black.

3.12.2 SITE-BASED CENTROIDS
Centroids can be calculated based on the averages of the data points in cartesian space of
the data, based on Bray-Curtis similarity and with reduced dimensionality represented in MDS
plots. The centroids are demarked by black symbols on the bootstrapped tmMDS plot above
(Figure 3.13).
3.12.3 PERMUTATIONAL DISPERSION
The degree of dispersion around the site-based centroids through permutationallyderived computations reveal no pairs that have significant differences in the degree of dispersion
in the Variable group. The degree of dispersion overall is the highest in the Variable group (site
averages of 51.6 to 57.6) when compared to the Core (site averages of 6.8 to 12.1) and the Dynamic
(21.8-31.6).
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3.12.4 PERMANOVA
A PERMANOVA analysis was performed, with the nested components of site and colony
evaluated as drivers of variability (Table 3.8). The component of site-to-site variability explains
19% of total variability in the microbiome. Colony-to-colony variability explains 22%, while the
remaining 58% of variability is unexplained or stochastic. The stochastic variability increases as
we move from the Core to the Dynamic to the Variable groups.

Table 3.8. PERMANOVA data for Variable Microbiome; df: degrees of freedom, SS: sum-of-squares,
%: percent contribution, MS: mean square, P(perm): p-value based on permutations; perms: number of
permutations, P(MC): p-value based on random Monte Carlo draws.

Source
Site
Colony(Site)
Res
Total

df
6
14
42
62

SS
45608
52889
1.38E+05
2.37E+05

%
19.2455
22.3179
58.4353

MS
7601.4
3777.8
3297.3

Pseudo-F
2.0121
1.1457

P(perm)
0.0001
0.0404

perms
9842
9632

P(MC)
0.0001
0.0776

3.12.5 ANALYSIS OF SIMILARITY
ANOSIM uses calculations of R (from -1.0 to +1.0) based on rank-order from the similarity
matrix. As the R statistic approaches +1, there is perfect separation among the groups. In the
Variable microbiome, fewer sites show significant separation. The R-statistic for the pair (1)
Bonaparte and Norsel, again, has an R-statistic that is a negative number, which reveals more
interspersion than expected with random permutation (Table 3.9).
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Table 3.9. ANOSIM data for Variable Microbiome.

Groups
Bon, Del
Bon, Jan
Bon, Kil
Bon, Lag
Bon, Lit
Bon, Nor
Del, Jan
Del, Kil
Del, Lag
Del, Lit
Del, Nor
Jan, Kil
Jan, Lag
Jan, Lit
Jan, Nor
Kil, Lag
Kil, Lit
Kil, Nor
Lag, Lit
Lag, Nor
Lit, Nor

R Statistic
0.037
0.315
0.56
0.306
0.316
-0.016
0.51
0.796
0.431
0.483
0.112
0.427
0.105
0.105
0.289
0.449
0.426
0.56
0.055
0.192
0.128

Significance
Level %

Possible
Actual
Permutations Permutations

27.4
0.1
0.02
0.3
0.02
56.2
0.06
0.02
0.01
0.01
7.9
0.03
7.7
7.1
0.3
0.03
0.01
0.03
20.8
3.2
7

24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310
24310

9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999
9999

Number ≥
Observed
2736
11
1
26
1
5621
5
1
0
0
784
2
768
710
27
2
0
2
2076
321
699

3.13 DISTANCE BASED REDUNDANCY ANALYSIS
Distance Based Redundancy Analysis (dbRDA) is an ordination routine that uses a
resemblance matrix to determine patterns based on a set of predictor variables using constrained
ordination. It is a means to link a principle coordinate analysis and multivariate multiple
regression. Each environmental factor can be displayed as a vector to demonstrate the amount of
variability attributed to each, linking the biological and environmental data.
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3.13.1 EFFECT OF NEIGHBORING INVERTEBRATES
Video archives of each of the sample collections were reviewed for visual taxonomy of
adjacent invertebrates. The presence or absence of (1) red algae (Gigartina sp., Cystoclonium sp.,
Plocamium sp., and Pantoneura sp.), (2) brown algae (Desmarestia sp. and Himantothallus sp.),
(3) sponges (Mycale sp., Artemisina sp., Dendrilla sp., and undescribed), and (4) bryozoa (2 spp.)
were recorded at each of the 27 sites of collection. Coralline algae, green algae, bivalves,
echinoderms were also noted; however, their presence was too sparce for analysis of contribution
to microbiome variability. With the data collected, a dbRDA was performed on normalized square
root transformed data with Hellinger distance using these four groups as vectors (Figure 3.14).
When the complete microbiome was included for analysis, only 8.43% of total variation was
explained by 4 axes in the model (Axis 1, 3.28%; Axis 2, 2.57%, and Axis 3, 1.58%; Axis 4, 0.99).
Analysis of the Core microbiome with the dbRDA revealed that only 10.5% of the variation was
explained by the presence or absence of the groups of invertebrates, (Axis 1, 5.03%; Axis 2, 3.46%,
and Axis 3, 1.51%; Axis 4, 0.53).

Figure 3.14. Distance-based redundancy analysis based on adjacent invertebrates as determined by visual
taxonomy from videos recorded at the time of each collection.
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13.13.2 EFFECT OF ENVIRONMENTAL FACTORS
A dbRDA was performed based on the environmental factors of (1) water temperature, (2)
depth grade, and (3) distance of the collection site from Palmer Station (Figure 3.15). Depth grade
was stratified based on the data collected by dive computers for each collection as follows: A: 24
- 25.0 m; B: 26 - 27.5 m; C: 27.6 - 28.5 m, D: 28.6 – 30 m, E >30 m. Distance was also graded
based on linear, rather than navigable distance, to Palmer Station using calculations in Google
Earth: A: ≤ 875 m; B: 2170-2400 m; C: 2600-3000 m; D ≥ 4000 m. The analysis revealed minimal
effect of the environmental variables on total variation of the colony- and site-based data clouds.
The dbRDA of the complete microbiome composition showed that only 7.6% of the variability of
the data was explained by the three axes (Axis 1, 3.24%; Axis 2, 2.52%, and Axis 3, 1.83%). When
the Core microbiome was analyzed, less than 10% of total variation was explained by 3 axes in
the model (Axis 1, 5.00%; Axis 2, 2.97%, and Axis 3, 1.97%).

Figure 3.15. Distance-based redundancy analysis based on environmental factors of depth, water
temperature, and distance from Palmer Station.
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3.14 HEATMAP OF THE CORE MICROBIOME MEMBERS
The heatmap of square root transformed ASV occurrence data for the core microbiome is
shown with hierarchical clustering based on the sample composition is seen on the y-axis (Figure
3.16). Synoicum adareanum microbiome (SaM) ASVs are ranked and numbered and shown on the
x-axis. Nodes with significant clusters are indicated from top to bottom (p < 0.05); the order of
clustering inside the node, denoted by red lines, was not significant. The vertical line drawn at
SaM_ASV6 demarcates the cutoff of ASVs that were present in all 63 samples.
In the patterns seen in the heatmap, there is a specific species that visually stands out. There
are four ASVs that dominate the heatmap on the left, but there is one, Sam_ASV15, that has an
interesting pattern. As a member of the core, it has ASV representation in at least 80% of samples,
but there is a notably high amount of this species in some samples as compared to others. Alison
Murray discovered genomic correlations between this ASV and specific primers, leading to the
identification of the microbial producer of palmerolide A, with taxonomic affilitation to a
Verrucomicrobia Opitutaceae sp. The taxonomic affiliations of the other members of the core
microbiome included seven Proteobacteria Microbulbifer ASVs (SaM_ASV1, Sam_ASV2,
SaM_ASV4, SaM_ASV5, SaM_ASV10, SaM_ASV17, and SaM_ASV18). Several others were
identified as Proteobacteria, including a Pseudovibrio sp. (SaM_ASV3), a Verrucomicobia
Lentimonas sp. (SaM_ASV14), a Endozoicomonas sp. (SaM_ASV7), a Nitrosomonas sp.
(SaM_ASV13), a Hoeflea sp. (SaM_ASV6), a Rhodospirillales sp. (SaM_ASV8), a
Bdellovibrionaceae

(SaM_ASV9),

a

Halocynthiibacter

sp.

(SaM_ASV16),

and

a

Rhodobacteraceae sp. (SaM_ASV21). A Nitrospirota Nitrospira sp. (SaM_ASV11), an
Actinobacteria Solirubreobacterales (no genus assigned, SaM_ASV20), and two Bacteroidetes
Cryomorphaceae sp. (SaM_ASV19) and Lutibacter (SaM_ASV12) are also represented.3
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Figure 3.16. Heatmap of square-root transformed ASV occurrence data for members of the Core
microbiome. The dendrogram is based on hierarchical clustering of the samples. From “Uncovering the
Core Microbiome and Distribution of Palmerolide in Synoicum adareanum Across the Anvers Island
Archipelago, Antarctica,” by A. E. Murray, et al, Mar Drugs 2020, 18(6), 298. CC 4.0 by MDPI. Used with
permission.
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Binning of the 16S rRNA gene data that has been acquired from the metagenome echoes the
findings of the 16S rRNA gene iTag sequencing (Figure 3.17). The metagenomic sunburst diagram
demonstrates the composition based on relative abundance of specific genera of the microbiome.
If we overlay the genus and species information from the ASV assignments, we see a similar
breakdown, further confirming our microbiome composition findings.

Figure 3.17. Sunburst diagram of the taxonomic composition of the metagenomic data, which reflects
the composition of the ASV occurrence data from 16S rRNA iTag sequencing.
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3.15 DISCUSSION AND CONCLUSIONS
Statistical analysis of the microbiome of Synoicum adareanum was performed after
stratification of the microbial consortia into three subgroups: Core, Variable, and Dynamic. The
Core microbiome is comprised of 21 distinct ASVs that make up nearly 95% of the total ASV
occurrences. These bacterial ASVs have persistence across at least 80% of the samples collected
with substantial coherence of the structure of the core microbial community. Though statistically
significant colony-to-colony differences were observed, the overall dispersion based on
PERMDISP was the smallest for this subgroup. The permutational dispersion of the data increased
with the Variable subgroup and was highest with the Dynamic subgroup.
Distanced-based redundancy analysis revealed only 8.4% and 10.5% of the variability in ASV
occurrence is explained by the presence of adjacent invertebrates in the complete and Core
microbiome. When the environmental factors of depth, temperature, and distance from Palmer
Station were considered, these had a minimal effect on the composition as well.
There was not a direct correlation with palmerolide A levels and microbial ASV occurrence, a
finding likely explained by bioaccumulation of the secondary metabolite in the invertebrate tissues
leading to varied levels on metabolomic analysis, rather than the population size of the producer
in any given sample. Nonetheless, establishing the core membership of the Synoicum adareanum
microbiome was key in identifying the microbial producer of palmerolide A. In fact, the heatmap
of the Core microbiome gives visual representation to the importance of SaM_ASV15, the driver
of Clade 2. Through genomic correlations, this ASV was identified as possessing the pal BGC and
therefore the palmerolide A producer. The metagenome-assembled genome has since been
assembled. The producer represents a new genus of the phylum Veruccomicrobia and has been
named Candidatus Synoicohabitans palmerolidicus.
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The experimental design of this project is unprecedented in the marine environment of
Antarctica, with a spatial survey, quantitative metabolomic analysis, and genomic sequencing of
63 individual samples. Additionally, identification of the bacterium whose genome contains the
biosynthetic gene cluster responsible for the production of palmerolide A opens up new
opportunities for biotechnological production and potentially drug development for this potent
macrolide with great pharmaceutical promise. Biotechnology could offer means of obtaining
adequate mass of the compound while avoiding the ecological impact of mass harvesting of the
organism.
Additionally, new questions arise about the chemical ecology surrounding this host-associated
relationship. Future studies can determine whether the core microbiome and microbial community
as a whole is conserved in the ascidians of the same species beyond the Anver’s Island
Archipelago. It is unknown whether palmerolide A is also the principle metabolite in
geographically distant Synoicum adareanum. Further genomic investigations can also determine
the level of co-evolution between this microbial producer and its host.

3.16 EXPERIMENTAL METHODS
Similarity-matrix and hierarchical clustering analyses were performed using PRIMER v.7
and PERMANOVA+ (PRIMER-e, Auckland, New Zealand). Analyses were performed on the
complete microbiome as well as the three microbiome fractions in most cases. The ASV
occurrence data was square root transformed for all analyses. A heatmap based on the Core ASV
occurrence was generated with the transformed data, and hierarchical clustering with group
average parameter was employed, which was integrated with SIMPROF confidence using 9,999
permutations and a 5% significance level. Bray-Curtis resemblance matrixes were created using
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ASV occurrences without the use of a dummy variable. Then threshold metric Multi-Dimensional
Scaling (tmMDS) was conducted based on Kruskal fit scheme 1, including 500 iterations, and a
minimum stress of 0.001. Similarity profile testing through SIMPROF were performed based on
a null hypothesis that no groups would demonstrate differences in ASV occurrences. This
clustering algorithm was also used to generate confidence levels on the MDS plot, which were set
to 65% and 75%. In addition, 95% bootstrap regions were calculated with 43 bootstraps per group,
set to ensure a minimum rho of 0.99. In order to assess the contribution of each factor to the
variance of the microbial community in this nested experimental design, Site(Colony),
permutational multivariate analysis of variance (PERMANOVA) was used. Site-based centroids
were calculated and the PERMDISP algorithm was used to determine the degree of dispersion
around the centroid for each site. Overall site-to-site difference in dispersion was determined and
pairwise comparisons were also calculated with 9,999 permutations used to determine significance
(P(perm) <0.05). Exploratory analysis of the major ASV contributors to similarity was performed
using the SIMPER procedure based on sites and colonies, with a cut off for low contributions set
to 70%.

3.16
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CHAPTER FOUR:
BIOSYNTHETIC POTENTIAL OF PSEUDOVIBRIO SP. STR. TUNPSC04-5.I4

4.1 INTRODUCTION TO PEPTIDOMICS AND PROTEOMICS
4.1.1

HISTORY OF BIOINFORMATICS TO INFORM PROTEIN SEQUENCING
At the intersection of biology, chemistry, and technology is the field of Bioinformatics.

Many believe that the birth of bioinformatics occurred with the sequencing of the human genome
in the 1990’s; however, the field of bioinformatics dates back to almost sixty years ago, when early
computational biologists developed methods for data analysis of protein sequencing. Fredrick
Sangar and his group were the first to sequence a protein: insulin. This achievement proved the
polypeptide theory and was a groundbreaking concept that displaced the previous scientific belief
that proteins were without definite structure.1 Margaret Oakley Dayhoff, a mathematician and
physical chemist who is widely known as the founder of bioinformatics, was the first to create a
computational software to manage the abundance of data from the study of protein sequences. One
such program, Comprotein, was developed for punch-card computers in the 1960’s and was
comprised of several combinatorial algorithms that focused on the overlapping of protein
fragments (Figure 4.1).2 Though seemingly rudimentary compared to today’s technology, this was
one of the first instances of computation being paired with biological discovery. Dayhoff created
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databases through her computational sequence alignment methods that were invaluable in the
study of evolutionary biology and phylogeny, but also contributed to the study of cosmic matters
and biophysics.1 In 1965, Margaret Dayhoff and her colleague Richard Eck first published the
Atlas of Protein Sequence and Structure, a culmination of the computational sequencing work
performed on seventy proteins.3,4 This foundational groundwork inspired the field of
bioinformatics and the drive to decipher molecular information extended to the study of the
genome, resulting in full genome sequencing in the 1990’s.1

Figure 4.1. Example of Dayhoff’s flowchart for the program MAXLAP, within Comprotein, which was
designed to determine the maximum overlap in protein sequences. Comprotein is one of the first
computational software tools created for management of protein sequences. From “Proceedings of the
December 4-6, 1962, Fall Joint Computer Conference.” Copyright 1962 by ACM. Reprinted with
permission.
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With the exploration of the genome and an increase in understanding of molecular biology,
the theory behind the next phase of cellular and biomolecular understanding shifted from the “one
gene-one protein-one function” model to a systems or network biology. This conceptually allowed
for a multidirectional relationship between biological pathways and variability based on molecular
contexts. Biomolecules are viewed not just in terms of their genetic origin, but also in the reality
of dynamic modulation that is directed by external and internal changes that occur over the course
of time.5 This developing knowledge is derived from the study of these systems in tandem and in
isolation, but within the context of the system as a whole. The tremendous amount of data gathered
through analysis of these biological systems requires sophisticated information processing to make
the data biologically useful.6 Biological research disciplines that comprise the “omics” are now
extensive,

with

subsets

including

genomics,

proteomics,

lipidomics,

metabolomics,

pharmacogenomics, phenomics, secretomics, and interactomics.
The utility of mass spectrometry (MS) and the literature on the subject are most robust for
proteomics and metabolomics, though mass spectrometry has also been used in genomics as well
as other omic subclasses. A variety of modes and analysis tools specific to mass spectrometry have
been developed for these purposes.
4.1.2

TOP-DOWN VERSUS BOTTOM-UP APPROACHES
Of particular interest in the realm of bioinformatics are the rising disciplines of proteomics

and peptidomics, fields in which the versatility and comprehensive nature of mass spectrometry is
being fully realized. Prior to the development of mass spectrometry and proteomics, peptide
sequencing was a long and tedious process, involving ion exchange column use, electrophoresis,
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and sequential degradation of large proteins from the amino terminus to the carbonyl terminus
through Edman degradation.1,7 Currently, the primary instrument for proteomic analysis is mass
spectrometry (MS) and many of the approaches used for proteomics can be applied to analyze the
shorter amino acid sequences of peptides, as in peptidomics.
There are two primary divisions of MS for proteomics, denoted by the terms “bottom-up”
proteomics and “top-down” proteomics (Figure 4.2).8 Bottom-up proteomics involves digestion of
a protein into fragments and analysis of these fragments for potential amino acid sequencing and
protein identification. A strategy of comparing the fragmentation pattern from MS/MS to known
databases is known as “mass fingerprinting” and can help with positive identification of proteins.9

Figure 4.2. Mass spectrometry-based strategies to identify and characterize proteins. Bottom-up
approaches focus on amino acid sequencing from mixtures of proteins or peptides. Top-down approaches
start from a single protein or simple mixture of proteins and characterize the full protein mass and
fragmentation of the intact, rather than digested, protein. From “Mass spectrometry for proteomics,” by X.
Han, A. Aslanian, and J.R. Yates, Curr Opin Chem Biol. 2008 Oct; 12(5): 483-490. Copyright 2008 by
Elsevier. Reprinted with permission.
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One of four approaches can be used in “bottom-up” proteomics: (1) data dependent
acquisition (DDA), (2) directed approach, (3) targeted approach, and (4) data independent analysis
(DIA). Data Dependent Acquisition utilizes an algorithm that selects the most abundant peptides
in real time and delivers these ions, often via a radiofrequency-only quadrupole, to a collision
chamber for fragmentation and mass analysis. This heuristic approach to protein analysis, with
automatic selection of precursor ions is based on the relative abundance of ions in a survey scan.
Most of the ion peaks found in data obtained from the initial scan in this method do not undergo
further analysis, as the peptides found in lower abundance are less likely to be selected for
fragmentation and, therefore, for sequencing.5 DDA is commonly used on Fourier transformcollision induced dissociation (CID) devices. This method is also known as “shotgun” or
“discovery” proteomics. A directed approach can also be taken by strategically selecting certain
proteome segments by creating an inclusion list based on mass to charge ratio (m/z) ranges, for
further analysis and quantification.10
Targeted approaches focus on a very small subset of the proteome and result in highly
reproducible data. If the target is a known peptide, selected reaction monitoring (SRM) can be
utilized. Triple quadrupole (QQQ) instrumentation is used after liquid chromatography (LC)
separation. The first portion of the experiment involves selection of a specific m/z for the initial
quadrupole, followed by isolation in the second quadrupole, and, fragmentation is subsequently
induced in the third quadrupole.11,12 In SRM-MS/MS mode, specific precursor ion fragment
masses, known as SRM transitions, are selected and quantified. This information is then used to
deduce the presence and quantity of the digests of a particular protein of interest. This is a very
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sensitive technique with a broad dynamic range, but validation of the assays is a limiting factor for
the use of SRM.12
Data Independent Analysis attempts to identify all proteins within a sample. There is no
application of an ion transmission window for DIA and, therefore, all parent ions are delivered to
the collision cell for fragmentation and analysis, resulting in a near-100% duty cycle.
Chromatographic peaks and retention times are used in the extensive deconvolution process in
order to tie the precursor ions to the product ions. 13 One of the primary advantages of DIA is the
ability to detect and identify proteins in very low concentrations.14 While DDA systematically
ignores many of the proteins in lower concentration, the analysis of proteins in low abundance
becomes a primary strength in DIA. However, reproducibility and scan rates often suffer with this
approach.13
Top-down proteomics, on the other hand, characterizes intact proteins and their fragments
for confident identification. This approach is invaluable for increased peptide sequence coverage
and mapping, protein quantification, and the characterization of posttranslational modifications
(PTMs) and protein isoforms.15,16 Absolute and relative quantification are important components
of the systems biology perspective and both can be obtained through MS. Metabolic labeling,
isotopic labeling, and chemical derivatization are used to aid in protein quantification.15 PTMs are
covalent modifications that are enzymatically made to proteins after ribosomal protein synthesis.
These include addition or removal of a molecular group or a change in the peptide sequence that
is irreversible.5 Protein isoforms are a family of proteins with slight variability that perform similar
biological roles and often arise from a single gene sequence. A top-down proteomics experiment
can be optimized for PTM identification and localization. Limitations to top-down proteomics
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include difficulty with protein separation, ionization, and fragmentation due to the large, often
globular, nature of undigested proteins.16
In both bottom-up and top-down proteomics, proper subcellular preparation is crucial. The
extensive protein dynamic range within a biological system is one of the most challenging sample
preparation issues. Whole protein fragmentation is another crucial step in sample preparation for
bottom-up approaches. Proteolysis, or the protein digest process, involves hydrolysis of amide
bonds. Many of the proteolytic agents have bond specificity, cleaving bonds through hydrolysis at
certain amino acid sites. For example, trypsin, a protease commonly used in sample preparation
for discovery proteomics, cleaves arginine and lysine residues at the carboxyl side.
Endoproteinases, chymotrypsin, subtilisin, and elastase are other examples of digestive enzymes
used in sample preparation. In order for the primary amino acid sequence to be exposed to the
enzymes for selective hydrolysis, detergents (SDS and CHAPS) and chaotropes (urea and thiourea)
are used.16
PTMs are another key area for proteomic analysis and often require additional sample
processing steps to improve identification. PTMs are a result of chemical modifications to parent
proteins and peptides. These increase the overall diversity of the proteome and are key for most
biological cascades. MS can be used to detect these critical modifications through identification of
mass shifts. A measured parent peptide ion undergoes fragmentation, and these fragments are
compared against the predicted protein in a database. Differences in mass of the protein and
predicted mass from the DNA sequence can be used to infer the presence of PTMs. The mass to
charge ratios of the fragment ions can confirm the presence of such modifications. A number of
PTMs are possible, including biotinylation, acetylation, ubiquination, phosphorylation,
methylation, oxidation, and glycosylation. Potential locations of the modifications are based on
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database predictions of the amino acid sequence from the DNA sequence. Computational methods
for structure elucidation can assist in proper identification and placement of the modifications.16
4.1.3

MASS SPECTROMETRY FOR PROTEOMIC ANALYSIS
Mass Spectrometry is one of the key instruments and an unbiased tool that is commonly

used for proteomic analysis. The three main components of mass spectrometers include the ion
source with ion optics, the mass analyzer, and the electronics for data processing. Each mode of
mass spectrometry has different utility, benefits, and limitations. A listing of different MS
instrument types with their primary applications in proteomics is listed in Figure 6 and will be
discussed in this section.
4.1.3.1 IONIZATION SOURCES
The two primary ionization sources for bottom-up proteomics are nanoelectrospray
ionization (nESI) and Matrix-Assisted Laser Desorption Ionization (MALDI). These soft
ionization techniques are optimal for proteomics because of the nonvolatile, polar, and thermally
unstable nature of proteins and peptides.15 Electrospray ionization is a form of ionization that
involves desorption and aerosolization of the analyte of interest from the liquid solvent. The result
is often a multi-charged species that effectively extends the mass range for the experiment.
Nanoelectrospray ionization has a similar mechanism, but a small electrospray needle is used, and
the flow rate is therefore reduced. Liquid chromatography (LC) instrumentation is often used for
protein separation prior to introduction of the sample by nanoelectrospray. With the development
of nanoelectrospray ionization, there is improved sensitivity for MS proteomics, discriminating
even to subpicomole concentrations. However, throughput is often decreased and extensive
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preparation of samples is required.17 The goal of nanoelectrospray ionization is to ionize, but not
fragment the proteins as the subsequent stage of MS typically involves fragmentation.
Matrix Assisted Laser Desorption Ionization (MALDI) methods were first introduced in
the late 1990’s and demonstrated a substantial mass range with the ability to ionize proteins with
masses in excess of 50,000 Daltons.18 Prior to this, desorption of ions through secondary ion mass
spectrometry (SIMS) was limited to proteins with a mass less than about 2,000 Daltons. In
MALDI, an analyte is mixed with a substance that absorbs energy, known as a matrix. The
substance is placed on a plate for analysis by automated means or manually. A laser beam is used
to irradiate the mixture of analyte and matrix causing ionization with sublimation. Positive mode
MALDI results in protonated molecular ions, denoted by [M+H]+, whereas negative mode results
in deprotonated molecular ions, denoted by [M-H]-. MALDI is paired with a mass analyzer, often
a time of flight (ToF), for measurement of the ionized molecule or protein of interest. Protein
analysis can then be performed resulting in the ability to map the relative molecular distributions.19
4.1.3.2 PEPTIDE FRAGMENTATION
The ionization methods used in the collision cell result in a variety of ions, the tuning of
which are based on the instrumentation used and the intensity of fragmentation. Low energy
conditions facilitation fragmentation at the amide bonds which comprise the peptide backbone.
The result of this fragmentation is b-type ions (containing the N-terminus) and y-type ions
(containing the C-terminus). As an increase in fragmentation energy is provided, the fragmentation
pattern also produces a-type, c-type, and z-type ions, which represent fragmentation due to
additional proton abstraction and of side chain components. The mass difference of the same type
of fragments can be evaluated sequentially and then used to infer the amino acid residue lost in the
fragmentation process. This allows the peptide sequence to be theoretically reconstructed. The
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massive amount of information that is produced by a MS proteomics experiment must not only be
managed effectively, but also translated into meaningful data. Bioinformatic protein databases can
be used to streamline the process of sequence elucidation by utilizing these fragmentation patterns.
Tandem MS/MS and MSn are particularly useful for sequencing, especially de novo peptide
sequencing, and for confirmation of amino acid sequences based on in silico experiments.20
Several instrumental modalities can be used to induce peptide fragmentation, including
collision-induced dissociation (CID), beam-type, and electron transfer dissociation (ETD). In CID,
ions are introduced to a reagent gas. The resulting collisions lead to a conversion of kinetic energy
into internal energy relaxation and fragmentation, often through proton transfer. In ion traps, a
specific frequency can be applied in order to cause excitation of ions with a specific mass to charge
ratio. Further fragmentation is unlikely and the resulting pattern is comprised of predominately btype and y-type ions. In beam-type fragmentation, both the fragments and the precursor ions
undergo further collision, resulting in more fragmentation of the less stable b-type ions. Therefore,
y-type ions are the predominant ions seen. Finally, ETD results in collisions between the peptide
and ETD reagents, resulting in predominate fragments to c-type and z-type ions.16
4.1.1.3 MASS ANALYZERS
Mass analyzers that are most useful for proteomics experiments include quadrupoles, Time
of Flight (ToF), linear Ion traps (LIT), Orbitraps, and Fourier Transform-Ion Cyclotron Resonance
(FT-ICR).16 A QToF device typically places a triple quadrupole in line with a time of flight mass
analyzer. The first quadrupole is used as a jet ion guide, the second for precursor ion selection via
mass filtering, and the third for fragmentation in the collision cell. Ions then enter the mass analyzer
through ion compression optics in a manner orthogonal to the flight tube. A reflectron can be used
to further improve mass accuracy. A multichannel detector that converts time into a mass to charge
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ratio is used to create the spectra. The Orbitrap and Linear Ion Trap-type mass spectrometers have
a different configuration. Using electrospray, proteins are sprayed directly from the LC to the inlet
source. As stated above, desolvation occurs through the addition of heat and the ions are guided,
focused, filtered, and then transferred to the ion trap via a quadrupole or an octopole. Ions with the
same m/z are delivered to a collision cell where energy is added through a high-pressure cell and
fragmentation ensues. The remaining parent ions and correlating fragments are then detected in a
low-pressure trap. If even more mass accuracy and resolving power is needed, an Orbitrap can be
used. The peptide ions are passed to a higher-energy collisional dissociation (HCD) cell and then
transferred as an ion packet with the assistance of the C-trap to the spindle-shaped Orbitrap mass
analyzer. In this device, the ions with the same mass-to-charge ratio oscillate with the same
frequency. A Fourier transform is used to convert the frequency-based ion current to a m/z value
for production of a spectra.16 The utility of mass spectrometry for proteomics has expanded over
the last couple of decades, particularly with the development of Fourier Transform Ion Cyclotron
Resonance (FT-ICR).9 This technology has improved accuracy and sensitivity of mass spectral
acquisition, making protein elucidation even more achievable. FT-ICR instruments have superior
mass accuracy but at the expense of speed, sensitivity, and instrument cost.
4.1.4

PROTEOMIC AND PEPTIDOMIC DATABASES
As Big Data analysis, public repositories, and data sharing continue to advance, it will be

important to streamline data input in order to ensure that the plethora of information is utilized
effectively. Big data produced from genomics is often placed in public repositories, whereas
proteomic databases are less cohesive and less utilized. This is in part a result of the highlycomplicated nature of proteomics and peptidomics, with data extending beyond peptide
sequencing and into the realms of posttranslational modifications and complex interactions. This
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creates a unique challenge to the field of bioinformatics, particularly as the sheer volume of data
increases with the rise of more effective, high-throughput analytical methods that help elucidate
these biological languages of life. Many researchers in the fields of computational biology and
bioinformatics are advocating for a centralized “resourceome” that would classify data according
to common algorithms and serve as a global and cohesive cross-linked ontology.21
The data from proteomic experiments can be divided into three main categories: raw data,
processed data with peptide/ protein identification and quantification, and the resulting biological
conclusions. Correlating with the degree of processing and interpretation, a variety of databases
have been formulated to improve data sharing and interpretation. These programs use a variety of
algorithms to match, identify, and score protein and peptide fragments.22 After tandem mass
spectral data is obtained, for example, peptides and proteins can be identified via in silico
experiments based on digestions on proteins in collective databases. Since homologous peptides
can be found in multiple proteins, inferences based on additional fragments can increase the
confidence of protein identification.16 The future of proteomics in the field of bioinformatics is
promising as instrumentation and technology continue to advance. There are profound
implications for bioinformatic innovation and application with the potential for discovery of novel
molecular mechanisms, metabolic biomarkers, therapeutic targets, and natural products.
4.1.5

DE NOVO SEQUENCING TECHNIQUES
Deconvoluting mass spectra of nonribosomal peptide synthetase (NRPS) products is

particularly challenging as many peptidic natural products (PNP) are comprised of amino acid
residues that extend beyond the proteogenic amino acids and can incorporate hundreds of
nonstandard amino acids.23 Additionally, PNP can be linear or macrocyclic in nature. PTMs often
occur and increase the complexity of identifying structures through bioinformatic means.
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4.2 NON-RIBOSOMAL PEPTIDE SYNTHETASES
Nonribosomal peptide synthetases (NRPS) are multi-modular megaenzymes that act in an
assembly-line fashion to biosynthesize many peptidic secondary metabolites that have diverse
structures, such as heterocyclic rings, non-proteogenic amino acids, prenylations, glycosylation,
and other modifications.24–26 Type I NRPS systems are found primarily in fungi and rely on a
single iteratively-acting enzyme for synthesis.27 Type II NRPS systems, on the other hand, are
commonly found in bacterial species and contain multiple enzymatic domains that act primarily in
a non-iterative fashion. Each enzymatic domain within the megaenzyme has a discrete role in a
step of the biosynthetic process. The action of these megaenzymes is often co-linear, and therefore,
the function and subsequent structural addition or alteration can be hypothesized based on the
information gathered from the biosynthetic gene cluster (BGC) that encodes for the molecular
machinery. NRPS megaenzymes are sometimes hybridized with polyketide synthase (PKS)
components to enhance the architectural diversity of the product. There are three main steps to
NRPS biosynthesis: initiation, elongation, and termination.
4.2.1

INITIATION
In a manner analogous to acyl carrier proteins (ACPs) seen in polyketide synthases (PKS),

NRPS utilize a 4’phosphopantetheinyl (ppant) arm linked to a conserved serine of the protein to
tether the amino acid subunits to and facilitate the transfer of the monomers to the growing
peptide.28 The ppant arm in NRPS systems is a derivative of Coenzyme A, as seen in PKS systems
(see Chapter II). Adenylation (A) domains are responsible for activation of the monomeric amino
acid through trans-esterification to form an aminoacyl-adenylate.27 Fidelity of the enzymatic
domain to a specific substrate is guided by two active sites (A1 and A2) that confer a degree of
specificity through non-covalent interactions. Sometimes strict specificity guides selection, while
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other times a degree of enzymatic promiscuity can introduce architectural diversity by selecting a
variety of amino acids. The A domain is responsible for transfer of the aminoacyl-adenylate to the
free thiol of the ppant arm of the PCP, creating a covalent linkage. Some tailoring enzymes act
while the monomer is covalently linked to the ppant arm.
4.2.2

ELONGATION - CONDENSATION DOMAINS
Condensation (C) domains are responsible for sequential peptide bond formation and

elongation of the growing peptide chain. C domains catalyze peptide bond formation through the
nucleophilic attack of the thioester carbon on the upstream amino acid by the free amine of the
amino acid bound to the downstream PCP. The thioester bond is cleaved, and the elongated peptide
is then acted upon by the subsequent amino acid that is bound to the next PCP.
4.2.3

TAILORING
A variety of tailoring enzymes introduce an additional level of structural diversity to NRPS

products. For example, NRPS can incorporate D-configured amino acids or, alternatively, can
transform a D-configured residue to L-configuration through an epimerization (E) domain.29 As
seen in other biosynthetic pathways, carbon-methyltransferase (cMT) domains and nitrogenmethyltransferase (nMT) domains utilize S-adenosyl methionine (SAM) as a substrate to transfer
a methyl group to either a carbon or a nitrogen. The action of n-MTs typically occurs cis-to the
core biosynthetic process; however, cMTs do not usually act on amino acid residues while they
are tethered to the PCP. Carbon methyltransfers in NRPS systems typically occur on the residues
during the precursor stage.30 Furthermore, formylation domains are seen commonly in prokaryotic
NRPS systems which lead to N-formylation in the anabaenopeptilides and gramicidins.31,32
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Additionally, macrocyclization can occur as part of the mechanism to release the NRPS
product from the megaenzyme, but cyclases are modifying enzymes that are typically cis-acting
that can introduce heterocyclic rings using a different mechanism, as seen in bacitracin.24
Thiazolines from cysteine and oxazolines from threonine or serine can be introduced by cyclases
acting to catalyze intramolecular cyclization on residues that have side chains with a βnucleophiles to form a five-membered rings.27
4.2.4

TERMINATION
Thioesterase (TE) domains are the canonical domain responsible for termination of the

biosynthesis of NRPS products and result in cleavage of the thioester bond and release of the
molecule in either its linear form or macrocylic form.

4.3 DETERMINING THE BIOSYNTHETIC POTENTIAL OF PSEUDOVIBRIO SP. STR. TUNPSC045.I4
One of the core members of the microbiome of the Synoicum adareanum collected in the
Antarctic waters is a new species of Pseudovibrio, currently referred to as Pseudovibrio sp. str.
TunPSC04-5.I4.33 The Pseudovibrio spp. are of particular interest in regards to chemotherapeutic
and antibiotic drug discovery and development, as their associated genomes code for PKS and
NRPS, the key enzymes for secondary metabolite synthesis.33–35 In this project, mass spectrometry
is used in combination with annotative software for annotation of biosynthetic gene clusters to
confirm the biosynthetic potential of Pseudovibrio sp. str. TunPSC04-5.I4 through identification
of predicted peptides based on the genomic sequencing (Figure 4.3).
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There were two experimental arms to evaluating the biosynthetic potential of Pseudovibrio
sp. str. TunPSC04-5.I4. The bioinformatic arm of the experiment started with the assembled
genome. The genome was run through the antibiotics and secondary metabolites analysis shell
(antiSMASH) pipeline for initial cluster annotation. The non-ribosomal peptide synthetase
(NRPS) biosynthetic gene clusters (BGCs) appeared to have a complete modular assembly
encoding four peptide products. The antiSMASH algorithm also included predicted structures of
the compounds. Validation of the predicted clusters encompassed both the predicted structures and
insights from a detailed inspection of the domain annotations of the BGCs. Modules of polyketide
synthase (PKS) origin were associated with some clusters, though these components were not
included in the structural prediction by antiSMASH.
The other arm of the project included evaluation of the peptidic metabolites from a culture
of Pseudovibrio sp. str. TunPSC04-5.I4. Biomass of the bacterial isolate was processed for
proteomic analysis. Reverse phase LC was followed by nanoelectrospray mass spectrometery. The
information and insights from the BGCs and structural predictions were used in conjunction with
in silico fragmentation to interrogate the mass spectrometry data. De novo peptide sequencing,
custom database searches with particular focus on fragments of possible permutations of the
predicted peptide using PEAKS 8.5 software (Bioinformatics Solutions, Inc.), as well as
dereplication of peptidic natural products and molecular networking, were performed using Global
Natural Product Social Molecular Networking (GNPS).36,37
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Figure 4.3. Workflow showing the two arms of the project. The vertical portion of the flow chart
shows the peptidomic process of identifying peptidic natural products from the bacterial extract of
Pseudovibrio sp. str. TunPSC04-5.I4. The horizontal arm shows the computational components from
genome assembly to biosynthetic gene cluster annotation and peptide structure prediction.

4.4 GENOME SEQUENCING OF PSEUDOVIBRIO SP. STR. TUNPSC04-5.I4
In earlier work, sixteen bacterial isolates were successfully characterized from Synoicum
adareanum to search for the producer of palmerolide A.33 Of the isolates characterized, most were
Gammaproteobacteria of 5 genera: Shewanella, Moritella, Photobacterium, Psychromonas,
Pseudoalteromonas. One, however, was an Alphaproteobacteria, a Pseudovibrio sp.33 Liquid
cultures from all sixteen isolates were used to screen for the presence of palmerolide A based on
liquid chromatography (LC) techniques, but none revealed the presence of the secondary
metabolite.
Biosynthetic gene clusters are not always constitutively expressed, and therefore do not
always result in translation of the necessary biosynthetic machinery to produce a compound. This
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silencing of defensive or pro-survival BGCs can often occur in laboratory cultures where bacterial
isolates are grown in monoculture and have no need for chemical defense, or in nutrient-rich media
where chemical competition is not necessary. One genome from the cultivar library was sequenced
to screen for BGCs that may be responsible for the palmerolide family of compounds - a
Pseudovibrio sp. isolate. This genus is known to be rich in BGCs, but this was the first isolated
from Antarctica. It has an interesting phenotype and branching cell division pattern (Figure 4.4).

Figure 4.4. Pseudovibrio sp. str. TunPSC04-5.I4 (a) stained with 4’,6-diamidino-2-phylindole which
targets A-T rich sites, and (b) SEM image demonstrating the interesting branching patterns seen with cellular
division of the bacterium. Both images taken at DRI by the Murray Lab.

The genome proved this organism to be biosynthetically talented with forty BGCs
identified (Figure 4.5). Two type-3 PKS BGCs, Two type-1 PKS BGCs, four NRPS BGCs, one
Terpene BGC, five BGCs associated with saccharides, one associated with a bacteriocin, and 21
putative BGCs were identified. Not one was consistent with palmerolide A production; however,
because of the wealth of BGCs, the biosynthetic potential of the organism became a source of
interest for natural product discovery.
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Figure 4.5. Pseudovibrio sp. str. TunPSC04-5.I4 is biosynthetically talented with BGCs that encode
for NRPS, PKS, Terpene synthase, among others. The antiSMASH annotations of the bacterial genome
revealed forty BGCs for secondary metabolite production.
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4.4.1

NONRIBOSOMAL PEPTIDE SYNTHETASE CLUSTERS
NRPS, PKS, and putative Biosynthetic Gene Clusters were present in the annotated

genome, indicating the capacity for production of valuable secondary metabolites. Four
compounds, all peptides, were predicted from the biosynthetic NRPS gene clusters produced by
IMG-ABC and AntiSMASH (v 3.0 and later v 4.2.0) and are described blow. The two peptides
containing only one unknown amino acid in the predicted secondary metabolite structure became
the focus for validation of the predictive databases using mass spectral analysis. Algorithms used
for prediction of amino acid residues embedded within the antiSMASH v 3.0 included Stachelhaus
code, NRPS Predictor3 SVM, pHMM, PrediCat, and SANDPUMA ensemble.
4.4.1.1 BIOSYNTHETIC GENE CLUSTER A:
Biosynthetic Gene Cluster A consists of 65,729 base pairs on six genes (Figure 4.6). The
complement strand encodes for a series of modules consistent with ten amino acid residues in the
sequence: tyrosine-threonine-glycine-glycine-arginine-proline-cystiene-unknown-valine-proline.
Module 1 contains a C domain and an A domain with consensus for tyrosine specificity; however,
phenylalanine is also called by the pHMM algorithm. A PCP is also present. A C domain and an
A domain with specificity for threonine (2 of 5 predictions; pHMM: dhab-dht and no prediction
from PrediCAT or Stachelhaus code), and PCP is present in Module 2. Module 3 and 4 both
contain C domains, A domains with algorithmic consensus for glycine (3 of 5 predictions; pHMM:
ser and no prediction from PrediCAT), and PCPs, though on different genes. The next contig
includes a C domain and an A domain for arginine (3 of 5 predictions; pHMM: ornathine and no
prediction from PrediCAT) and a PCP, followed by a C domain, an A domain for proline (4 of 5
predictions; no prediction from PrediCAT), and then a C domain, a possible cyclization domain
for the census cysteine (4 of 5 predictions; no prediction from PrediCAT), which would result in
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the formation of a 5-membered ring. This tailoring enzyme was considered when custom databases
were created for interrogation of the MS2 data using de novo sequencing techniques. Module 8,
which contains a C domain, an A domain that lacks consensus, and a PCP, is capped by the first
of three thioesterases encoded in this BGC.

Figure 4.6. Biosynthetic Gene Cluster A, 65.7 Kbp in length and comprised of six contigs. The product
is predicted to be ten amino acids in length with at least one adenylation domain lacking consensus for
an amino acid specificity prediction. There are three thioesterase domains present in the BGC.

Module 10 through Module 13 are on a single gene. Module 10 contains a C domain and
an A domain with specificity for valine (3 of 5 predictions; Stachelhaus code: aile/ile and no
prediction from PrediCAT), followed by a PCP. Module 11 is comprised of a C domain, an A
domain with specificity for proline (3 of 5 predictions; no prediction from PrediCAT or
Stachelhaus code), a PCP, followed by a short PKS segment which includes a single elongation
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through a ketosynthase (KS). This is followed by a KR, which would reduce the β-carbonyl to a
secondary alcohol. The second TE caps this series of domains. An additional TE is present on a
separate gene.
4.4.1.2 BIOSYNTHETIC GENE CLUSTER B:
Biosynthetic Gene Cluster B consists of 37,015 base pairs with all core biosynthetic
modules on a single gene (Figure 4.7). The complement strand encodes for a series of modules
consistent with six amino acid residues in the sequence: glycine-aspargine-unknown-unknownunknown-glycine based on algorithmic specificity predictions. The BGC starts with a C domain
followed by an A domain with consensus specificity to a glycine residue (4 of 5 predictions; no
prediction from PrediCAT) and a PCP in module 1. Module 2 consists of a C domain follows and
then an A domain with specificity to asparagine (4 of 5 predictions; no prediction from PrediCAT)
and a PCP. Module 3 through Module 5 contain C domains followed by a lack of consensus for
the adenylation specificity. PCPs are present in each module. Module 6 has a C domain followed
by an A domain with specificity to glycine (4 of 5 predicitons; no prediction from PrediCAT).
There is no evidence of a thioesterase encoded within the BGC. The 3’ end is flanked by a
transposase.

Figure 4.7. Biosynthetic Gene Cluster B, 37 Kbp in length and comprised of six contigs. The product
is predicted to be six amino acids in length with three adenylation domains lacking consensus for an
amino acid specificity prediction.
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4.4.1.3 BIOSYNTHETIC GENE CLUSTER C:
Biosynthetic Gene Cluster C consists of 24,293 base pairs on three genes (Figure 4.8). The
compliment strands encode for an NRPS that would produce a peptide that is seven residues in
length with the predicted sequence: unknown-asparagine-unknown-glycine-glycine-unknownunknown. The BGC starts with an epimerization domain followed by a C domain. The algorithms
did not have a consensus prediction for the A domain selecting the initial amino acid residue. The
second module consists of a condensation domain followed by an adenylation with consensus
specificity for asparagine (4 of 5 predictions; no prediction from PrediCAT) and a PCP. Module 3
contains a C domain and an A domain without consensus, and a PCP. The only algorithm that
predicts the residue specificity is pHMM (trp); however, tyrosine is included in the predicted
structure associated with the BGC. Module 4 consists of a C domain followed by an A domain
with specificity to glycine (4 of 5 predictions; no prediction from PrediCAT) and a PCP. Module
5 consists of a C domain followed by an adenylation with specificity to glycine (5 of 5 predictions)
and a PCP. Modules 6 and 7 consist of a C domain and adenylation domain that also lacks a
substrate consensus, though one of five algorithms, pHMM, predicts asparagine (no predictions
otherwise). Module 8 is a thioesterase, which would serve as the terminal domain for this NRPS
megaenzyme.
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Figure 4.8. Biosynthetic Gene Cluster C, 24.3 Kbp in length and comprised of three contigs. The
product is predicted to be seven amino acids in length with multiple adenylation domains lacking
consensus for an amino acid specificity prediction.

4.4.1.4 BIOSYNTHETIC GENE CLUSTER D
Biosynthetic Gene Cluster D consists of 15,532 base pairs on two genes (Figure 4.9). The
compliment strands encode for an NRPS that would be four amino acids in length with the
sequence: glycine-unknown-asparagine-asparagine. The BGC starts with a C domain, an A domain
with specificity for glycine (all 5 predictions) and a PCP. Module 2 has a C domain but the
associated A domain lacks consensus for the amino acid specificity. The next two modules contain
C domains and A domains with asparagine specificity (4 of 4 of 5 predictions; no prediction from
PrediCAT). There is also an epimerization domain present. Interestingly, the BGC may continue
beyond what is assembled as a BGC at this point. There is no termination domain, but additional
C domain(s) with unusual A domains are present. The location of the epimerization is also unusual
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and may be explained if further downstream modules are detected. Genomic efforts in the future
may capture this BGC to completeness. For purposes of this experiment, the GXNN sequence was
still used for de novo interrogation of the MS2 data.

Figure 4.9. Biosynthetic Gene Cluster D, 15.5 Kbp in length and comprised of two contigs. The product
is predicted to be four amino acids in length with one adenylation domain lacking consensus for an
amino acid specificity prediction.

4.5 MASS SPECTROMETRY ACQUISITION
After biomass of the bacterial culture was processed through a series of steps including
lyophilization and desalting, the samples were prepared for LC-MS/MS analysis. Most of the data
was obtained on an Orbitrap QE+, which has a mass accuracy of +/- 0.02 amu. During instrument
maintenance, some samples were run on an Orbitrap XL, which has a mass accuracy of +/- 0.5amu.
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4.6 MANUAL DE NOVO SEQUENCING EFFORTS
Initially, a manual de novo sequencing method was adopted (Figure 4.10). The b6 ion was
used for manual interrogation of the data since the unknown amino acid is in the 8th position and
the fragmentation of the b7 ion could be influenced by the identity of the unknown in the adjacent
position. In silico fragmentation was performed using ProteinProspector (UCSF) (Table 4.1). The
extracted ion chromatograms targeting the MS2 fragment of 632.3151 revealed the presence of
ions that correlated with predicted m/z in the MS2, though sensitivity was reduced on the Orbitrap
XL instrument based on unit mass resolution of +/- 0.5 amu (Figure 4.11). In addition, the
possibility of posttranslational modifications and cyclization, increased the complexity of manual
analysis. The initial step for de novo sequencing involved identification of key fragment ions,
including, the b6 ion of Cluster A with an m/z of 632.3120 amu. This de novo sequencing method
was both onerous and inefficient; however, a bioinformatic approach proved more fruitful.

Figure 4.10. Expected fragmentation pattern for the predicted peptide associated with Biosynthetic
Gene Cluster A.
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Table 4.1. Key m/z peaks from in silico fragmentation of the predicted peptide shown includes the btype ions from the N-terminus until the peptide bond between the seventh and eighth amino acids. This
reflects fragmentation that would occur proximal to the unknown residue.
Key Peaks for b-type ions
aa residue
Y
T
G
G
R
P
C
position
1
2
3
4
5
6
7
+
b
--265.1183 322.1397 379.1612 535.2623 632.3151 735.3243
+2
b
--------268.1348 316.6612 368.1658

Figure 4.11. Mass Spectrum from MS2 data acquisition with the presence of predicted m/z of b6 ion at
632.31. This data was obtained on the Orbitrap XL which has a mass accuracy of +/-0.5 amu. The
remaining peaks did not align as would be expected with the in silico fragmentation prediction. Due to
the high mass tolerance of the instrument leading, manual analysis was not deemed an efficient strategy.
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4.7 BIOINFORMATIC DE NOVO SEQUENCING EFFORTS
A method was then utilized that included the use of PEAKS MS, Proteomic software with
capability for bioinformatic de novo peptide sequencing, database searches, and PTM
identification. A predicted reduction of the carboxy-terminus to an aldehyde arising from the
antiSMASH data was allowed for; however, the primary searches were performed using the nonreduced structure as there was no genomic evidence that could be found to support the reduction.
The data were screened against Uniprot and NCBI databases. A contaminant database, cRAP, was
downloaded and enabled to ensure that common contaminants would not appear as potential hits.
De novo hits were evaluated for quality, length, and novelty.
Custom FASTA databases were then created for both peptide sequences of interest:
YTGGRPCXVP and GXNN, where X signifies the unknown amino acid. This was later expanded
to include a custom database for XNYGGNX and four databases were designed around additional
PRISM annotations and predictions. All 20 standard proteogenic amino acid were included for
each potential permutation for the peptide based on the unknown amino acid residue. Both the
non-reduced and reduced carboxy-terminus were also considered. PEAKS MS 8.5 is limited to
detection of the proteogenic amino acids, though peptidic natural products also contain nonproteogenic amino acids; which, in our case a possible ornithine. Post-translational modifications
(PTMs) were enabled in the parameters for acetylation, dehydration, methylation, and oxidation
with a maximum of five PTMs for peptide to ensure a large enough window for these changes.
The data showed promising results for the presence of the peptide containing ten amino acids with
a sequencing confidence of over 90% with a ten-amino acid match with the unknown identified as
glutamine (Figure 4.12). A methylation on the threonine and arginine were predicted. Whole or
partial matches of the sequence were identified with variable locations of the methylated
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modification and one of three possible residues at the unknown site, which was most commonly
glutamine, but cysteine and asparagine were also present (Figures 5.13 and 5.14). The peptide
appeared to have variable sites of methylation and a non-reduced c-terminus.

Figure 4.12. Bioinformatic match to predicted peptide for Biosynthetic Gene Cluster A with the
unknown residue identified as glutamine. MS2 ions consistent with methylation of both threonine and
arginine. Positive identification based on the fragmentation pattern and ion intensity was accompanied
by only moderate confidence (-log10P of 10.75).
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Figure 4.13. Bioinformatic match to predicted peptide for Biosynthetic Gene Cluster A with the
unknown residue identified as proline. Peptide nine residues in length. MS2 ions consistent with
methylation of tyrosine. Positive identification based on the fragmentation pattern and ion intensity was
accompanied by only moderate confidence (-log10P of 13.35).
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Figure 4.14. Bioinformatic match to predicted peptide for Biosynthetic Gene Cluster A with the
unknown residue identified as glutamine. MS2 ions consistent with methylation of threonine. Positive
identification based on the fragmentation pattern and ion intensity was accompanied by relatively low
confidence (-log10P of 7.24).

B-type and y-type ions can be used to deduce whether the methylations are on the side
chains or on the backbone. BLAST and Sci-Finder databases were searched, and no structural
matches were found. A control run using the marine broth media did not show the presence of
these potential peptides and did not contain any hits to the custom databases that were ten amino
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acids in length. A single peptide was identified in the de novo search against the YTGGRPCXVP
custom database, TGGR(+14.02)PCY, but it was only seven amino acids in length and did not
correlate with the peptides of interest. Therefore, these de novo hits did not simply reflect
components of the media.
Pairing the in silico b-ions with the hits from PEAKS that did not bear PTMs, resulted in
identification of a few spectra with peaks matching two to three of the expected ions; however, no
single spectra from this method resulted in complete congruency with the prediction. Additionally,
a targeted parallel reaction monitoring (PRM) of MS1 targets and the expected MS2 ions was
utilized. This approach was performed with inclusion lists based on expected MS2 ions from in
silico fragmentation of unmodified predicted peptides using the tools in ProteinProspector
(UCSF). The reverse-phase method was extended to just over 90 minutes for the PRM experiments
(Figure 4.15). The data did not reveal peptide matches from the predicted YTGGRPCGVP. The
results of these experiments pointed to a high likelihood of structural deviation from the prediction
arising from the presence of PTMs or another structural variant.
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Figure 4.15. Targeted parallel reaction monitoring results based on inclusion list from expected ions
from in silico fragmentation. (a) Chromatograms – Total Ion Chromatogram, m/z of 268.14, m/z of
316.66, and m/z of 368.16. (b) MS2 of selected parent ion at Scan #15718, which contained fragments
at 268.19 and 368.24 amu.
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Though these results of the hits with the PTMs held promise, the associated confidence
levels were not optimal. A -log10P of ≥ 20 is desired for a more definitive identification of peptides
through the de novo sequencing methods of PEAKS MS. This prompted further investigations into
the data. The genome of Pseudovibrio sp. str. TunPSC04-5.I4 was submitted for repeat analysis
and annotation in an updated version of antiSMASH (v.4.2.0). Additional residues were included
in the predictions for the 10 amino acid sequence (Figure 4.16). Evidence of cyclization domains
appeared on the updated iteration of annotations, broadening the structural diversity that could be
introduced to the scaffold. The algorithms within PEAKS MS could not process cyclic peptides,
and a different approach was required.

Figure 4.16. Sequence prediction based on antiSMASH v.4.2.0.

4.8 MOLECULAR NETWORKING
Global natural Products Social Molecular Networking (GNPS) is a robust tool for
visualizing chemical relationships based on MS2 data.37 Nodes represent distinct compounds based
on a consensus spectrum that is created from multiple MS2 spectra. The neighbors within a cluster
are structurally related. Those sharing an edge have at least six MS2 fragments in common.
DEREPLICATOR is a tool designed to identify known natural products based on databases of
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known peptidic natural products.38 In this project, the DEREPLICATOR results were overlaid with
the spectral network to identify structural clues to aid in identification of nodes that may match the
expected sequence and structure of the peptides predicted from the BGC annotations. One cluster
in particular contained hits from several known compounds with similarities to our predicted
peptide, most notably nostopeptolide A2, bacilomycin D5, and SCH-378161 (Figure 4.17). As a
result of obtaining these structural clues from neighboring known compounds, nodes 1590 and
1602 in the molecular network are both of interest and may represent the product of Biosynthetic
Gene Cluster A from the Pseudovibrio sp. str. TunPSC04-5.I4.
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Figure 4.17. GNPS Molecular Network with annotation of DEREPLICATOR hits. Nodes 1590 and
1602 share structural similarities with nostopeptolide A2, bacilomycin D5, and SCH-378161. These are
all cyclic and share residues predicted by the annotative tools regarding adenylation specificity.
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4.9 DISCUSSION AND CONCLUSIONS
In conclusion, a method has been developed to enhance drug discovery efforts through the
convergence of genomic data with NRPS BGCS, compound predictions based on BGC
enzymology, and mass spectrometry peptidomics of bacterial cultures. A biosynthetically talented
bacterium, Pseudovibrio sp. str. TunPSC04-5.I4, was isolated and its genome was sequenced in
earlier work. Pseudovibrio spp. are known to be rich in biosynthetic potential and this species was
no exception. The genomic data revealed a wealth of BGCs with four clusters being NRPS in
nature. Extracts of the bacterial cultures of the organism were processed using peptidomic
protocols. Orbitrap mass spectrometers were used to obtain MS2 data and the fragmentation
peptide sequencing based on fragmentation patterns was used to identify products that matched
the BGC-based predictions. The data from de novo sequencing attempts, targeted MS2 acquisition,
bioinformatic searches, and molecular networking with database annotations were combined to
identify potential matches between compounds in the bacterial extract and the predicted structures
of the peptides.
Several additional strategies could be employed to further explore the biosynthetic
potential of Pseudovibrio sp. str. TunPSC04-5.I4 and confirm the findings thus far. In addition,
varying cultivation conditions is another strategy to heighten NRPS product yields. Methods to
synthesize peptides arising from the predicted structures from this project can be considered. This
would serve a two-fold purpose: to enhance mass spectral confidence by matching retention time
and fragmentation patterns when using a parallel method of analysis, and to produce adequate
mass of a potentially novel peptide for bioactivity assessments.
This method has been developed for validation of secondary metabolite prediction
databases through the use of mass spectrometry for compound confirmation. Triangulation of the
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biosynthetic gene cluster data, compound structure predictions based on BGC enzymology, and
peptidomic analysis of the bacterial cultures represents a new method of secondary metabolite
drug discovery. This project also highlights the powerful but evolving nature of bioinformatics
and the innate limitations that exist in the predictive and in silico tools. Bioinformatic tools can
be used to enhance drug discovery efforts; however, there are limitations to overcome. There is a
need for tools to aid in peptide sequencing of cyclic natural products, of identification of nonstandard amino acids in peptide sequences, and the inclusion of a wider array of posttranslational
modifications that are seen in peptidic natural products. Modeling the complexity of Nature is a
tremendous task; however, new algorithms, new models, and further understanding of biosynthetic
enzymology will help us to continue to bridge this gap.

4.10 EXPERIMENTAL METHODS
A sample of Synoicum adareanum was collected by SCUBA from the coastal waters near
the Anvers Island Archipelago. A strain of Pseudovibrio sp. was isolated from the invertebrate
tissues and successfully cultured. Genomic sequencing and assembly was pursued. The assembled
DNA of Pseudovibrio sp. str. TunPSC04-5.I4, was run through an annotative pipeline to identify
biosynthetic gene clusters using IMG-ABC34 and antiSMASH35 databases, which focus on
secondary metabolite predictions. The MS-Product tool within ProteinProspector (UCSF) was
used for in silico fragmentation of the predicted peptides.
After Antarctic collection of Synoicum adareanum, a Pseudovibrio strain was isolated and
preserved as a glycerol stock. To prepare the bacteria for biomass for NRPS characterization,
Pseudovibrio sp. str. TunPSC04-5.I4 was grown up from the glycerol stock in Marine 2216 broth
at 10ºC on a constant shaker at 150 rpm. Growth was monitored by enumeration of DAPI-stained
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cells following Porter and Feig (1980) such that cultures were harvested at the beginning of
stationary phase growth (S.1) when secondary metabolite concentration is often the highest.39 Cells
were pelleted and the pellet, supernatant, and media (as a blank) were stored frozen at -80ºC until
extraction. To prepare biomass for MS analysis, the broth culture was centrifuged, the cell pellet
and supernatant were separated, and then frozen. After the cell pellet and supernatant were
lyophilized, a three-day methanol extraction was performed on both the centrifuged cell pellet and
the supernatant. The extract was dried under nitrogen. The samples were then desalted and peptides
eluted using 300mg C18 Sep-Pak (Waters) cartridge columns as per proteomic protocol. C18 was
activated with 1 column volume of ACN. Then the cartridge was equilibrated with 2 column
volumes of H20 with 0.1% formic acid. The sample was added to bind to the C18. Three column
volumes of H20 with 0.1% formic acid were applied for the wash/desalting step. Peptide elution
was then performed in a fresh collection tube with 90% ACN/10%H20 with 0.1% formic acid.
Alternatively, for samples used in separate rounds of data acquisition (DDA and targeted
approaches), a protein precipitation was used. Methanol (~40 µL/mg of sample) was added
followed by chloroform (~30 µL/mg of sample) and then by water (~40 µL/mg of sample). The
samples were centrifuged at 9,000 g x 45 minutes. They were then vortexed x 10 minutes and
centrifuged again at 9,000 g x 30 minutes. The aqueous layer was removed and discarded.
Methanol (~20 µL/mg of sample) was added to the organic layer. The samples were centrifuged
again at 9,000 g for 20 minutes. The supernatant was removed and discarded. The pellet was dried
under nitrogen and then resuspended in 1% ACN and water with 0.1% FA. The samples were
vortexed and sonicated for 10 minutes, centrifuged at 20,000 g for 10 minutes. The supernatant
was used for LC-MS analysis.
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The samples were resuspended in 1% acetonitrile, 0.1% formic acid in dH2O and injected
on a ThermoScientific Orbitrap QExactive Mass Spectrometry device for a bottom-up, though
non-digested, proteomic approach. The peptide separation was performed on a C18 column using
an Ultimate3000 UHPLC (Thermo) with a gradient of 4% acetonitrile to 40% acetonitrile in water
with 0.1% formic acid over approximately 60 minutes. This was followed by a wash of 90%
acetonitrile and equilibration with water and 0.1% formic acid. Using nanoelectrospray, the
elutants were run on a hybrid quadrupole-Orbitrap Q Exactive Plus mass spectrometer (Thermo).
Xcalibur was used to initially process the Orbitrap data. De novo peptide sequencing and
custom database searches, with particular focus on fragments of possible permutations of the
predicted peptide, were performed using PEAKS 8.5 software.
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CHAPTER FIVE:
CHEMICAL INVESTIGATION OF IRISH DEEP-SEA CORAL, DRIFA SP.

5.1 CORAL CHEMISTRY
Corals are a rich source of natural products. As far back as the eighteenth century, Right
Reverend Erich Pontoppidan, Bishop of Bergen, wrote about discovering corals in The Natural
History of Norway. In his writings he describes the beauty of the specimen which “expanded like
a flower in full bloom” and of how the fishermen would often sell coral bushes to the apothecaries
in the village for medicinal use.1 These corals were applied topically or worn as beads around the
neck to prevent the plague and other infections.1
The phylum Cnidaria is second only to Porifera as a source of new natural products from
marine invertebrates that are reported annually.2 Alcyonacean corals lack the calcium carbonate
skeletons of scleractinian corals, have little physical defense, and are nonmotile. Therefore, they
have adapted to thrive in the hostile and highly competitive marine environment using chemical
defenses. Soft-bodied corals of the order of Alcyonacea produce secondary metabolites from a
number of chemical classes. Terpenes are the predominant class of natural products from corals
and include sesquiterpenes, diterpenes, and other complex large terpenes (Figure 5.1).
Interestingly, terpene biosynthesis is also seen in terrestrial plants and it is not uncommon to see
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similar scaffolds between the two. Additionally, sterols with unique sites of oxidation are found in
corals. Often utilized by the marine invertebrates as feeding deterrents, antifouling agents, and to
gain a competitive advantage, terpenes from corals often demonstrate bioactivity against human
disease as antiviral agents, antiinfectives, and antitumor agents.3 Comprising over 3,000 species,
members of the subclass Octocorallia are morphologically defined by having polyps with radial
symmetry and eight tentacles with lateral extensions, called pinnules, and are a particularly rich
source of natural product exploration.4 Most of the bioactive compounds derived from coral
compounds, upwards of eighty percent, are isolated from octocorals.3
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Figure 5.1. Selected natural products from Cnidaria.

5.2 BIODIVERSITY AND CHEMODIVERSITY OF THE DEEP SEA
Ninety-five percent of the ocean’s sea floor exceeds depths of 1,000 meters where water
temperatures are approximately 4 °C. Over half of the 5,100 coral species known are found in
deep-sea systems.5 Cold water corals (CWC) create coral gardens in benthic regions ranging from
200 to 1000 meters in depth.5 These reef systems support a wide range of marine fauna and are
hotspots for biodiversity in the deep sea.6 There are over 250,000 known marine macroorganism
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species, but this number is estimated to account for only a quarter of the estimated diversity. The
vast majority of which are yet-to-be discovered deep-sea animals.7 CWCs have adapted to survive
in an environment without light, with low nutrient levels, and with extremely high pressures. Since
light does not penetrate into the deep sea beyond about 250 m, mechanical and chemical sensing
in macroorganisms are even more crucial than in shallow water environments. Additionally,
metabolism of marine organisms slows to compensate for slower currents and reduced food
availability. Pressure increases by an atmosphere for every ten meters of depth; as a result, the
deepest parts of the oceans are estimated to have pressures in excess of 1,000 atm.8 The adaptations
required for survival in these extreme environments are not only physiological, but also
biochemical in nature, leading to the production of unique natural products (Figure 5.2).
Interestingly, these compounds often exhibit high rates of affinity to biological targets implicated
in human disease.8 Natural products from the deep sea comprise less than 2% of known natural
products; however, the rate of bioactivity from deep-sea compounds is estimated to be as high as
75%.7
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Figure 5.2. Selected natural products from deep-sea Octocorallia.
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5.3 COLLECTION OF DRIFA SP.
Colloquially called cauliflower corals due to their similarity in appearance to the vegetable,
Drifa sp. belong to the family Nephtheidae (Gray 1862; Cnidaria Anthozoa Octocorallia
Alcyonacea Alcyonliina Nephtheidae), which thrive in cold water benthic environments, including
in deep-sea coral reefs. The Nephtheidae family contains twenty genera and approximately 500
species, including Drifa sp., and are known to produce steroidal and terpenoid secondary
metabolites. The chemistry of Drifa sp., however, has not been described.4,9
Four samples of Drifa sp. were collected by remotely operated vehicle (ROV) from the
head of a submarine canyon to the north of the Porcupine Ridge Bank of the Irish Continental
Margin (54.26007932°N, 11.58046619°W) at a depth of 823 meters (Figures 5.3 and 5.4). The
organisms were lyophilized and then stored at -20 °C after a portion of each organism was obtained
for a voucher. The voucher was later used for genomic sequencing efforts by Professor A. Louise
Allcock, from National University Ireland Galway and supported by Science Foundation Ireland,
to identify the species; however, genomic barcoding did not amplify the MutS gene that is often
characteristic of octocorals, and there are no comparator sequences from this genus in Genbank,
making species identification challenging. Even with a barcode and comparator sequences,
identification can still be challenging because of the slow rate of evolution of the mitochondrial
genome in octocorals.10 The organisms collected may represent a new species.
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Figure 5.3. Specimens of Drifa sp. from deep sea Ireland collected by ROV Holland I deployed from
RV Celtic Explorer. All four of the invertebrates were collected for chemical investigation. The red dots
on the photo on the right indicate a span of 10 cm. Subsea photographs copyright Marine Institute,
Oranmore, Ireland. Used with permission.

Figure 5.4. The site of deep sea collection of Drifa sp. samples was in a submarine canyon north of the
Porcupine Bank on the Irish Continental Margin. The exact GPS coordinates and site are indicated by
the yellow thumbtack.
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5.4 CHEMICAL ANALYSIS OF DRIFA SP.
The lyophilized organisms were batched for a dichloromethane (DCM) Soxhlet extraction
at 40 °C followed by a DCM:water partition. Normal phase medium pressure liquid
chromatography (MPLC) afforded thirteen fractions (Figure 5.5). A gradient of hexanes to ethyl
acetate was used, followed by the introduction of 20% methanol in ethyl acetate. Fractions D, E,
and F correlated with chromatographic UV peaks at 280 and 320 nm during the hexanes to ethyl
acetate gradient. Fraction J was collected at the transition from 100% ethyl acetate isocratic and
20% methanol portion of the method and was also associated with UV activity. Based primarily
on an NMR-guided fractionation process, fractions D, E, F, and J were selected for further
purification using iterations of high performance liquid chromatography (HPLC), resulting in the
isolation of three compounds NEA-1 through NEA-3.

Figure 5.5. Following lyophilization and a DCM extraction with a Soxhlet apparatus, MPLC was used
for initial separation of the extracted compounds. This yielded 13 fractions. Material from column
washes using solvents with varying polarity were also collected.
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5.5 DRIFA SP. CHEMISTRY – A NEW DITERPENE
5.4.1

ELUCIDATION OF NEA-1
NEA-1 was isolated as a yellow oil from the MPLC Fraction D after iterations of normal

phase HPLC were performed (Figure 5.6). The formula of C23H30O4 was obtained from high
resolution electrospray ionization mass spectrometry (HRESIMS) with an [M + H]+ of 371.2214
amu (calculated for C23H31O4 371.2222, Δmmu 0.8) with nine degrees of unsaturation. Structure
elucidation utilizing NMR data revealed a new compound (Table 5.1), NEA-1.

Figure 5.6. Separation scheme for the isolation of NEA-1.
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Table 5.1. NMR data for NEA-1 in CDCl3 (400 MHz).

pos
2
3
4
5
6
7
8
9
10
11
12
1′
2′
3′
4′
5′
6′
7′
8′
9′
10′
11′
12′
OHa
OHb

δC, type
79.1, C
132.4, CH
116.4, CH
107.5, C
158.2, C
111.7, C
151.4, C
132.3, C
118.7, C
191.1, CH
7.6, CH3
40.2, CH2
22.6, CH2
123.3, CH
135.8, C
39.6, CH2
26.6, CH2
124.1, CH
131.4, C
25.7, CH3
17.7, CH3
16.0, CH3
25.4, CH3

δH, (J in Hz)

HMBC

5.80, d (10.1)
6.86, d (10.1)

C-2, C-10, C-12’, C-1’
C-2, C-9, C-10

10.08, s
2.14, s
1.78, t
2.13, m
5.11, t

C-5, C-6, C-7
C-6, C-7, C-8

C-2’, C-5’, C-11’

1.99, t
2.05, m
5.07, t

C-4’, C-5’, C-7’, C-8’
C-10’

1.68, s
1.59, s
1.58, s
1.43, s
12.31, s
6.37, s

C-7’, C-8’, C-10’
C-7’, C-8’, C-9’
C-5’, C-3’, C-4’
C-2, C-3, C-1’
C-5, C-6, C-7, C-8
C-6, C-7, C-8, C-9

Two proton signals, H-11 (δH 10.08, s), and OHa (δH 12.31, s) are associated with
particularly downfield 1H chemical shift (δH) indicating association with functional groups that are
highly electron withdrawing, leading to proton deshielding and greater δH values (Figure 5.7). A
series of proton shifts consistent with olefinic signals are observed from 5.07 to 6.86. Twelve of
the twenty-three carbons have

13

C chemical shifts (δC) consistent with sp2 hybridization were
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determined to be olefinic or aromatic (Figure 5.8). The 13C NMR spectrum contains three signals
with chemical shifts that are quite downfield, C-11 (δC 191.1, CH), C-6 (δC 158.2, C), and C-8 (δC
151.4, C). Based on chemical shifts alone, C-11 and H-11 were determined to be consistent with
an aldehyde functionality. The most downfield proton shift of OHa would be consistent with a
carboxylic functionality; however, there is no correlating carbon shift to solidify this conjecture,
as C-6 and C-5 shifts are lower than what would be expected with a carboxylic acid.

Figure 5.7. 1H NMR spectrum for NEA-1 in CDCl3 (400 MHz).
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Figure 5.8. 13C NMR spectrum for NEA-1 in CDCl3 (100 MHz).

Phase-sensitive gHSQCAD was used to assign the protons to their respective carbons (Figure 5.9).
The HSQC confirmed the assignment of H-11 to C-11, but there was no carbon assignment for
OHa or OHb. Therefore, these likely share a bond with a heteroatom, which based on the molecular
formula derived from the HRMS data this is oxygen. The COSY correlations, which were few,
were paired with the gHSQC data to begin building the spin-coupled systems (Figure 5.10).
Vinylic proton H-4 (δH 6.86, d, J=10.1) was assigned to C-4 (δC 116.4, CH) and shares a COSY
correlation and J-value with vinylic proton H-3 (δH 5.80, d, J=10.1). The singlet vinyl proton H-3′
(δH 5.11, t) was assigned to C-3′. H-3′ shares a COSY correlation with the allylic protons H3-11′
(δH 1.58, s) assigned to C-11′ (δC 16.0, CH3). Additionally, H3-9′ (δH 1.68, s) is assigned to C-9′
(δC 25.7, CH3) and shares a COSY correlation with H-7′ (δH 5.07, t) assigned to C-7′, as does H310′ (δH 1.59, s), assigned to C-10′ (δC 17.7, CH3). This forms a gem-dimethyl on a quaternary
carbon that is the olefinic partner to C-7′.
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Figure 5.9. gHSQCAD spectrum for NEA-1 in CDCl3 (500 MHz).

Figure 5.10. COSY correlations were used to help determine the spin-coupled systems of the molecule,
including allylic coupling; in CDCl3 (500 MHz).
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HMBC correlations were used to extend and connect the structure (Figure 5.11). H-11 (δH
10.08, s) showed multiple correlations including C-5 (δC 107.5, C), C-6 (δC 158.2, C), and C-7 (δC
111.7, C), while H3-12 (δH 2.14, s) shares multiple correlations with C-6, C-7, and C-8 (δC 151.4,
C), forming a conjugated system between two olefins and the carbonyl of the aldehyde. The H-3
(δH 5.80, d) HMBC correlations include C-2 (δC 79.1, C), C-10 (δC 118.7, C), C-12′ (δC 25.4, CH3),
and C-1′ (δC 40.2, CH2). H-4 shares COSY correlation with H-3, extending this system to C-9 (δC
132.3, C). Based on chemical shift values, C-9 and C-10 are olefinic and the HMBC correlations
with H-3 (δH 5.80, d) and H-4 (δH 6.86, d) point to a position in conjugation with C-4 (δC 116.4,
CH) and C-3 (δC 132.4, CH). The chemical shift of C-2 (δC 79.1, C) is consistent with carbon
bearing oxygen. This quaternary carbon shares correlations with H-3 (δH 5.80, d), the H3-12′ (δH
1.43, s), and to H2-1′ (δH 1.78, t). These correlations led to the conclusion that the molecule
contains a pyran ring. Based on the HMBC correlations with OHb (δH 6.37, s), H-3 (δH 5.80, d),
and H-4 (δH 6.86, d), C-9 and C-10 were determined to serve as the olefinic bridgehead carbons
that connect the pyran ring to the highly substituted phenyl ring with an aldehyde, two phenol
groups, and a methyl group.
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Figure 5.11. gHMBCAD NMR spectrum of NEA-1 in CDCl3 (500 MHz). HMBC correlations were
used to continue expanding on the structure along with chemical shifts and multiplicity.

H3-10′ shares HMBC correlations with C-7′ (δC 124.1, CH), C-8′ (δC 131.4, C), and C-9
(δC 25.7, CH3), confirming the presence of a gem-dimethyl on an olefinic quaternary carbon, as
hypothesized based on the COSY correlations. HMBC correlations were used to piece together
more aliphatic signals with the olefinic signal at C-7′ connecting to the methylenes C-6′ (δC 26.6,
CH2) and C-5′ (δC 39.6 CH2). The COSY-correlations of H3-11′ and H3-3′ were used in conjunction
with HMBC correlations to establish another substituted olefin on the chain. The HMBC
correlations of the vinylic proton H-3′ extended the chain to methylenes C-2′ (δC 22.6, CH2) and
C-1′ (δC 40.2, CH2). The aforementioned H-2 correlation with C-1′ showed the site of attachment
of the aliphatic chain to the benzopyran ring system. The aliphatic region in the HMBC was key
in determining this side chain, representing biosynthesis from two isoprene units as is typical for
terpenes.
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Determined through a combination of chemical shift data, proton multiplicity, and COSY
and HMBC correlations, the structure of NEA-1 represents a new carbon scaffold containing a
chromene core with a highly substituted benzopyran ring system with an aldehyde, methyl, and
two phenol features on the aromatic ring, along with a monoterpene tail (Figure 5.12).
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Figure 5.12. Proposed structure for NEA-1 with COSY correlations indicated by bold lines.

UV spectroscopy in ACN reveals λmax (log ε) at 198 nm, with additional peaks noted at
λ (log ε) 258 nm, 307 nm, and 369 nm (Figure 5.13). FTIR transmittance, thin film was also
obtained (Figure 5.14).
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Figure 5.13. UV spectrum of NEA-1 in acetonitrile (ACN) (10 ug/mL).

Figure 5.14. FTIR spectrum of NEA-1, thin film.
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5.4.2

MOLECULAR NETWORKING
Molecular networking using MS2 data from LC-QToF data was used to evaluate the

chemical space of MPLC Fractions D, E, and F with NEA-1 (Figure 5.15).11 Nodes represent
consensus spectra for a given molecule, which are connected via edges if six or more fragments
are shared between the nodes. What resulted was a rich network indicating the presence of
analogues in the fractions. Some of these analogues have the same parent mass, indicating the
presencce of consitutional isomers with different placement of substituents or different
configurations of the side chain. Additionally, some represent compounds with an extra degree of
unsaturation, perhaps a carboxylic acid functionality, and additional CH2 groups. The wealth of
the secondary metabolites that this coral provides should be explored in future studies.

Figure 5.15. Molecular Networking based on MS2 data using GNPS (UCSD)11 reveals fragmentation
patterns that are consistent with analogues of NEA-1.
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5.5 DRIFA SP. CHEMISTRY – STEROIDS
There are over 200 sterols that have been characterized from soft corals. These often contain a
3β-hydroxy-Δ5-cholestane nucleus and a side chain eight to ten carbons in length at C-17.12
Atypical sterols may contain a varied chain length anywhere from zero to twelve carbons, a side
chain in a location different than C-17, oxidation of the side chain, or even oxidation in the core
sterol scaffold.12
5.5.1

ELUCIDATION OF NEA-2

NEA-2 was isolated as iridescent crystals from MPLC Fraction-J, the fraction that eluted at
the introduction of 20% CH3OH, 80% EtOAc. A portion of the resultant crystals were submitted
to x-ray crystallography, while the remaining sample used for further attempts at isolation. Normal
phase HPLC did not result in optimal separation. The fraction was not soluble in water and,
therefore, not amenable to standard reverse phase separation. Reverse non-aqueous reverse phase
(DCM : CH3OH) was used to achieve separation (Figure 5.16). Additionally, recrystallization
techniques with hexanes, EtOAc, and CH3OH were used to further purify the compound.
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Figure 5.16. Separation scheme for the isolation of NEA-2.

The fraction was analyzed using HRESIMS in positive mode on a ToF MS and the base peak
was consistent with a molecular formula of C27H44O3 with an m/z of 381.3165 amu for the
[M - 2H2O + H]+ ion (calculated for C27H41O 381.3157, Δmmu 0.8) (Figure 5.17).

Figure 5.17. ESI-HRMS spectrum for NEA-2. The base peak of 381.3165 is consistent with the
[M - 2H2O + H]+ (calculated for C27H41O 381.3157, Δmmu 0.8) of a known trihydroxyl steroid natural
product.
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The crystal structure revealed a 3, 7, 19-trihydroxy steroid with an aliphatic side chain (Figure
5.18). The initial crystal structure was unable to resolve the unit cell with the side chain and NMR
techniques had to be used to confirm this feature.

Figure 5.18. Crystals of NEA-2 with microscopic image of crystal in the inlay on the right and model from
x-ray crystallography showing two molecules NEA-2 with hydrogen bonding on the left. Grey spheres
represent carbon, pink spheres hydrogen, and red spheres oxygen atoms.

Less than forty of the identified steroids in soft corals have a hydroxyl or acyl feature at C19.13 NMR analysis was consistent with (3β,7β,22E)-cholesta-5,22-diene-3,7,19-triol. Since the
steroid represents a known natural product, NMR data was carefully compared to the chemical
shift values in the literature (Table 5.2).
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Table 5.2. NMR data for NEA-2 (CD3OD, 1H 400 MHz, 13C 100 MHz) compared to literature
values15 (CD3OD, 1H 500 MHz, 13C 125 MHz). Lit: literature values; Exp: Experimental values
experimental values. Asterisks indicate overlapping signals that precluded J-value calculations.
pos
1a
1b
2a
2b
3
4a
4b
5
6
7
8
9
10
11a
12a
12b
13
14
15a
15b
16a
16b
17
18
19a
19b
20
21
22
23
24
25
26
27

δC, type - Lit
34.5, CH2
-32.8, CH2
-72.2, CHO
42.6, CH2
-140.2, C
131.2, CH
73.5, CHO
42.5, CH
50.7, CH
43.3, C
23.1, CH2
-41.5, CH2
-44.3, C
58.8, CH
27.4, CH2
-30.2, CH2
-57.0, CH
13.0, CH
63.6, CH2O
-41.7, CH
21.7, CH3
139.7, CH
127.6, CH
42.9, CH2
22.9, CH
22.9, CH3
22.8, CH3

δC, type - Exp
34.5
32.7
72.2
42.5
140.2
131.2
73.4
42.5
50.6
43.3
23.1
41.5
44.2
58.8
27.4
30.3
57.1
13
63.5
41.8
21.7
139.7
127.6
42.9
23.1
22.9
22.9

δH, (J in Hz) - Lit
0.98, m
2.05, m
1.78, m
1.4, m
3.46, m
2.31, m
2.25, m
-5.49, br s
3.66, d (8.0)
1.8, m
0.99, m
-1.74, m
1.60,m
1.14, m
2.04, m
-1.06, m
1.78, m
1.40, m
1.67, m
1.28, m
1.12, m
0.78, s
3.85, d (11.5)
3.60, d(11.5)
2.05, m
1.02, d (6.5)
5.22, dd(15.0,8.0)
5.3, ddd (15.0,7.5,7.0)
1.82, dd (13.0,6.5)
1.57, m
0.87, d (7.0)
0.87, d (7.0)

205

δH, (J in Hz) - Exp
0.95, m
2.04, m
1.79, m
1.41, m
3.46, m
2.32, m
2.26, m
5.49, br s
3.66 d (6.63)
1.79, m
0.96, m
1.76*, m
1.60, m
1.14m
2.04, m
1.06, m
1.77, m
1.41, m
1.67, m
1.29, m
1.13, m
0.78, s
3.86, d (11.6)
3.60, d (11.6)
2.05, m
1.02, d (6.25)
5.23, dd
5.29, ddd (15.4,7.5,7.0)
1.82*, m
1.57*, m
0.88, d (6.5)
0.88, d (6.6)

Figure 5.19. 1H NMR spectrum for NEA-2 in CD3OD (400 MHz).
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Figure 5.20. 13C NMR spectrum for NEA-2 in CD3OD (100 MHz).
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Figure 5.21. Proposed structure of NEA-2.

Initially isolated from Antipahes subpinnata collected off of the San-Hsian-Tai coast, Taiwan,
this polyhydroxylated steroid was shown to be toxic to brine shrimp.14 It was later also identified
in the soft coral Nephthea erecta, also belonging to the Nephtheidae family, off the coast of
Taiwan, and the gorgonian Pacifigorgia senta collected from the South China Sea.13,15 The
compound was tested and found to have bioactivity against HepG2, Hep3B, MCF-7/ADR, PC-3,
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and HCT-116 tumor cell lines.13 Similar 19-oxygenated steroids from the Nephthea chabrolii were
isolated and found bioactive against P-388 mouse lymphocytic leukemia cell lines.16
5.5.2

ELUCIDATION OF NEA-3
NEA-3 was isolated as a clear crystal from the MPLC Fraction D after iterations of normal

phase HPLC were performed (Figure 5.22).

Figure 5.22. Separation scheme for the isolation of NEA-3.

A portion of the crystals were submitted for x-ray crystallography. The unit cell could not
be fully resolved by crystallographic methods, as the aliphatic side chain. A full data set was
obtained and is being used for full structure elucidation and confirmation of the side chain.
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Figure 5.23. Image of crystals of NEA-3 with microscopic image of crystal cut and mounted on the
left and crystallographic model of NEA-3 on the right. Grey spheres represent carbon, light blue
spheres hydrogen, and red spheres oxygen atoms. Large grey spheres represent carbons which are not
fully resolved through crystallography.

Figure 5.24. 1H NMR spectrum for NEA-3 in CDCl3 (400 MHz).
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Figure 5.25. 13C NMR spectrum for NEA-3 in CDCl3 (100 MHz).

HO

Figure 5.26. Proposed structure of NEA-3.

The proposed structure, (3β,5α,22E)-24-norergosta-5,22-dien-3-ol, has been isolated from
a number of marine organisms. It was isolated from the sea urchin Echinus esculentus with a suite
of Δ5 sterols in the1970’s by John Goad and colleagues, who characterized the GS-MS
fragmentation properties of the compound.17 A South Korean collection of the coral
Dendronephthya gigantea off the coast of Jeju Island resulted in the isolation of 26,27-
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dinorergosta-5,22-dien-3-ol after the crude ethanolic extract revealed anti-inflammatory
bioactivity through reduction in the expression of the COX-2 and iNOS, both pro-inflammatory
mediators.18

5.6 DISCUSSION AND CONCLUSIONS
The deep sea is a rich source of secondary metabolites arising from evolutionary adaptations
to promote survival in the harsh and extreme environments of cold-water coral reef systems. Four
samples of Drifa sp. collected from Porcupine Bank of the Celtic Continental Margin of Ireland’s
marine territory have been evaluated for secondary metabolites. A prominent portion of the
secondary metabolome is a compound that represents a novel carbon skeleton with a highly
substituted benzopyran core. Molecular networking of MS2 data is suggestive of analogues of this
compound. Additionally, two steroidal natural products have been isolated. One is a known
trihydroxy steroid with potent bioactivity against multiple tumor cell lines. The other is a 3hydroxy steroid. Preliminary screening for bioactivity of MPLC fractions and HPLC subfractions
demonstrates activity against Enterococcus faecium. Chemical investigation of this Drifa sp. will
continue in search of analogues of the novel chromene compound as well as the source for the
bioactivity.

5.7 EXPERIMENTAL METHODS
The four individuals of Drifa sp. were collected by ROV Holland 1 from the deep sea
(54.26007932 N 11.58046619 W) at a depth of 823 meters during a 2018 cruise of the RV Celtic
Explorer (Cruise CE18012). In situ photographs were taken to aid in taxonomy and for collection
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metadata. Any epibionts were removed and a small voucher was removed and placed in 96%
ethanol. The remainder of the biomass was lyophilized and then stored at -20 °C.
Upon arrival at the University of South Florida, the specimens were extracted with 100%
dichloromethane via reflux (40 °C) with a Soxhlet apparatus. Initial separation was performed
using MPLC with a silica column. A gradient of hexanes to ethyl acetate was used followed by
20% methanol and 80% ethyl acetate for seven minutes. Iterations of MPLC and HPLC ensued as
outlined in the schematics above. All resulting fractions we dried using passive air or nitrogen.
All 1H NMR spectra were recorded on a Bruker Neo 400 MHz or on a Varian 500 MHz
Direct Drive instrument with direct detection, and 13C NMR spectra were recorded at 100 or 125
MHz, respectively.
Agilent Technologies 6540 UHD Accurate Mass LC/MS Q-ToF was used to obtain the
MS/MS profiles. The MPLC fractions were prepared at 0.25mg/mL in ACN, whereas the pure
compounds were prepared at 0.1mg/mL in ACN. A Zorbax Eclipse plus C18 column was used and
20 uL of sample was injected with a 20-minute LC method from water with 0.1% formic acid
(solvent A) to ACN 0.1% formic acid (solvent B). The method was set to span 0 to 100% B. MS
was acquired in positive mode with a mass range set from a m/z of 100 to 1000. For MS2, collision
energy of 0 was set to confirm isolation of identified peaks, followed by collision energy of 10 and
40. Acquisition rate was 3 spectra/second. MS selection threshold was set to 1000.
A molecular network was created using the online workflow (https://ccmsucsd.github.io/GNPSDocumentation/) on the GNPS website (http://gnps.ucsd.edu).11 The data
was filtered by removing all MS/MS fragment ions within +/- 17 Da of the precursor m/z. MS/MS
spectra were window filtered by choosing only the top 6 fragment ions in the +/- 50 Da window
throughout the spectrum. The precursor ion mass tolerance was set to 0.02 Da and a MS/MS
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fragment ion tolerance of 0.02 Da. A network was then created where edges were filtered to have
a cosine score above 0.7 and more than 6 matched peaks. Further, edges between two nodes were
kept in the network if and only if each of the nodes appeared in each other's respective top 10 most
similar nodes. Finally, the maximum size of a molecular family was set to 100, and the lowest
scoring edges were removed from molecular families until the molecular family size was below
this threshold. The spectra in the network were then searched against GNPS' spectral libraries. The
library spectra were filtered in the same manner as the input data. All matches kept between
network spectra and library spectra were required to have a score above 0.7 and at least 6 matched
peaks.
IR spectrum was recorded with an Agilent Cary 630 FTIR. UV absorptions were measured
using an Agilent Cary 60 UV-Vis spectrophotometer.
X-ray crystallography was done by Lukasz Wojtas at the University of South Florida. Xray diffraction data were measured on Bruker D8 Venture PHOTON II CPAD diffractometer
equipped with a Cu Kα INCOATEC ImuS micro-focus source (λ = 1.54178 Å). Indexing was
performed using APEX3 (Difference Vectors method).19 Data integration and reduction were
performed using SaintPlus.20 Absorption correction was performed by multi-scan method
implemented in SADABS.21 Space group was determined using XPREP implemented in
APEX3.19 Structure was solved using SHELXT22 and refined using SHELXL-201823 (full-matrix
least-squares on F2) through OLEX2 interface program.24 Chains are heavily disordered and were
refined with restraints. All hydrogen atoms were placed in geometrically calculated positions and
were included in the refinement process using riding model with isotropic thermal parameters.
Crystal data and refinement conditions are shown in accompanying table (Appendix, Table 1).
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CHAPTER SIX:
CONCLUSION

Cold water marine invertebrates are a prolific source of structurally diverse molecules.
From Antarctica to the deep-sea coral reefs of Ireland, cold water invertebrates have made
evolutionary adaptations for survival that enhance the chemodiversity seen in these unique
environmental milieus. There is a dynamic interplay of intricately designed biosynthetic
machinery, of microbial-host associations, and of chemical accumulation and defense, leading a
wide array of compounds suitable for biological targets. The implications of this from both a
chemical ecology standpoint and human disease standpoint are vast. The research included in this
dissertation has led to conclusions, but in a way true to the discovery sciences, has also generated
another phase of questions to and hypotheses to explore.
A discovery fifteen years ago prompted a cascade of research into the biosynthesis of the
potent vacuolar-ATPase inhibitor, palmerolide A. Though initially isolated from an Antarctic
invertebrate, there was a hypothesis that the compound was produced by a host-associated
microbe. The metagenomic material from the bacterial pellet was rich in biosynthetic gene clusters,
one of which had great congruence to a retrobiosynthetic scheme that was devised based on the
chemical architecture of palmerolide A. Each enzymatic domain was explored, and the
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biosynthesis was delineated. Though many domains represent canonical type-I polyketide
synthase enzymes, several are unusual including a luciferase-like monooxygenase that serves as a
hydroxylase, a cassette of enzymes with an HMG-CoA Synthetase that installs a β-branch, and a
termination cyclization domain that is comprised of a truncated condensation domain that has
sequence homology to a non-ribosomal peptide synthetase enzyme. Additionally, a total of five
variants of the pal A cluster were identified in parallel work to assemble and annotate the
metagenome-assembled genome of the new bacterial species Candidatus Synoicohabitans
palmerolidicus. The pal biosynthetic gene cluster is the first to be delineated from the marine
environment of Antarctica. Additionally, this substantial interdisciplinary and multi-institutional
team effort has resulted in a significant contribution to our understanding of polyketide
biosynthesis.
In the species of the Antarctic ascidian, Synoicum adareanum, a persistence of a core
microbiome was seen across 63 samples pointing to a coherence of community structure that likely
contributes to host and microbe survival. The concentration of palmerolide A, the biologicallyactive compound that prompted the research, did not directly correlate with a specific microbial
amplicon sequence variant; however, due to a precedent of bioaccumulation and sequestration of
toxic compounds in other marine invertebrates, this was not surprising. The genomic material,
specifically key components of the pal biosynthetic gene cluster, were key in the identification of
the microbial producer of palmerolide A from the established members of the core microbiome.
The work to identify the members of the core microbiome within the microbial consortia has paved
the path for the next phase of exploration, including an expansion of the spatial survey and further
inquiry into the ecological significance of this coherent core, both in regards to primary and
secondary metabolism within the holobiont.
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The hypothesis that palmerolide is produced by a microbial symbiont have been
substantiated through the distinct, but interrelated aims of this work. This expands the potential for
drug development by harnessing the molecular machinery for palmerolide A production though
biotechnological means, namely though targeted cultivation followed by large-scale fermentation
of the producing organism or through heterologous expression of the pal biosynthetic gene cluster.
The wealth of biosynthetic gene clusters is not confined to the palmerolide A producer and
in fact, another member of the core microbiome of Synoicum adareanum, Pseudovibrio sp. str.
TunPSC04-5.I4 possesses a genome replete with biosynthetic potential. Several non-ribosomal
peptide synthetase biosynthetic gene clusters were identified. Since many peptidic natural products
demonstrate potent bioactivity against human disease, this biosynthetic potential was investigated.
Triangulation of the biosynthetic genomic data, compound structure predictions based on the
enzymology of the biosynthetic gene clusters, and peptidomic analysis of the bacterial cultures
represents a new method of secondary metabolite drug discovery. The combination of powerful
bioinformatic tools can be used to interrogate big data produced by genomics and peptidomics in
a way that converges to discover new molecules. As the field of bioinformatics matures, the links
between gene clusters, chemistry, and even bioactivity will become more robust, only enhancing
this new wave of natural products chemistry.
The mainstay of natural products chemistry is isolation and characterization of secondary
metabolites, and methods including NMR-guided fractionation remain fruitful. An NMR-guided
approach to the discovery of novel compounds from four samples of an Irish deep-sea Drifa sp.
resulted in the discovery of a novel terpene with a new carbon scaffold containing a chromene
core. Molecular networking points to the presence of additional analogues in the fractionated
extract of the coral. Steroidal natural products were also isolated from the coral. The novel
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compound is an example of the chemical richness that is yet-to-be discovered in the deep sea.
There are many regions in the world that are underexplored, including cold water coral reefs.
Technology, such as SCUBA and remotely operated vehicles, have expanded the reach to marine
environments that were previously inaccessible to human exploration. Careful observations,
sampling, and analysis in these environments can lead to a greater understanding of what lies below
the oceans’ surface and for conservation efforts to preserve the Earth’s natural resources.
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APPENDIX A: EXPERIMENTAL DATA TO SUPPORT CHAPTER 5
Table 1. Crystal data and structure refinement for SOX_J.
Identification code
SOX_J
Empirical formula
C27H44O3
Formula weight
416.62
Temperature/K
100.0
Crystal system
orthorhombic
Space group
P212121
a/Å
12.3257(4)
b/Å
12.4865(4)
c/Å
32.8700(10)
α/°
90
β/°
90
γ/°
90
3
Volume/Å
5058.9(3)
Z
8
3
ρcalcg/cm
1.094
-1
μ/mm
0.533
F(000)
1840.0
3
Crystal size/mm
0.2 × 0.17 × 0.02
Radiation
CuKα (λ = 1.54178)
2Θ range for data collection/° 7.574 to 148.928
Index ranges
-15 ≤ h ≤ 15, -15 ≤ k ≤ 14, -41 ≤ l ≤ 40
Reflections collected
117905
Independent reflections
10343 [Rint = 0.0800, Rsigma = 0.0342]
Data/restraints/parameters
10343/650/689
2
Goodness-of-fit on F
1.065
Final R indexes [I>=2σ (I)] R1 = 0.0581, wR2 = 0.1664
Final R indexes [all data]
R1 = 0.0657, wR2 = 0.1749
Largest diff. peak/hole / e Å-3 0.25/-0.30
Flack parameter
-0.13(6)
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Asymmetric unit of 5e. Anisotropic displacement parameters were drawn at 50% probability
level.
Second part of disorder was omitted for clarity.

223

checkCIF/PLATON report
Structure factors have been supplied for datablock(s) SOX_J
THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE
FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED
CRYSTALLOGRAPHIC REFEREE.
No syntax errors found.

CIF dictionary

Interpreting this report

Datablock: SOX_J
Bond precision:

C-C = 0.0036 A

Cell:

a=12.3257(4)
alpha=90
100 K

Temperature:

Volume
Space group
Hall group
Moiety formula
Sum formula
Mr
Dx,g cm-3
Z
Mu (mm-1)
F000
F000’
h,k,lmax
Nref
Tmin,Tmax
Tmin’

Wavelength=1.54178
b=12.4865(4)
beta=90

Calculated
5058.9(3)
P 21 21 21
P 2ac 2ab
C27 H44 O3
C27 H44 O3
416.62
1.094
8
0.533
1840.0
1844.89
15,15,41
10354[ 5753]
0.899,0.989
0.899

c=32.870(1)
gamma=90

Reported
5058.9(3)
P 21 21 21
P 2ac 2ab
C27 H44 O3
C27 H44 O3
416.62
1.094
8
0.533
1840.0
15,15,41
10343
0.776,1.000

Correction method= # Reported T Limits: Tmin=0.776 Tmax=1.000
AbsCorr = MULTI-SCAN
Data completeness= 1.80/1.00

Theta(max)= 74.464

R(reflections)= 0.0581( 8837)

wR2(reflections)= 0.1749( 10343)

S = 1.065

Npar= 689

The following ALERTS were generated. Each ALERT has the format
test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.
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Alert level B
PLAT220_ALERT_2_B NonSolvent
PLAT220_ALERT_2_B NonSolvent

Resd 1
Resd 2

C
C

Ueq(max)/Ueq(min) Range
Ueq(max)/Ueq(min) Range

10.0 Ratio
9.2 Ratio

Alert level C
PLAT213_ALERT_2_C
PLAT213_ALERT_2_C
PLAT213_ALERT_2_C
PLAT222_ALERT_3_C
PLAT222_ALERT_3_C
PLAT250_ALERT_2_C
PLAT250_ALERT_2_C
PLAT417_ALERT_2_C

Atom C24
has ADP max/min Ratio .....
Atom C26
has ADP max/min Ratio .....
Atom C27
has ADP max/min Ratio .....
NonSolvent Resd 1 H
Uiso(max)/Uiso(min) Range
NonSolvent Resd 2 H
Uiso(max)/Uiso(min) Range
Large U3/U1 Ratio for Average U(i,j) Tensor ....
Large U3/U1 Ratio for Average U(i,j) Tensor ....
Short Inter D-H..H-D
H1
..H7
.
1/2+x,1/2-y,1-z =
PLAT417_ALERT_2_C Short Inter D-H..H-D
H12
..H52
.
x,-1+y,z =

3.1 prolat
3.3 prolat
3.2 prolat
10.0 Ratio
10.0 Ratio
3.1 Note
2.9 Note
2.13 Ang.
4_556 Check
2.12 Ang.
1_545 Check

Alert level G
PLAT002_ALERT_2_G
PLAT003_ALERT_2_G
PLAT007_ALERT_5_G
PLAT072_ALERT_2_G
PLAT171_ALERT_4_G
PLAT172_ALERT_4_G
PLAT173_ALERT_4_G
PLAT178_ALERT_4_G
PLAT187_ALERT_4_G
PLAT301_ALERT_3_G
PLAT301_ALERT_3_G
PLAT411_ALERT_2_G
PLAT412_ALERT_2_G
PLAT412_ALERT_2_G
PLAT412_ALERT_2_G
PLAT412_ALERT_2_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT791_ALERT_4_G
PLAT811_ALERT_5_G
PLAT860_ALERT_3_G

Number of Distance or Angle Restraints on AtSite
Number of Uiso or Uij Restrained non-H Atoms ...
Number of Unrefined Donor-H Atoms ..............
SHELXL First Parameter in WGHT Unusually Large
The CIF-Embedded .res File Contains EADP Records
The CIF-Embedded .res File Contains DFIX Records
The CIF-Embedded .res File Contains DANG Records
The CIF-Embedded .res File Contains SIMU Records
The CIF-Embedded .res File Contains RIGU Records
Main Residue Disorder ..............(Resd 1 )
Main Residue Disorder ..............(Resd 2 )
Short Inter H...H Contact H3B
..H35
.
1+x,y,z =
H16B
..H24A
.
Short Intra XH3 .. XHn
x,y,z =
Short Intra XH3 .. XHn
H16B
..H34A
.
x,y,z =
Short Intra XH3 .. XHn
H56B
..H64A
.
x,y,z =
H56B
..H74A
.
Short Intra XH3 .. XHn
x,y,z =
Model has Chirality at C2
(Sohnke SpGr)
Model has Chirality at C5
(Sohnke SpGr)
Model has Chirality at C11
(Sohnke SpGr)
Model has Chirality at C13
(Sohnke SpGr)
Model has Chirality at C14
(Sohnke SpGr)
Model has Chirality at C17
(Sohnke SpGr)
Model has Chirality at C19
(Sohnke SpGr)
Model has Chirality at C23
(Sohnke SpGr)
Model has Chirality at C42
(Sohnke SpGr)
Model has Chirality at C45
(Sohnke SpGr)
Model has Chirality at C51
(Sohnke SpGr)
Model has Chirality at C53
(Sohnke SpGr)
Model has Chirality at C54
(Sohnke SpGr)
Model has Chirality at C57
(Sohnke SpGr)
Model has Chirality at C59
(Sohnke SpGr)
Model has Chirality at C63
(Sohnke SpGr)
Model has Chirality at C33
(Sohnke SpGr)
Model has Chirality at C73
(Sohnke SpGr)
No ADDSYM Analysis: Too Many Excluded Atoms ....
Number of Least-Squares Restraints .............
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34 Note
34 Report
6 Report
0.12 Report
1 Report
3 Report
6 Report
2 Report
2 Report
27% Note
27% Note
2.10 Ang.
1_655 Check
2.02 Ang.
1_555 Check
2.08 Ang.
1_555 Check
2.11 Ang.
1_555 Check
1.95 Ang.
1_555 Check
S Verify
S Verify
R Verify
S Verify
S Verify
S Verify
S Verify
R Verify
S Verify
S Verify
R Verify
S Verify
S Verify
S Verify
S Verify
R Verify
R Verify
R Verify
! Info
650 Note

PLAT883_ALERT_1_G
PLAT910_ALERT_3_G
PLAT912_ALERT_4_G
PLAT955_ALERT_1_G
PLAT978_ALERT_2_G
PLAT992_ALERT_5_G

0
2
9
42

ALERT
ALERT
ALERT
ALERT

level
level
level
level

2
18
6
24
3

ALERT
ALERT
ALERT
ALERT
ALERT

type
type
type
type
type

1
2
3
4
5

No Info/Value for _atom_sites_solution_primary .
Missing # of FCF Reflection(s) Below Theta(Min).
Missing # of FCF Reflections Above STh/L= 0.600
Reported (CIF) and Actual (FCF) Lmax Differ by .
Number C-C Bonds with Positive Residual Density.
Repd & Actual _reflns_number_gt Values Differ by

A
B
C
G

=
=
=
=

Please
1
2
1
0
2

Do !
Note
Note
Units
Info
Check

Most likely a serious problem - resolve or explain
A potentially serious problem, consider carefully
Check. Ensure it is not caused by an omission or oversight
General information/check it is not something unexpected

CIF construction/syntax error, inconsistent or missing data
Indicator that the structure model may be wrong or deficient
Indicator that the structure quality may be low
Improvement, methodology, query or suggestion
Informative message, check

It is advisable to attempt to resolve as many as possible of the alerts in all categories. Often the
minor alerts point to easily fixed oversights, errors and omissions in your CIF or refinement
strategy, so attention to these fine details can be worthwhile. In order to resolve some of the more
serious problems it may be necessary to carry out additional measurements or structure
refinements. However, the purpose of your study may justify the reported deviations and the more
serious of these should normally be commented upon in the discussion or experimental section of a
paper or in the "special_details" fields of the CIF. checkCIF was carefully designed to identify
outliers and unusual parameters, but every test has its limitations and alerts that are not important
in a particular case may appear. Conversely, the absence of alerts does not guarantee there are no
aspects of the results needing attention. It is up to the individual to critically assess their own
results and, if necessary, seek expert advice.
Publication of your CIF in IUCr journals
A basic structural check has been run on your CIF. These basic checks will be run on all CIFs
submitted for publication in IUCr journals (Acta Crystallographica, Journal of Applied
Crystallography, Journal of Synchrotron Radiation); however, if you intend to submit to Acta
Crystallographica Section C or E or IUCrData, you should make sure that full publication checks
are run on the final version of your CIF prior to submission.
Publication of your CIF in other journals
Please refer to the Notes for Authors of the relevant journal for any special instructions relating to
CIF submission.

PLATON version of 18/09/2020; check.def file version of 20/08/2020

226

Datablock SOX_J - ellipsoid plot
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APPENDIX B: PERMISSIONS AND COPYRIGHTS
From:
To:
Subject:
Date:

Chasers of the Light
Avalon, Nicole
Re: Form Submission - Partnerships & Collaborations - Poem Inquiry
Thursday, October 1, 2020 10:22:13 AM

Hello Nicole!
Thank you so much for your kindness in reaching out! Please, feel free to use that poem in
your dissertation, I am honored to be a part of it.
I hope so much this finds you doing well, and if you need anything else let me know!
Best Wishes
Tyler Knott + Sarah Linden
chasersofthelight.com
ChasersOfTheLight@gmail.com

On Sep 30, 2020, at 9:36 AM, Squarespace <no-reply@squarespace.info> wrote:
Name: Nicole Avalon
Email Address: neavalon@usf.edu
Social Media Handles @ :
Subject: Poem Inquiry
Event Date: 11/3/2020
Message: Hello Tyler,
I am a graduate student at the University of South Florida and am about to defend
my PhD dissertation. One of your poems really resonated with me the day I joined
the lab that I am working in. I am a marine natural product chemist and the
significance of the ocean as a place of joy, freedom, and discovery is very real for
me. Your work has spoken to me in some difficult times. I have two of your
books and have given out several copies as gifts over the last couple of years. I
would love to include one of your poems in my dissertation with proper
attribution. Would this be okay with you?
This poem specifically:
Promise me
you will not spend
so much time
treading water
and trying to keep your
head above the waves
that you forget,
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truly forget,
how much you have always
loved
to swim.
--tyler knott gregson
Thank you in advance for your time and the consideration!
Nicole Avalon
(Sent via Chasers of the Light)

[EXTERNAL EMAIL] DO NOT CLICK links or attachments unless you recognize the sender and
know the content is safe.
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permission may also be granted for any electronic version of that work, provided that
the material is incidental to your work as a whole and that the electronic version is
essentially equivalent to, or substitutes for, the print version.
2. 5. An alternative scope of licence may apply to signatories of the STM Permissions
Guidelines, as amended from time to time.
3. Duration of Licence
3. 1. A licence for is valid from the date of purchase ('Licence Date') at the end of the
relevant period in the below table:
Scope of Licence
Post on a website

Duration of Licence
12 months

Presentations
12 months
Books and journals Lifetime of the edition in the language purchased
4. Acknowledgement
4. 1. The Licensor's permission must be acknowledged next to the Licenced Material in
print. In electronic form, this acknowledgement must be visible at the same time as the
figures/tables/illustrations or abstract, and must be hyperlinked to the journal/book's
homepage. Our required acknowledgement format is in the Appendix below.
5. Restrictions on use
5. 1. Use of the Licensed Material may be permitted for incidental promotional use and
minor editing privileges e.g. minor adaptations of single figures,
changes of format,
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other changes including but not limited to, cropping, adapting, omitting material that
affect the meaning, intention or moral rights of the author are strictly prohibited.
5. 2. You must not use any Licensed Material as part of any design or trademark.
5. 3. Licensed Material may be used in Open Access Publications (OAP) before
publication by Springer Nature, but any Licensed Material must be removed from OAP
sites prior to final publication.
6. Ownership of Rights
6. 1. Licensed Material remains the property of either Licensor or the relevant third party
and any rights not explicitly granted herein are expressly reserved.
7. Warranty

IN NO EVENT SHALL LICENSOR BE LIABLE TO YOU OR ANY OTHER PARTY OR
ANY OTHER PERSON OR FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL
OR INDIRECT DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, VIEWING OR USE OF THE
MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH
OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT
OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON
LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF
THIRD PARTIES), AND
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN.
8. Limitations
8. 1. BOOKS ONLY:Where 'reuse in a dissertation/thesis' has been selected the
following terms apply: Print rights of the final author's accepted manuscript (for clarity,
NOT the published version) for up to 100 copies, electronic rights for use only on a
personal website or institutional repository as defined by the Sherpa guideline
(www.sherpa.ac.uk/romeo/).
9. Termination and Cancellation
9. 1. Licences will expire after the period shown in Clause 3 (above).
9. 2. Licensee reserves the right to terminate the Licence in the event that payment is not
received in full or if there has been a breach of this agreement by you.
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For Journal Content:
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication), advance
online publication, day month year (doi: 10.1038/sj.[JOURNAL ACRONYM].)
For Adaptations/Translations:
Adapted/Translated by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication)

Note: For any republication from the British Journal of Cancer, the following
credit line style applies:
Reprinted/adapted/translated by permission from [the Licensor]: on behalf of Cancer
Research UK: : [Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL
NAME] [REFERENCE CITATION (Article name, Author(s) Name),
[COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from The [the Licensor]: on behalf of Cancer Research UK:
[Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL NAME]
[REFERENCE CITATION (Article name, Author(s) Name), [COPYRIGHT] (year
of publication), advance online publication, day month year (doi: 10.1038/sj.
[JOURNAL ACRONYM])
For Book content:
Reprinted/adapted by permission from [the Licensor]: [Book Publisher (e.g.
Palgrave Macmillan, Springer etc) [Book Title] by [Book author(s)]
[COPYRIGHT] (year of publication)
Other Conditions:
Version 1.2
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Creative Commons Corporation (“Creative Commons”) is not a law firm
and does not provide legal services or legal advice. Distribution of
Creative Commons public licenses does not create a lawyer-client or other
relationship. Creative Commons makes its licenses and related
information available on an “as-is” basis. Creative Commons gives no
warranties regarding its licenses, any material licensed under their terms
and conditions, or any related information. Creative Commons disclaims
all liability for damages resulting from their use to the fullest extent
possible.

Using Creative Commons Public Licenses
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Creative Commons public licenses provide a standard set of terms and conditions
that creators and other rights holders may use to share original works of
authorship and other material subject to copyright and certain other rights
specified in the public license below. The following considerations are for
informational purposes only, are not exhaustive, and do not form part of our
licenses.
Considerations for licensors: Our public licenses are intended for use by
those authorized to give the public permission to use material in ways otherwise
restricted by copyright and certain other rights. Our licenses are irrevocable.
Licensors should read and understand the terms and conditions of the license they
choose before applying it. Licensors should also secure all rights necessary before
applying our licenses so that the public can reuse the material as expected.
Licensors should clearly mark any material not subject to the license. This
includes other CC-licensed material, or material used under an exception or
limitation to copyright. More considerations for licensors.

Considerations for the public: By using one of our public licenses, a licensor
grants the public permission to use the licensed material under specified terms
and conditions. If the licensor’s permission is not necessary for any reason–for
example, because of any applicable exception or limitation to copyright–then that
use is not regulated by the license. Our licenses grant only permissions under
copyright and certain other rights that a licensor has authority to grant. Use of the
licensed material may still be restricted for other reasons, including because
others have copyright or other rights in the material. A licensor may make special
requests, such as asking that all changes be marked or described. Although not
required by our licenses, you are encouraged to respect those requests where
reasonable. More considerations for the public.
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Creative Commons AttributionShareAlike 4.0 International Public
License
By exercising the Licensed Rights (defined below), You accept and agree to be bound
by the terms and conditions of this Creative Commons Attribution-ShareAlike 4.0
International Public License ("Public License"). To the extent this Public License may
be interpreted as a contract, You are granted the Licensed Rights in consideration of
Your acceptance of these terms and conditions, and the Licensor grants You such rights
in consideration of benefits the Licensor receives from making the Licensed Material
available under these terms and conditions.
Section 1 – Definitions.
a. Adapted Material means material subject to Copyright and Similar Rights that is
derived from or based upon the Licensed Material and in which the Licensed
Material is translated, altered, arranged, transformed, or otherwise modified in a
manner requiring permission under the Copyright and Similar Rights held by the
Licensor. For purposes of this Public License, where the Licensed Material is a
musical work, performance, or sound recording, Adapted Material is always
produced where the Licensed Material is synched in timed relation with a moving
image.
b. Adapter's License means the license You apply to Your Copyright and Similar
Rights in Your contributions to Adapted Material in accordance with the terms and
conditions of this Public License.
c. BY-SA Compatible License means a license listed at
creativecommons.org/compatiblelicenses, approved by Creative Commons as
essentially the equivalent of this Public License.
d. Copyright and Similar Rights means copyright and/or similar rights closely
related to copyright including, without limitation, performance, broadcast, sound
recording, and Sui Generis Database Rights, without regard to how the rights are
labeled or categorized. For purposes of this Public License, the rights specified in
Section 2(b)(1)-(2) are not Copyright and Similar Rights.
e. Effective Technological Measures means those measures that, in the absence
of proper authority, may not be circumvented under laws fulfilling obligations
under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996,
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and/or similar international agreements.
f. Exceptions and Limitations means fair use, fair dealing, and/or any other
exception or limitation to Copyright and Similar Rights that applies to Your use of
the Licensed Material.
g. License Elements means the license attributes listed in the name of a Creative
Commons Public License. The License Elements of this Public License are
Attribution and ShareAlike.
h. Licensed Material means the artistic or literary work, database, or other material
to which the Licensor applied this Public License.
i. Licensed Rights means the rights granted to You subject to the terms and
conditions of this Public License, which are limited to all Copyright and Similar
Rights that apply to Your use of the Licensed Material and that the Licensor has
authority to license.
j. Licensor means the individual(s) or entity(ies) granting rights under this Public
License.
k. Share means to provide material to the public by any means or process that
requires permission under the Licensed Rights, such as reproduction, public
display, public performance, distribution, dissemination, communication, or
importation, and to make material available to the public including in ways that
members of the public may access the material from a place and at a time
individually chosen by them.
l. Sui Generis Database Rights means rights other than copyright resulting
from Directive 96/9/EC of the European Parliament and of the Council of 11
March 1996 on the legal protection of databases, as amended and/or succeeded, as
well as other essentially equivalent rights anywhere in the world.
m. You means the individual or entity exercising the Licensed Rights under this
Public License. Your has a corresponding meaning.
Section 2 – Scope.
a. License grant.
1. Subject to the terms and conditions of this Public License, the Licensor
hereby grants You a worldwide, royalty-free, non-sublicensable, nonexclusive, irrevocable license to exercise the Licensed Rights in the Licensed
Material to:
A. reproduce and Share the Licensed Material, in whole or in part; and
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B. produce, reproduce, and Share Adapted Material.
2. Exceptions and Limitations . For the avoidance of doubt, where Exceptions
and Limitations apply to Your use, this Public License does not apply, and
You do not need to comply with its terms and conditions.
3. Term . The term of this Public License is specified in Section 6(a) .
4. Media and formats; technical modifications allowed
. The Licensor authorizes
You to exercise the Licensed Rights in all media and formats whether now
known or hereafter created, and to make technical modifications necessary to
do so. The Licensor waives and/or agrees not to assert any right or authority
to forbid You from making technical modifications necessary to exercise the
Licensed Rights, including technical modifications necessary to circumvent
Effective Technological Measures. For purposes of this Public License,
simply making modifications authorized by this Section 2(a)(4) never
produces Adapted Material.
5. Downstream recipients .
A. Offer from the Licensor – Licensed Material . Every recipient of the
Licensed Material automatically receives an offer from the Licensor to
exercise the Licensed Rights under the terms and conditions of this
Public License.
B. Additional offer from the Licensor – Adapted Material. Every recipient
of Adapted Material from You automatically receives an offer from the
Licensor to exercise the Licensed Rights in the Adapted Material under
the conditions of the Adapter’s License You apply.
C. No downstream restrictions . You may not offer or impose any additional
or different terms or conditions on, or apply any Effective Technological
Measures to, the Licensed Material if doing so restricts exercise of the
Licensed Rights by any recipient of the Licensed Material.
6. No endorsement . Nothing in this Public License constitutes or may be
construed as permission to assert or imply that You are, or that Your use of
the Licensed Material is, connected with, or sponsored, endorsed, or granted
official status by, the Licensor or others designated to receive attribution as
provided in Section 3(a)(1)(A)(i) .
b. Other rights.
1. Moral rights, such as the right of integrity, are not licensed under this Public
License, nor are publicity, privacy, and/or other similar personality rights;
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however, to the extent possible, the Licensor waives and/or agrees not to
assert any such rights held by the Licensor to the limited extent necessary to
allow You to exercise the Licensed Rights, but not otherwise.
2. Patent and trademark rights are not licensed under this Public License.
3. To the extent possible, the Licensor waives any right to collect royalties from
You for the exercise of the Licensed Rights, whether directly or through a
collecting society under any voluntary or waivable statutory or compulsory
licensing scheme. In all other cases the Licensor expressly reserves any right
to collect such royalties.
Section 3 – License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following
conditions.
a. Attribution.
1. If You Share the Licensed Material (including in modified form), You must:
A. retain the following if it is supplied by the Licensor with the Licensed
Material:
i. identification of the creator(s) of the Licensed Material and any
others designated to receive attribution, in any reasonable manner
requested by the Licensor (including by pseudonym if designated);
ii. a copyright notice;
iii. a notice that refers to this Public License;
iv. a notice that refers to the disclaimer of warranties;
v. a URI or hyperlink to the Licensed Material to the extent
reasonably practicable;
B. indicate if You modified the Licensed Material and retain an indication
of any previous modifications; and
C. indicate the Licensed Material is licensed under this Public License, and
include the text of, or the URI or hyperlink to, this Public License.
2. You may satisfy the conditions in Section
3(a)(1) in any reasonable manner
based on the medium, means, and context in which You Share the Licensed
Material. For example, it may be reasonable to satisfy the conditions by
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providing a URI or hyperlink to a resource that includes the required
information.
3. If requested by the Licensor, You must remove any of the information
required by Section 3(a)(1)(A) to the extent reasonably practicable.
b. ShareAlike.
In addition to the conditions in Section
3(a) , if You Share Adapted Material You
produce, the following conditions also apply.
1. The Adapter’s License You apply must be a Creative Commons license with
the same License Elements, this version or later, or a BY-SA Compatible
License.
2. You must include the text of, or the URI or hyperlink to, the Adapter's
License You apply. You may satisfy this condition in any reasonable manner
based on the medium, means, and context in which You Share Adapted
Material.
3. You may not offer or impose any additional or different terms or conditions
on, or apply any Effective Technological Measures to, Adapted Material that
restrict exercise of the rights granted under the Adapter's License You apply.
Section 4 – Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use
of the Licensed Material:
a. for the avoidance of doubt, Section
2(a)(1) grants You the right to extract, reuse,
reproduce, and Share all or a substantial portion of the contents of the database;
b. if You include all or a substantial portion of the database contents in a database in
which You have Sui Generis Database Rights, then the database in which You
have Sui Generis Database Rights (but not its individual contents) is Adapted
Material, including for purposes of Section 3(b) ; and
c. You must comply with the conditions in Section
substantial portion of the contents of the database.

3(a) if You Share all or a

For the avoidance of doubt, this Section 4 supplements and does not replace Your
obligations under this Public License where the Licensed Rights include other
Copyright and Similar Rights.
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Section 5 – Disclaimer of Warranties and Limitation of Liability.
a. Unless otherwise separately undertaken by the Licensor, to the extent
possible, the Licensor offers the Licensed Material as-is and asavailable, and makes no representations or warranties of any kind
concerning the Licensed Material, whether express, implied,
statutory, or other. This includes, without limitation, warranties of
title, merchantability, fitness for a particular purpose, noninfringement, absence of latent or other defects, accuracy, or the
presence or absence of errors, whether or not known or discoverable.
Where disclaimers of warranties are not allowed in full or in part, this
disclaimer may not apply to You.
b. To the extent possible, in no event will the Licensor be liable to You
on any legal theory (including, without limitation, negligence) or
otherwise for any direct, special, indirect, incidental, consequential,
punitive, exemplary, or other losses, costs, expenses, or damages
arising out of this Public License or use of the Licensed Material,
even if the Licensor has been advised of the possibility of such
losses, costs, expenses, or damages. Where a limitation of liability is
not allowed in full or in part, this limitation may not apply to You.
c. The disclaimer of warranties and limitation of liability provided above shall be
interpreted in a manner that, to the extent possible, most closely approximates an
absolute disclaimer and waiver of all liability.
Section 6 – Term and Termination.
a. This Public License applies for the term of the Copyright and Similar Rights
licensed here. However, if You fail to comply with this Public License, then Your
rights under this Public License terminate automatically.
b. Where Your right to use the Licensed Material has terminated under Section 6(a) ,
it reinstates:
1. automatically as of the date the violation is cured, provided it is cured within
30 days of Your discovery of the violation; or
2. upon express reinstatement by the Licensor.
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor
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may have to seek remedies for Your violations of this Public License.
c. For the avoidance of doubt, the Licensor may also offer the Licensed Material
under separate terms or conditions or stop distributing the Licensed Material at any
time; however, doing so will not terminate this Public License.
d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.
Section 7 – Other Terms and Conditions.
a. The Licensor shall not be bound by any additional or different terms or conditions
communicated by You unless expressly agreed.
b. Any arrangements, understandings, or agreements regarding the Licensed Material
not stated herein are separate from and independent of the terms and conditions of
this Public License.
Section 8 – Interpretation.
a. For the avoidance of doubt, this Public License does not, and shall not be
interpreted to, reduce, limit, restrict, or impose conditions on any use of the
Licensed Material that could lawfully be made without permission under this
Public License.
b. To the extent possible, if any provision of this Public License is deemed
unenforceable, it shall be automatically reformed to the minimum extent necessary
to make it enforceable. If the provision cannot be reformed, it shall be severed
from this Public License without affecting the enforceability of the remaining
terms and conditions.
c. No term or condition of this Public License will be waived and no failure to
comply consented to unless expressly agreed to by the Licensor.
d. Nothing in this Public License constitutes or may be interpreted as a limitation
upon, or waiver of, any privileges and immunities that apply to the Licensor or
You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative
Commons may elect to apply one of its public licenses to material it publishes and
in those instances will be considered the “Licensor.” The text of the Creative
Commons public licenses is dedicated to the public domain under the CC0
249

Public Domain Dedication. Except for the limited purpose of indicating that
material is shared under a Creative Commons public license or as otherwise
permitted by the Creative Commons policies published at
creativecommons.org/policies , Creative Commons does not authorize the use
of the trademark “Creative Commons” or any other trademark or logo of Creative
Commons without its prior written consent including, without limitation, in
connection with any unauthorized modifications to any of its public licenses or
any other arrangements, understandings, or agreements concerning use of
licensed material. For the avoidance of doubt, this paragraph does not form part
of the public licenses.
Creative Commons may be contacted at creativecommons.org .

Additional languages available: العربية, čeština, Deutsch , Ελληνικά, Español ,
euskara , suomeksi , français , hrvatski , Bahasa Indonesia , italiano , 日本語, 한
국어, Lietuvių, latviski, te reo Māori, Nederlands , norsk , polski , português ,
română, русский, Slovenščina, svenska , Türkçe , українська, 中文, 華語.
Please read the FAQ for more information about official translations.
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Terms and Conditions
This agreement sets out the terms and conditions of the licence (the Licence) between you
and Springer Nature Customer Service Centre GmbH (the Licensor). By clicking
'accept' and completing the transaction for the material (Licensed Material), you also
confirm your acceptance of these terms and conditions.
1. Grant of License
1. 1. The Licensor grants you a personal, non-exclusive, non-transferable, world-wide
licence to reproduce the Licensed Material for the purpose specified in your order
only. Licences are granted for the specific use requested in the order and for no other
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another entity (as credited in the published version).
1. 3. If the credit line on any part of the material you have requested indicates that it
was reprinted or adapted with permission from another source, then you should also
seek permission from that source to reuse the material.
2. Scope of Licence
2. 1. You may only use the Licensed Content in the manner and to the extent permitted
by these Ts&Cs and any applicable laws.
2. 2. A separate licence may be required for any additional use of the Licensed
Material, e.g. where a licence has been purchased for print only use, separate
permission must be obtained for electronic re-use. Similarly, a licence is only valid in
the language selected and does not apply for editions in other languages unless
additional translation rights have been granted separately in the licence. Any content
owned by third parties are expressly excluded from the licence.
2. 3. Similarly, rights for additional components such as custom editions and
derivatives require additional permission and may be subject to an additional fee.
Please apply to
Journalpermissions@springernature.com/bookpermissions@springernature.com for
these rights.

2. 4. Where permission has been granted free of charge for material in print,
permission may also be granted for any electronic version of that work, provided that
the material is incidental to your work as a whole and that the electronic version is
essentially equivalent to, or substitutes for, the print version.
2. 5. An alternative scope of licence may apply to signatories of the STM Permissions
Guidelines, as amended from time to time.
3. Duration of Licence
3. 1. A licence for is valid from the date of purchase ('Licence Date') at the end of the
relevant period in the below table:
Scope of Licence
Post on a website

Duration of Licence
12 months

Presentations
12 months
Books and journals Lifetime of the edition in the language purchased
4. Acknowledgement
4. 1. The Licensor's permission must be acknowledged next to the Licenced Material in
print. In electronic form, this acknowledgement must be visible at the same time as the
figures/tables/illustrations or abstract, and must be hyperlinked to the journal/book's
homepage. Our required acknowledgement format is in the Appendix below.
5. Restrictions on use
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5. 1. Use of the Licensed Material may be permitted for incidental promotional use and
minor editing privileges e.g. minor adaptations of single figures, changes of format,
colour and/or style where the adaptation is credited as set out in Appendix 1 below. Any
other changes including but not limited to, cropping, adapting, omitting material that
affect the meaning, intention or moral rights of the author are strictly prohibited.
5. 2. You must not use any Licensed Material as part of any design or trademark.
5. 3. Licensed Material may be used in Open Access Publications (OAP) before
publication by Springer Nature, but any Licensed Material must be removed from OAP
sites prior to final publication.
6. Ownership of Rights
6. 1. Licensed Material remains the property of either Licensor or the relevant third party
and any rights not explicitly granted herein are expressly reserved.
7. Warranty

IN NO EVENT SHALL LICENSOR BE LIABLE TO YOU OR ANY OTHER PARTY OR
ANY OTHER PERSON OR FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL
OR INDIRECT DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, VIEWING OR USE OF THE
MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH
OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT
OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON
LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF
THIRD PARTIES), AND
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN.
8. Limitations
8. 1. BOOKS ONLY:Where 'reuse in a dissertation/thesis' has been selected the
following terms apply: Print rights of the final author's accepted manuscript (for clarity,
NOT the published version) for up to 100 copies, electronic rights for use only on a
personal website or institutional repository as defined by the Sherpa guideline
(www.sherpa.ac.uk/romeo/).
9. Termination and Cancellation
9. 1. Licences will expire after the period shown in Clause 3 (above).
9. 2. Licensee reserves the right to terminate the Licence in the event that payment is not
received in full or if there has been a breach of this agreement by you.
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Appendix 1 — Acknowledgements:
For Journal Content:
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication), advance
online publication, day month year (doi: 10.1038/sj.[JOURNAL ACRONYM].)
For Adaptations/Translations:
Adapted/Translated by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication)
Note: For any republication from the British Journal of Cancer, the following
credit line style applies:
Reprinted/adapted/translated by permission from [the Licensor]: on behalf of Cancer
Research UK: : [Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL
NAME] [REFERENCE CITATION (Article name, Author(s) Name),
[COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from The [the Licensor]: on behalf of Cancer Research UK:
[Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL NAME]
[REFERENCE CITATION (Article name, Author(s) Name), [COPYRIGHT] (year
of publication), advance online publication, day month year (doi: 10.1038/sj.
[JOURNAL ACRONYM])
For Book content:
Reprinted/adapted by permission from [the Licensor]: [Book Publisher (e.g.
Palgrave Macmillan, Springer etc) [Book Title] by [Book author(s)]
[COPYRIGHT] (year of publication)
Other Conditions:
Version 1.2
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.

255

“This is an open access article distributed under the Creative Commons Attribution License which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work
is properly cited.”
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so, I am required to have your permission in writing to add to my appendix. Could you please grant
me official permission to use your photo?
Thank you,
Nicole
-Nicole E. Avalon, MPAS, PhD
Bill J. Baker Lab
Department of Chemistry
University of South Florida
Tampa, FL 33620
neavalon@usf.edu
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From:
To:
Subject:
Date:

Bill Baker
Avalon, Nicole
Re: Permission for use of Esteinascidia turbinata photo
Wednesday, November 25, 2020 11:47:44 AM

Permission!
On 11/25/2020 11:44 AM, Avalon, Nicole wrote:
[EXTERNAL EMAIL] DO NOT CLICK links or attachments unless you recognize the sender and
know the content is safe.
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LIMITED LICENSE
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http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
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Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
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Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been peerreviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute
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articles however authors can update their preprints on arXiv or RePEc with their Accepted
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Policies for sharing publishing journal articles differ for subscription and gold open access
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and so links will help your users to find, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
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If you are affiliated with a library that subscribes to ScienceDirect you have additional
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represented as endorsing the use made of the work. The full details of the license are
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From:
To:
Cc:
Subject:
Date:

Allcock, Louise
Avalon, Nicole
Baker, Bill
Re: Request for Copyright Permission to Use Drifa Photos
Tuesday, December 1, 2020 2:37:08 AM

Dear Nicole,
We have a copyright agreement with the Marine Institute that allows us non-commercial usage in
connection with our research without seeking case-by-case permission. It is as follows:
The MI and the Grantee shall each retain copies of all images (still
and video) captured using the ROV (Holland 1) during the course of the
Survey.
The MI shall retain exclusive ownership of such images and controls
all rights or copyright with regards commercial use.
The MI shall provide royalty-free rights to the grantee to reproduce
the material, or portions thereof, in connection with their research
and promotion of their activity, in perpetuity.
All uses of the images, or portions thereof, by any party, shall acknowledge:
ownership of the images
the originator of the images (i.e. the grantee); and
the source of funding provided for the survey.
In the absence of a clear grantee data policy, the MI data policy will
apply—i.e. data must be archived in the Marine Institute and made
publicly available two years after the completion of the survey.
Data collected for PhD studies, or to fulfil EU project contract
obligations, must be archived in national or international data
centres and made publicly available one year after the completion of
the PhD study/ EU project.
During the period prior to the data being made publicly available, the
MI may wish to use certain images for publicity reasons. Such use
shall require the consent of the Grantee, whose consent shall not be
unreasonably withheld.
I have highlighted in red the important parts in this case: the royalty free-rights to the grantee to
reproduce the material in connection with their research. In this case, I am the grantee, and the
research is wholly connected to my SFI grant, so provided you credit ownership of the images
(Marine Institute), NUI Galway (the grantee), and the source of funding (MI and SFI), you are good to
use. The relevant information is in the line of acknowledgement that I asked you to include.   
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All the best
Louise
-Professor Louise Allcock
Head of Zoology and Director of the Ryan Institute’s Centre for Ocean Research & Exploration
(COREx)
NUI Galway

From: "Avalon, Nicole" <neavalon@usf.edu>
Date: Monday 30 November 2020 at 21:25
To: "Allcock, Louise" <louise.allcock@nuigalway.ie>
Cc: "Baker, Bill" <bjbaker@usf.edu>
Subject: Request for Copyright Permission to Use Drifa Photos
Dear Professor Allcock,
In my dissertation I would like to use two of the SFI images from the RV Celtic Explorer (Cruise
CE18012) of the Drifa sp. samples that were collected. Could you please grant me permission to do
so?
Thank you for your consideration,
Nicole
-Nicole E. Avalon, MPAS, PhD
Bill J. Baker Lab
Department of Chemistry
University of South Florida
Tampa, FL 33620
neavalon@usf.edu

[EXTERNAL EMAIL] DO NOT CLICK links or attachments unless you recognize the sender and
know the content is safe.
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